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Abstract
Brain-derived neurotrophic factor (BDNF) is a secretory protein known to be essential
for brain function, including key aspects of synaptic transmission. Its levels are decreased
in a number of conditions including neurodegenerative diseases, thus generating a need
for well-tolerated drugs increasing BDNF levels in the brain. The sphingosine analogue
fingolimod, also designated FTY720, is one of a still very small number of drugs readily
diffusing into the brain and extensively used in humans following its approval for the
treatment of multiple sclerosis. It acts as a functional antagonist on the G protein-coupled
receptor sphingosine 1-phosphate receptor 1 (S1P1R) thereby preventing the exit of
lymphocytes from lymph nodes. Recently, FTY720 has been shown to increase BDNF
levels in the brain and the main objective of the work was to investigate whether S1P1R
plays a role in the action of the drug on neurons. This study reports on the successful
generation of mutant neurons lacking S1P1R from mouse embryonic stem cells, using a
modified differentiation protocol. While the interpretation of the data was complicated by
a high variability encountered in the culture system, preliminary data suggests a role of
S1P1R in the long-term effects of pFTY720 on BDNF levels in vitro. As the BDNF gene
has been recently reported to be not only expressed by neurons, but also by
megakaryocytes, FTY720-dependent effects were also investigated in primary rat
megakaryocytes.
This work establishes that sphingosine receptors were found to be expressed at the mRNA
level in ES cell-derived neurons and primary rat megakaryocytes and reveals an
unexpected complexity of FTY720 signalling in these cells.
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1Introduction
1.1 Overview
Neurodegenerative diseases represent an ever growing problem for society due to the
increased life expectancy in industrialised countries (Wyss-Coray 2016). While there is a
wide spectrum of neurodegenerative disorders some of the most frequent diseases
including Parkinson’s (PD) as well as Alzheimer’s disease (AD) have been shown to
include cell death as well as the loss of synaptic contacts (Przedborski et al. 2003). These
observations have increasingly focused attention on the potential use of neurotrophic
factors to combat neurodegeneration. These factors are broadly defined as a class of
substances preventing the death of neurons and positively regulating synaptic plasticity
(Weissmiller and Wu 2012; Allen et al. 2013). By far the most thoroughly investigated
molecule in this category is the growth factor designated brain-derived neurotrophic
factor (BDNF; for review see Bibel and Barde 2000 and Park and Poo 2013). Like all
other members of the family (see below), BDNF exerts its neuroprotective effects through
the activation of a receptor tyrosine kinase. In the case of BDNF this is the tropomyosin
receptor kinase B (TrkB) (Klein et al. 1990). The evidence for a significant “trophic” role
of BDNF comes not only from the results of in vitro assays or of genetically manipulating
animals lacking BDNF (Bibel and Barde 2000; Rauskolb et al. 2010; Park and Poo 2013),
but also from human genetics including loss-of-allele mutation and a valine for
methionine substitution in pro-BDNF (Egan et al. 2003; Gray et al. 2006; Notaras et al.
2015). Furthermore, BDNF turned out to be also present in human blood at relatively high
concentrations (Yamamoto and Gurney 1990), and a number of studies have associated
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BDNF levels in human blood with various conditions such as depression or Alzheimer’s
disease (Laske et al. 2011; Bus et al. 2015). Conversely physical exercise generally
recognised to retard cognitive decline during ageing increases BDNF levels in human
blood (Griffin et al. 2011; Tuon et al. 2014). Up until very recently, the origin of BDNF
in human blood has remained unclear. BDNF was speculated to somehow diffuse from
the brain into the blood circulation where it was thought to be accumulated by circulating
platelets (Serra-Millas 2016). Indeed, it has been shown early on that human platelets, but
not mouse platelets contain significant levels of BDNF (Yamamoto and Gurney 1990),
As the levels of BDNF in mouse and human brains are comparable, it appears unlikely
that BDNF in human platelets, would be brain-derived. Our laboratory recently reported
that human and rat megakaryocytes express the BDNF/Bdnf gene and translate the
corresponding mRNAs, thus clarifying the cellular origin of blood BDNF (Chacon-
Fernandez et al. 2016). These non-neuronal cells express sphingosine 1-phosphate
receptor mRNAs (see Chapter 7) and use the same promoters as neurons to transcribe the
BDNF/Bdnf gene (Chacon-Fernandez et al. 2016).
Unlike growth factors acting on the hematopoietic lineage such as erythropoietin, BDNF
cannot be administered as a recombinant protein to improve neuronal function. This is
not just because of its unfavourable physicochemical characteristics including high
isoelectric point (Barde et al. 1982), but also because of its short half-life in plasma it
does not seem to be able to access the brain at therapeutically relevant quantities
(Pardridge et al. 1994; Sakane and Pardridge 1997). Alternative strategies are being
developed consisting in the development of drugs aiming at activating the BDNF receptor
TrkB or at increasing BDNF transcription by using compounds accessing the brain and
targeting neuronal receptors (Cazorla et al. 2011; English et al. 2013). In the brain, BDNF
is primarily expressed by excitatory neurons and it has been known for some time that
increased excitatory inputs on such neurons increase Bdnf mRNA and protein from
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typically extremely low resting levels (Castren et al. 1993). In particular, glutamate
receptor agonists, designated Ampakines, have been used extensively in an initial
approach and with some success in animal models whereby it remained unclear whether
excitotoxicity could be sufficiently separated from beneficial effects (Lauterborn et al.
2009). Additionally, it has been shown that the combined administration of Ampakines
with BDNF is more effective in improving motor function in a post-stroke mouse model
compared to Ampakine treatment alone (Clarkson et al. 2015). More recently, it was
realised that a drug introduced for the treatment of multiple sclerosis increased BDNF
levels, both in vitro and in vivo (Deogracias et al. 2012). In addition, it could be shown
that this sphingosine analogue, designated fingolimod (FTY720) improves the locomotor
behaviour of animals lacking the gene Mecp2, a model of a disease called Rett syndrome
(Deogracias et al. 2012). Importantly, these findings formed the basis of a small clinical
trial exploring the potential beneficial effects of FTY720 administered to children
suffering from this neurodevelopmental disease (Naegelin et al. 2015). FTY720 is a
sphingosine 1-phospate receptor modulator and there is overwhelming evidence to
indicate that the downregulation of the sphingosine 1-phosphate receptor 1 (S1P1R) on
T-lymphocytes explains its beneficial effects in the context of multiple sclerosis (Chun
and Brinkmann 2011). In 2012, our group proposed that FTY720, well-known to diffuse
into the brain (Foster et al. 2007), may activate S1P1R on neurons, potentially explaining
the increase of BDNF levels in an activity-dependent manner (Deogracias et al. 2012).
However, FTY720 is known to also activate other S1P receptors and both the cellular
localisation of these receptors as well as their pre- or post-synaptic role in increasing
neurotransmission remain unclear, including the important question as to whether the
receptor itself or other molecules may be involved in regulating BDNF levels.
The core of this project was to clarify the role of the S1P1 receptor on neurons in
mediating BDNF increase in the nervous system. To this end, neurons derived from
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embryonic stem (ES) cells were used as a tool to dissect the role of this receptor in
mediating the mode of action of FTY720. This system allows the generation of uniquely
homogenous populations of neurons (Bibel et al. 2004; Bibel et al. 2007) and comparisons
to be made between wild-type (WT) and mutant neurons lacking S1P1R. Additionally,
given the expression of BDNF in a pattern similar to neurons in megakaryocytes, the
expression of S1P1R was also investigated in these cells to explore possible effects of
FTY720 on Bdnf mRNA levels outside the nervous system.
1.2 Sphingosine and its Receptors
Sphingosine metabolism
Sphingosine belongs to the family of sphingolipids. It is an 18-carbon amino alcohol with
an unsaturated hydrocarbon chain and a primary constituent of sphingolipids, a class of
cell membrane lipids (Figure 1.1 and 1.4; (Chun and Brinkmann 2011)). Sphingosine is
generated from the membrane lipid sphingomyelin, which is first broken down to the
intermediate ceramide by the enzyme sphingomyelinase, followed by its hydrolysis to
sphingosine through the enzyme ceramidase. Sphingosine is phosphorylated by one of
the two known sphingosine kinases 1 and 2 (SphK1 and 2) to sphingosine 1-phospate
(S1P) (Pyne et al. 2016) and transported out of the cells by the transporter spinster 2
(Figure 1.1 and (Kawahara et al. 2009; Donoviel et al. 2015)). Cells such as red blood
cells as well as blood platelets release considerable amounts of S1P so that its levels may
reach about 1 µM in the blood and 0.1 µM in the lymph (Tani et al. 2005; Pappu et al.
2007; Yanagida and Hla 2016). These concentrations are thought to be considerably
higher than in other interstitial fluids thus allowing lymphocytes via S1P receptor-
mediated chemotaxis to exit the lymph nodes and enter the vascular system (Arnon et al.
2011; Zhang et al. 2012).
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Figure 1.1 Sphingosine metabolism
Ceramide is either synthesised de novo from dihydroceramide via the dihydroceramide
desaturase (Des) or by hydrolysis of sphingomyelin by the enzyme sphingomyelinase
(SMase). Ceramidase cleaves ceramide and produces sphingosine, which can be converted
back to ceramide via ceramide synthase 1 (CerS). One of the two sphingosine kinases
(SphK1/2) phosphorylates sphingosine to its active form sphingosine 1-phosphate (S1P),
which is also interconvertible due to the activity of the sphingosine 1-phosphate
phosphatase (SPP). S1P is either transported out of the cell by the transporter spinster 2
(Spns2) or degraded by sphingosine 1-phosphate lyase (S1PL). Sphingosine also
accumulates in the nucleus, where it is phosphorylated by SphK2. Figure adapted from
(Pyne et al. 2016).
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The five sphingosine receptors
Initially the sphingosine receptors were referred to as endothelial differentiation gene
(EDG) receptors. The EDG family consists of eight members (Takuwa et al. 2002), with
the first member EDG-1, having been discovered as a transcript expressed during the
course of in vitro differentiation of endothelial cells (Hla and Maciag 1990). The later
discoveries by homology cloning of EDG-3 and EDG-5 expanded the family
(MacLennan et al. 1994; Yamaguchi et al. 1996), and it is only in 1998 that S1P was
discovered as a high affinity ligand for EDG-1 (Lee et al. 1998; Zondag et al. 1998).
Subsequent studies revealed that in fact S1P is a ligand for five members of the then
orphan receptor family (Im et al. 2000; Spiegel 2000) and the receptors were renamed to
S1P1R (EDG-1), S1P2R (EDG-5), S1P3R (EDG-3), S1P4R (EDG-6) and S1P5R
(EDG-8) (Chun et al. 2002). S1P has a high affinity to four of the five receptors (Kd in
the range of 2 – 27 nM) and binds S1P4R with a distinctly lower affinity (Kd = 63 nM)
(Im et al. 2000; Spiegel 2000; Van Brocklyn et al. 2000). The S1P receptors exhibit about
20 % sequence identities with the cannabinoid receptors 1 and 2 and 30 % with the
lysophosphatidic acid receptors 1-3 (Hla et al. 1999; Ishii et al. 2004).
Signal transduction through S1P receptors
All five S1P1Rs are heterotrimeric G protein-coupled receptors (GPCR) undergoing a
conformational change after ligand binding, allowing the receptor to interact with a
trimeric G protein (Figure 1.2 and (Blaho and Hla 2014).
Trimeric G proteins consist of three different subunits, namely Gα, Gβ and Gγ and its
inactive state, the Gα subunit is bound to guanosine diphosphate (GDP). Upon activation,
GDP is replaced by guanosine triphosphate (GTP), leading to the interaction of the Gα
subunit with membrane bound proteins signalling to downstream pathways (Oldham and
Hamm 2008). Once the GTP bound-Gα subunit is hydrolysed by regulator of G protein
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signalling (RGS) proteins it is inactivated and downstream signalling is terminated
(Oldham and Hamm 2008).
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Figure 1.2 Downstream signalling pathways of S1P1-5R.
S1P1R signals through Gi/o protein and thereby inhibits adenylyl cyclase (AC), activates
PI3K-Akt/Rac, ERK and PLC pathway. S1P2R and S1P3R are both coupled to Gi/o, Gq and
G12/13 and activate the PI3K-Akt/Rac and ERK pathway, as well as PLC and Rho/ROCK.
S1P4R and S1P5R both couple through Gi/o and G12/13. S1P4R was shown to inhibit AC and
activate ERK pathway, whereas S1P activates AC and PI3K-Akt/Rac over S1P5R. Figure
adapted from (Sanchez and Hla 2004; Brinkmann 2007).
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The five sphingosine receptors are coupled to a variety of G proteins. Major contributors
leading to different G protein associations are the cell types expressing the receptors, as
well as the conformational change of the receptors induced by its ligands (Oldham and
Hamm 2008; Nygaard et al. 2009). S1P1R is thought to be primarily coupled to Gi/o
protein, S1P2R and S1P3R to Gi/o, Gq and G12/13, while S1P4R and S1P5R are coupled to
Gi/o and G12/13 (Figure 1.2 and (Blaho and Hla 2014)). How the binding of S1P acts to
each of these five receptors and which signalling pathways are activated has been the
object of considerable work and the complexity of these interactions is not thoroughly
clarified yet. Not least because of the difficulties in studying these interactions in relevant
cells of sufficient purity.
S1P1R is thought to primarily signal through the Gi/o protein thus leading to a decrease
of cyclic adenosine monophosphate (cAMP) levels and an increase of intracellular Ca2+.
In addition, it activates the GTPase Ras/mitogen-activated protein kinase kinase
(MEK)/extracellular signal-regulated kinase (ERK) pathway as well as Akt through the
phosphoinositide 3-kinase (PI3K) pathway (Im et al. 1997; Lee et al. 1998; Okamoto et
al. 1998; Zondag et al. 1998; Rakhit et al. 1999; Kim et al. 2000; Igarashi et al. 2001;
Morales-Ruiz et al. 2001). In neurons, activation of ERK1/2 via the Gi/o coupled S1P1R
was confirmed by the demonstration of a S1P1R-dependent increase in neurogenesis in
the hippocampus (Ye et al. 2016), as well as neuroprotective effects in cortical neurons
(Di Menna et al. 2013). However, the S1P-elicited increase of intracellular Ca2+ levels is
not completely inhibited by the addition of pertussis toxin (PTX), known to specifically
ribosylate adenosine diphosphate (ADP) and inhibit Gi/o, thus suggesting the involvement
of other G proteins. Indeed, the addition of specific phospholipase C (PLC) inhibitors
completely abolishes the S1P-dependent Ca2+ increase (An et al. 1999), suggesting the
activation of other receptor subtypes including S1P2R and S1P3R. The involvement of
S1P4R can be excluded due to a complete inhibition of PLC activation after PTX addition
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(Graler et al. 2003).  S1P3R activation is thought to be the most effective pathway leading
to increased intracellular Ca2+ levels by signalling through the Gq protein which binds and
activates PLCβ (Ancellin and Hla 1999; Kon et al. 1999; McCudden et al. 2005). In
addition, receptor deletion studies in mouse embryonic fibroblasts (MEFs) suggest that
S1P2R is not involved in any PLC activation, as Ca2+ signalling is unaffected in S1p2r-/-
cells while it is significantly reduced in the S1p3r-/- line (Ishii et al. 2002). This is in line
with reduced inositol trisphosphate (IP3) concentrations observed in S1p3r-/- MEFs by the
same research group (Ishii et al. 2001). Activation of PLC not only increases the
concentration of IP3, leading to the release of Ca2+ from the endoplasmic reticulum
(Putney and Tomita 2012), but also activates protein kinase C-dependent pathways
involved in cell migration (Gonda et al. 1999; Gorshkova et al. 2008) and nuclear factor-
κB (NF-κB) activation (Siehler et al. 2001). All of these pathways have been shown to
involve Gq protein activation by the S1P3R. Importantly, cell migration is also regulated
by S1P via the Rho family GTPase including Rac which is activated by the Gi/o protein.
Intriguingly, S1P activates cell migration upon binding of S1P1R and S1P3R, but inhibits
it when signalling through S1P2R due to an altered Rac activity and the involvement of
phosphatase and tensin homolog (PTEN) (Takuwa et al. 2002; Sanchez et al. 2005). This
S1P2R mediated inhibition of Rac is preceded by activation of the Rho/Rho-associated
protein kinase (ROCK) pathway through G12/13 protein (Sugimoto et al. 2003) and
interestingly it has been shown that the Gi/o mediated activation of PI3K is still inducing
the Akt pathway after S1P2R stimulation (Figure 1.2 and (Okamoto et al. 2000)).
In summary, signal transduction through S1P receptors is highly complex and far from
being fully understood. The recent elucidation of the S1P1R crystal structure significantly
advanced the field (Hanson et al. 2012), as it now allows the development of specific
receptor agonists. The crystal structure also greatly helped to understand how different
conformational changes of the receptor influences its signalling behaviour (Hanson et al.
 Chapter 1
11
2012) and it is to be expected that the elucidation of the structure of other sphingosine
receptors will similarly facilitate the understanding of S1P signalling.
Functions of sphingosine receptors outside the nervous system
S1P receptors are involved in a variety of processes including cell survival, migration and
proliferation (Pyne et al. 2016). Additionally, S1P is known to enhance endothelial barrier
function by a variety of mechanisms including adherence and tight junction assembly
(Wang and Dudek 2009), the deregulation of which may cause various pathologies such
as  inflammation, fibrosis and cancer (Pitman et al. 2015; Aoki et al. 2016; Gonzalez-
Fernandez et al. 2016). S1P1-3R are also expressed ubiquitously outside the nervous
system, including the immune and cardiovascular systems. The S1P4R is primarily found
in the hematopoietic and lymphatic system while the S1P5R is expressed on endothelial
cells (Brinkmann 2007; van Doorn et al. 2012). Studies of the S1P4R revealed that it is
involved in immunosuppressive functions and regulates the release of specific cytokines
by T cells (Wang et al. 2005). S1P5R on endothelial cells helps sustaining the integrity
of the blood brain barrier (BBB) and reducing the ingress of immune cells into the brain
(van Doorn et al. 2012). A deletion study of the S1P2R indicated that mice were born
with no apparent defects outside the nervous system (MacLennan et al. 2001; Ishii et al.
2002). S1p3r-/- mice are viable and failed to reveal any specific phenotype (Ishii et al.
2001). Investigations of the effects of S1P in those mice revealed a role for S1P3R in the
regulation of heart rate as S1P induced bradycardia in WT mice but not in mice lacking
S1P3R (Forrest et al. 2004; Sanna et al. 2004). This is not surprising given that S1P3R is
expressed on mouse ventricular myocytes (Forrest et al. 2004). The combined deletion of
S1P2R and S1P3R revealed increased embryonic lethality compared with single receptor
deletions (Ishii et al. 2002). By contrast, S1p1r-/- mice die at around E12 to E14.5 with
early defects in vascular maturation explained by incomplete wrapping of blood vessels
with vascular smooth muscle cells, frequently causing lethal intrauterine bleeding (Liu et
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al. 2000; Kono et al. 2004). Defects were also observed in the developing brain, including
increased cell death in the telencephalon and diencephalon (Liu et al. 2000; Mizugishi et
al. 2005). In situ hybridisation results indicate that S1P1R is prominently expressed
throughout the brain, including the ventricular zone at E14, a highly neurogenic region
(McGiffert et al. 2002). Yet the cellular resolution of these experiments and the presence
of S1P1R in blood vessels makes it difficult to dissect the molecular mechanisms leading
to neuronal cell death during embryogenesis. In the context of human pathology, it is by
far the expression of S1P1R by lymphocytes that received most attention (Garris et al.
2014). Indeed, the receptor plays a crucial role in allowing the cells to sense the S1P
gradient between the interstitial compartment and the blood or lymph (Arnon et al. 2011).
For example, the egress of immature T cells from the thymus is prevented by their low
expression of S1P1R (Matloubian et al. 2004). As these cells mature, S1p1r mRNA levels
increase, allowing them to sense the S1P gradient and to leave the thymus (Matloubian et
al. 2004; Lo et al. 2005). Once in the blood, the high S1P concentration induces S1P1R
internalisation on T and B cells which favours the interaction with specific chemokines
and the subsequent uptake into the lymph node (Cyster and Schwab 2012). There the
S1P1R is re-expressed but in case of an immune reaction where the sequestration of the
lymphocytes in lymph nodes is needed for effector differentiation, the S1P1R is
internalised and transcription of the S1p1r gene is only reactivated in effector T cells
(Shiow et al. 2006). The crucial role of S1P1R for the egress of lymphocytes into the
lymph by sensing the S1P gradient has been elegantly demonstrated in WT mice
supplemented with T and B cells lacking S1P1R (Allende et al. 2004; Matloubian et al.
2004). This was supported by the finding that loss of the S1P concentration gradient by
inhibition of S1P lyase (Schwab et al. 2005), or lack of both SphK1/2 in endothelial cells
also blocked lymphocyte egress from the lymph node. This occurred despite the presence
of S1P1R on lymphocytes (Pham et al. 2010). While the roles of the S1P gradient and of
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the S1P1R in sensing it, are now well appreciated, the biochemistry of intracellular
signalling is less clear. It is believed that S1P1R signalling either overcomes a retention
signal induced by a chemokine receptor or that it promotes a trans-endothelial migration
process (for review see (Cyster and Schwab 2012)). A similar chemotactic mechanism
seems to be used by megakaryocytes as activation of S1P1R triggers the elongation of
proplatelet extensions from the megakaryocytes into the sinusoids. The higher
concentration of S1P in the blood compared to the bone marrow activates the Rac GTPase
in megakaryocytes and thereby directs the formation of proplatelet extensions, eventually
leading to the release of platelets into the circulation (Figure 1.3 and (Zhang et al. 2012)).
 Chapter 1
14
Figure 1.3 S1P1R in megakaryocytes is involved in platelet release into the blood circulation
The high concentration of S1P in the blood generates a gradient which is sensed by the S1P1R
(yellow rectangular S1P1) expressed on megakaryocytes and thereby triggers the formation of
platelet protrusions, called proplatelets across the endothelium. Megakaryocytes are
multinucleated cells when mature as depicted by brown round objects in the figure. Figure taken
from (Hla et al. 2012). Reprinted with permission.
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Functions of sphingosine receptors in nerve cells
The generation of mice lacking S1p1r-/- mice revealed an early essential role for the
receptor with statistically significant losses of embryos starting at E13.5 (Liu et al. 2000).
Given the high level of expression of the receptors by cells associated with blood vessels,
the work largely focuses on the description of the developing vasculature and embryonic
haemorrhage leading to the death of embryos (Liu et al. 2000). However, it later became
clear that S1P1R, like the lysophosphatidic acid receptor LPA1 is expressed at significant
levels next to the developing ventricles, including the lateral ventricles (McGiffert et al.
2002). The expression of both receptors also overlaps in the developing cortex (McGiffert
et al. 2002). Massive cell death and a smaller number of mitotic cells were observed in
the telencephalon of S1p1r-/- mice (Mizugishi et al. 2005). However, it is not entirely clear
if these dramatic effects on neurogenesis can be entirely dissociated from those on the
developing vasculature eventually leading to the death of the embryos (see above). In the
adult mouse brain S1P1R, S1P2R, S1P3R and S1P5R were found to be expressed on
neurons, astrocytes, and microglia, while oligodendrocytes express S1P1R, S1P3R and
S1P5R (O'Sullivan and Dev 2016). S1P5R is expressed on oligodendrocytes throughout
their maturation and transduces distinct effects at different stages, including retraction of
processes early on during development, inhibition of oligodendrocyte precursor cell
migration and survival of mature oligodendrocytes (Jaillard et al. 2005; Novgorodov et
al. 2007). Somewhat unexpectedly, the genetic deletion of the receptor suggested that it
may not be essential for myelination (Jaillard et al. 2005). With regard to the possible
roles of S1P1Rs in neurons, the germline deletion of S1P2R led to increased excitatory
postsynaptic currents and to the development of lethal seizures in mice at about three
weeks postnatally (MacLennan et al. 2001), indicative of a role for S1P in regulating
neuronal excitability (Okada et al. 2009). Albeit these results were subsequently
challenged (Ishii et al. 2002), additional studies supported the notion that S1P may be a
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mediator of neuronal excitability (Zhang et al. 2006; Kajimoto et al. 2007). S1P2R was
also proposed to be involved in counteracting cell migration as S1P2R antagonists
increased migration of neuronal progenitor cells into ischemic brain regions with
increased S1P concentrations following the release from microglial cells (Kimura et al.
2008). S1P is further involved in the regulation of cell apoptosis where the balance
between the interconvertible lipids ceramide and S1P, also known as “ceramide/S1P
rheostat”, defines the fate of a cell (Cuvillier et al. 1996). Ceramide can be either
synthesised de novo from dihydroceramide, recycled from sphingosine over ceramide
synthase 1 or is else the result of sphingomyelin hydrolysis (Figure 1.1 and (Kitatani et
al. 2008)). While low ceramide concentrations promote neurite outgrowth, neuronal
survival and differentiation, high levels of the lipid lead to apoptosis (Czubowicz and
Strosznajder 2014). In a human neuroblastoma cell line S1P was shown to counteract the
ceramide-induced apoptosis by modulating pro- and anti-apoptotic factors through
S1P1R and S1P3R signalling (Czubowicz and Strosznajder 2014). Both receptors were
also found to be expressed on astrocytes with increased expression in multiple sclerosis
lesions (Van Doorn et al. 2010; Dusaban et al. 2017). Astrocytes are known to induce
neuroinflammation and several studies have reported on the role of S1P in this process
(Pebay et al. 2001; Sorensen et al. 2003; Kimura et al. 2008; Van Doorn et al. 2010; Choi
et al. 2011; Fischer et al. 2011). A recent publication now identified S1P3R as the main
receptor activated by S1P. It couples to G12/13 and activates RhoA thereby inducing the
release of pro-inflammatory cytokines (Dusaban et al. 2017).
Over the last decade researchers showed that signalling of these receptors can be used to
treat numerous neurological diseases. There are clinical studies ongoing (O'Sullivan and
Dev 2016) for the treatment of amyotrophic lateral sclerosis (Potenza et al. 2016), acute
stroke (Hasegawa et al. 2010), Rett syndrome (Deogracias et al. 2012), schizophrenia
(Jang et al. 2011; Muhle et al. 2013) and glioblastoma (Zhang et al. 2015).
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1.3 FTY720: Origin and Mode of Action
Discovery of FTY720
FTY720 is a sphingosine analogue and following its phosphorylation by endogenous
SphK2 it initially acts as a S1P1R agonist. However, FTY720 is considered to act as a
functional antagonist of S1P1R due to the realisation that chronic exposure to the drug
triggers the internalisation of the receptor (Matloubian et al. 2004). FTY720 was the first
oral drug approved for the treatment of relapsing-remitting multiple sclerosis (Figure 1.4
and (Chun and Brinkmann 2011)). Since 2010 it is traded under the name Gilenya® by
Novartis and is a derivative of myriocin, a fungal metabolite isolated from Ascomycete
Isaria sinclairii. Isaria sinclairii is the anamorph stage of the fungus Cordyceps sinclairii
and is classified under the family Clavicipitaceae (Adachi et al. 1995; Paterson 2008). In
traditional Chinese medicine Isaria sinclairii is used as a well-known remedy for the
treatment of a range of diseases and claims to be the “elixir leading to eternal youth’
(Chun and Brinkmann 2011). Another well-known fungus of the non-monophyletic
family Clavicipitaceae is Tolypocladium inflatum, which is the anamorph stage of
Cordyceps subsessilis (Sung et al. 2007). It is the source of cyclosporine, one of the most
widely used immunosuppressant in transplantation medicine (Chun and Brinkmann
2011).
Mode of action of FTY720 in the immune system
In the context of multiple sclerosis, the primary target of FTY720 is thought to be S1P1R
on lymphocytes following its phosphorylation to pFTY720 by the ubiquitously expressed
kinase SphK2 (Figure 1.4 and (Zemann et al. 2006)). The drug induces the internalisation
of S1P1R, thus preventing the lymphocytes to read S1P gradients and hindering their
egress from lymph nodes (Graler and Goetzl 2004; Matloubian et al. 2004). Indeed,
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decreased numbers of lymphocytes can readily be detected in the blood of FTY720-
treated patients (Brinkmann et al. 2004). While FTY720 was initially developed as an
immunosuppressant, clinical studies were discontinued as FTY720 did not show superior
effects to other drugs used in the context of the prevention of organ graft rejection
(Mansoor and Melendez 2008). Still, FTY720 does compromise the immune response
and at present three cases of progressive multifocal leukoencephalopathy have been
reported during the course of FTY720 treatment (FDA 2015; D'Amico et al. 2016). The
other main side effect is bradycardia due to early agonistic actions of FTY720 (Camm et
al. 2014). Studies in rodents explained these effects due to an agonistic action on the
S1P3R expressed on heart tissue (Forrest et al. 2004; Sanna et al. 2004). In humans
however, S1P3R in contrast to S1P1R, was not found to be expressed at significant levels
on myocytes (Mazurais et al. 2002), and treatment in patients with specific S1P1R agonist
still induced bradycardia (Gergely et al. 2012; Moberly et al. 2012). During early stages
of treatment, FTY720 acts as an agonist at S1P1R on myocytes and leads to the activation
of G-protein coupled inwardly rectifying potassium (GIRK) channels and subsequent
heart rate reduction (Bünemann et al. 1995; Koyrakh et al. 2005). Prolonged treatment
with FTY720 is thought to induce S1P1R internalisation as symptoms of bradycardia
typically subside within the first 24 h of treatment (Vargas and Perumal 2013; Camm et
al. 2014). This implies that close monitoring of patients treated with FTY720 is
mandatory during the initial phase of drug administration (Sanna et al. 2004; Faber et al.
2013).
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Figure 1.4 FTY720 is a structural analogue of sphingosine
Both, sphingosine and FTY720 consist of an amino alcohol group and a hydrocarbon chain. These
structural similarities led to the identification of S1P receptors as the primary target of the
biologically active form of FTY720. Sphingosine and FTY720 are phosphorylated by SphK1/2
to S1P or (S)-pFTY720, respectively (Chun and Brinkmann, 2011). Chemical synthesis leads to
the (S)- and (R)-enantiomer of pFTY720, but in vivo only (S)-pFTY720 is found and active
(Albert et al. 2005).
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Mode of action of FTY720 in the brain
Due to its lipophilicity FTY720 readily enters the brain and accumulates in the white
matter (Foster et al. 2007). Given the expression of S1P receptors by most brain cells,
including endothelial cells, it is then essential to better understand how FTY720 may act
on brain cells, a question that is at the core of this PhD thesis. Previous studies by our
laboratory revealed that FTY720 increases BDNF levels in the brain and ameliorates
symptoms of a mouse model of Rett syndrome: FTY720 injections into mice lacking
Mecp2, the gene mutated in most cases of Rett syndrome increases BDNF levels in the
brain of mutant animals and markedly improves their locomotor activity (Deogracias et
al. 2012). These findings also formed the basis of an exploratory clinical trial with a small
number of Rett syndrome patients (Deogracias et al. 2012; Naegelin et al. 2015). Further
experiments with primary cortical neurons showed that pFTY720 phosphorylated the
calcium-responsive elements (CRE)-binding protein (CREB) through activation of the
ERK pathway. In these studies, S1P1R was implicated as the primary target of pFTY720
as other S1P1R agonists elicited similar effects in vitro (Deogracias et al. 2012). The
neuroprotective activity of FTY720 in the central nervous system (CNS) is further
supported by a study demonstrating rapid reversal of neuronal damage in a rat model of
multiple sclerosis, namely the experimental autoimmune encephalomyelitis (EAE)
(Foster et al. 2009) and importantly, by studies indicating a reduced brain atrophy
observed in patients treated with FTY720 in clinical phase III trials (Kappos et al. 2010).
While there is little doubt that FTY720 also acts in the CNS in addition to its well-
documented activity of T lymphocytes, there is still a great deal of uncertainty as to how
the neuroprotective activity of FTY720 can be best explained. In an attempt to explore a
possible role of FTY720 in the mouse CNS in the context of EAE, S1P1R flanked by
loxP sites was deleted using a Cre driver under the control of a human glial fibrillary
acidic protein (GFAP) promoter. The outcome of the study was that the excision of the
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receptor rendered the animals unresponsive to FTY720 treatment and that S1P1R
excision alone reduced astrogliosis and ameliorated symptoms of EAE (Choi et al. 2011).
However, the interpretation of the results with regard to the identity of the cells targeted
by the S1p1r deletion is complicated by the fact that the human GFAP promoter used in
this study is expressed by most, if not all radial glial cells during development (Malatesta
et al. 2003). These cells are now well appreciated to be the progenitors not only of
astrocytes but also of major neuronal populations in the developing CNS (Hol et al. 2003;
Malatesta et al. 2003). Given the expression of multiple receptors by most cells in the
CNS including microglial cells, oligodendrocytes, and astrocytes it is not surprising that
a number of different effects of FTY720 have been reported in the brain of rodents.
Amongst the most intriguing physiological activities of S1P in the adult brain is the
regulation of the proliferation of neural stem cells. S1P receptor expression was identified
in stem cells isolated from the subventricular zone and S1P, possibly deriving from the
cerebrospinal fluid (CSF), showed to contribute to the quiescence of these adult stem cells
(Codega et al. 2014). FTY720 could therefore act as a functional antagonist explaining
the increased neurogenesis observed after FTY720 administration, possibly contributing
to improved learning and memory, an effect found in these animals (Efstathopoulos et al.
2015; Sun et al. 2016).
Elucidating the question of whether the effects of FTY720 on BDNF increase are receptor
mediated is even more crucial as a recent study suggests a non-receptor mediated mode
of action. Indeed, FTY720 has been shown to act through the inhibition of histone
deacetylases (HDAC). Strikingly, pFTY720 can be generated in the nucleus due to the
presence of SphK2 where it acts as a class I HDAC inhibitor on site (Hait et al. 2014).
This finding is highly relevant as HDAC inhibition has long been known to increase
BDNF levels and to facilitate fear extinction memory (Bredy et al. 2007).
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FTY720 and neurodegenerative diseases
A hallmark of neurodegenerative disorders is the loss of neurons either in discrete brain
regions such as the substantia nigra in the case of PD or the striatum in Huntington’s
disease (HD) or else more widespread in the case of AD, the most prevalent
neurodegenerative disorder (Yuan and Yankner 2000). In AD, brain atrophy is evident
with profound reductions in the volume of the hippocampus and the temporal lobe of the
cerebral cortex where the accumulation of amyloid-β peptides is suggested to be the
starting point of the neurodegenerative process (Hardy and Higgins 1992; Brunkhorst et
al. 2014). Later in the disease, neurofibrillary tangles are also observed and consist of
different protein aggregates, namely hyper-phosphorylated tau protein (Hyman et al.
2012). In terms of possible therapies, most attempts have targeted amyloid-β peptides
using a variety of humanised monoclonal antibodies whereby thus far this strategy failed
to halt the progression of the disease (Canter et al. 2016). Whether or not amyloid-β
plaques may be the appropriate target is a question frequently asked in view of the failures
of the clinical trials but at the same time human genetics indicate that a link between
amyloid precursor protein (APP) and proteolytic enzymes such as presenilin is very
strong indeed (Bagyinszky et al. 2014). This link is further strengthened by the
observation that three copies of APP as observed in Trisomy 21 have been linked with
early development of AD (Prasher et al. 1998). Interestingly, post-mortem analysis of AD
brain tissue showed altered metabolism of sphingolipids (van Echten-Deckert and Walter
2012), including increased levels of the neurotoxic metabolite ceramide (Filippov et al.
2012) as well as decreased levels of S1P (see also section 1.2.5 and (Couttas et al. 2014)).
The sphingosine analogue FTY720 is not only known to bind the S1P1R (section 1.3.3)
but also to inhibit ceramide synthase. Thus, beyond its ability to increase BDNF levels
(see below), this inhibitory activity on ceramide synthase is an additional reason to
consider FTY720 as a potential treatment option for AD (Berdyshev et al. 2009;
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Schiffmann et al. 2012). With regard to animal models of AD, a few studies have begun
to explore the potential of FTY720 to act as a neuroprotective agent in AD (Asle-Rousta
et al. 2013; Takasugi et al. 2013). In particular, Asle-Rousta and colleagues reported an
attenuation of the amyloid-β induced learning and memory impairment in rats as well as
protective effects of FTY720 on hippocampal neurons and inhibition of caspase-3
activation. Somewhat surprisingly, FTY720 was also shown to have a direct effect on
amyloid-β 40 and amyloid-β 42 production by an unknown S1P1R-independent
mechanism (Takasugi et al. 2013). Additionally, FTY720’s potential to increase BDNF
levels in the brain is increasingly appreciated (Doi et al. 2013; Fukumoto et al. 2014).
This is of considerable interest given a recent meta-analysis revealed decreased BDNF
levels in the blood of AD patients (Qin et al. 2016) and decreased levels of BDNF
transcripts in the pre-frontal cortex of patients in parallel with their cognitive decline
(Buchman et al. 2016). In cultures of cortical neurons FTY720 elicited its neuroprotective
effect in a BDNF-dependent manner. Bdnf mRNA, as well as protein levels were
increased after FTY720 exposure and attenuated amyloid-β toxicity (Doi et al. 2013). In
vivo, FTY720 has been shown to restore decreased BDNF levels proposed to play a major
role in the amelioration of amyloid-β induced memory impairment (Fukumoto et al.
2014).
Decreased BDNF levels have also been found in other neurodegenerative disorders
including HD (Zuccato and Cattaneo 2007). The loss of striatal and cortical neurons in
HD is caused by mutations in the HUNTINGTIN (HTT) gene, which then encodes for a
mutant huntingtin protein. Huntingtin has been suggested to contribute to BDNF
transcription in cortical neurons (Zuccato et al. 2001) and to facilitate the anterograde
transport of BDNF from the cortex to the striatum (Gauthier et al. 2004). Both functions
are compromised by mutations in the HTT gene leading to BDNF transport at reduced
levels from the cortex to the striatum, thus compromising the functions of these neurons
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(Ventimiglia et al. 1995). Due to its reported effects on BDNF levels (Deogracias et al.
2012), FTY720 was also tested in mouse models of HD and showed to increase life
expectancy of FTY720-treated mice (Di Pardo et al. 2014). The treatment was
accompanied by increased BDNF levels in the striatum as well as in the cortex, thus also
supporting the notion that newly synthesized BDNF is anterogradely transported from the
cortex to the striatum  (Di Pardo et al. 2014). Interestingly, lipid metabolism is also
disrupted in HD which may contribute to further increase the toxicity of mutated
huntingtin (Di Pardo et al. 2012). In line with the beneficial effects of FTY720 injections
in HD animal models, Di Pardo et al. also showed that the drug contributed to restore
lipid imbalance thus reducing the toxicity of mutated huntingtin (Di Pardo et al. 2014).
PD is a disease characterized by the loss of neurons in the substantia nigra and the
accumulation of Lewy Bodies consisting in large part of the presynaptic protein α-
synuclein as well as ubiquitin (Abeliovich and Gitler 2016). Alpha-synuclein has an
apolipoprotein-like structure (Clayton and George 1998) and while its physiological
function is poorly understood it is believed to play a role in various cellular functions,
ranging from neuroprotective actions to chaperone activities (Emamzadeh 2016).
Interestingly, α-synuclein has been identified as an antigen recognized by T cell receptors
in PD patients suggesting an autoimmune component in PD (Sulzer et al. 2017).
Misfolded α-synuclein forms aggregates that may cause neurotoxicity via a number of
different mechanisms including disrupted vesicular trafficking (Abeliovich and Gitler
2016). By contrast, the accumulation of ubiquitin may only represent an accompanying
pathology resulting from defective protein trafficking (Ciechanover 2005). Lewy Bodies
in the pathology of PD are found to be most abundant in neurons of the limbic as well as
motor system (Braak and Braak 2000). Association studies have also reported a
correlation between polymorphism of the BDNF gene and an increased risk of developing
PD (Liu et al. 2012). Also, in PD as well as HD, physical exercise, well known to increase
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BDNF levels in the CNS of rodents and in the blood of humans (see above) improves
clinical symptoms in patients and is used increasingly in the context of HD. Importantly,
exercise in mice prevents the decrease of BDNF in a mouse model of PD (Tuon et al.
2014). Interestingly, Lewy Bodies are not just found in the substantia nigra, but also in
the enteric nervous system causing decreased intestinal motility. Very recently, a mouse
model has been developed to replicate this pathology, and long-term treatment with
FTY720 increased gut levels of BDNF in these mice, improved gut motility and reduced
the aggregation of α-synuclein (Vidal-Martinez et al. 2016).
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1.4 BDNF
Neurotrophin family
The neurotrophin family consists of four different members in mammals and include the
founding member nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3) and
neurotrophin-4 (NT-4). They interact with Trk receptors, leading to their dimerization
and auto-phosphorylation of tyrosine residues (Kaplan et al. 1991; Barbacid 1995).
BDNF, the most abundant neurotrophin in the CNS binds and activates the TrkB receptor
(Barbacid 1994).
BDNF transcription and translation
In addition to the CNS, BDNF is known to be also expressed in several peripheral tissues,
including liver, lung, kidney, stomach, and bladder (Maisonpierre et al. 1990). In rodents,
the Bdnf gene encodes several transcripts from at least nine different tissue-specific
promoters (Figure 1.5 and (Aid et al. 2007). All Bdnf mRNA species direct the translation
of the same BDNF pre-pro-protein, with the exception of the transcripts including exon I
that add eight amino acids to the signal sequence and is believed to enhance the translation
efficiency of Bdnf (Koppel et al. 2015). Our group recently reported that in human and
rat, but not in mouse megakaryocytes, the expression pattern of the BDNF/Bdnf
transcripts is similar to the one found in neurons. Transcripts I and IV are found in
megakaryocytes, both known to be regulated by intracellular calcium levels (Figure 1.6
and 1.7 and (Aid et al. 2007; Chacon-Fernandez et al. 2016). In neurons, calcium entry is
activity-induced and regulated by L-voltage-gated calcium channels (L-VGCCs) and N-
methyl-D-aspartic acid (NMDA)-type glutamate receptors (NMDARs). This calcium
influx leads to the activation of calcium-responsive elements (CaRE) and thereby
regulates the activity-dependent transcription of Bdnf promoters (West et al. 2001).
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Figure 1.5 Mouse and rat Bdnf gene structure
The Bdnf gene in the mouse and rat consists of eight exons (I-VIII) on the 5’ end and one exon
(exon IX) on the 3’ end. The protein coding region is depicted in grey, the introns as fine lines
and the non-coding regions as coloured boxes. Every 5’ end exon can be spliced to exon IX which
has two different polyadenylation sites (poly A site). By initiating transcription in the intron
before the coding region the IXA transcripts containing a 5’ extended coding exon are generated.
Additionally, exon II has three different splice-donor sites (arrow A, B and C) and therefore three
different transcripts are known for this exon. Figure adapted from Aid et al. 2007 and Zheng et
al. 2012.
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One of the CaRE binding proteins is CREB which is of special interest as it is rapidly
phosphorylated following neuronal activation (Figure 1.6 and 1.7 and (West et al. 2001;
Chen et al. 2003; Zheng et al. 2011). CREB phosphorylation as well as activation of the
calcium responsive factor (CaRF) is further induced after the activation of the ERK
pathway, thereby regulating Bdnf transcription and its subsequent translation (Zheng et
al. 2012). Interestingly, it has been suggested that dependent on the mediation of calcium
influx by either L-VGCC or NMDAR, CaRF acts as an activator or repressor of Bdnf
exon IV transcription (Figure 1.7 and (Zheng et al. 2011; Lyons et al. 2016)). The primary
structure of pre-pro-neurotrophins including BDNF reveal the typical features of
secretory proteins and they are thought to be secreted into the endoplasmic reticulum
where pro-neurotrophins are N-glycosylated at a consensus sequence localized eight or
nine amino acids upstream of the furin-type cleavage site (Leibrock et al. 1989). In the
brain, BDNF is thought to be processed into its mature, biologically active form by a
recently identified endoprotease designated pro-protein convertase PC7 (Wetsel et al.
2013). The processing of endogenous pro-BDNF is a rapid process presumably assisted
by the chaperon function of its propeptide ensuring the correct formation of three
disulphide bridges leading to a structure designated “cysteine knot” shared by other
secretory proteins including transforming growth factor beta family members and
platelet-derived growth factor (McDonald and Hendrickson 1993). Regarding the
processing of pro-BDNF, pulse-chase experiments performed with cultured hippocampal
neurons revealed that it is rapidly converted into its mature form within the neurons
(Matsumoto et al. 2008). Like all neurotrophins, BDNF occurs in solution as a homodimer
as demonstrated by biochemical experiments as well as its crystal structure (Radziejewski
et al. 1992). Histochemical combined with biochemical studies suggest that the cleaved
BDNF pro-peptide is stored pre-synaptically in large dense core vesicles together with
mature BDNF (Dieni et al. 2012).
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Figure 1.6 Transcription factor regulating Bdnf I mRNA transcription by neuronal activity
Exon I and its transcription regulatory sites. Positions of cis-regulatory elements (CRE) are
depicted relative to the transcription initiation site (position 0). NMDARs and L-VGCCs mediates
transcription of Bdnf I mRNA through CREB activation. The upstream stimulatory factor 1
(USF1) and the subsequent binding to its binding element (USFBE) is only mediated through L-
VGCC. The continuous box of USFBE and CRE illustrates where their sequences overlap. Figure
adapted from Zheng et al. 2012.
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Figure 1.7 Activation of Bdnf IV mRNA transcription by neuronal activity in rodents
Exon IV and its transcription regulatory sites. Positions of cis-regulatory elements (CRE) are
depicted relative to the transcription initiation site (position 0). Transcription factors are
illustrated as pentagons if activated by Ca2+ influx through L-VGCC and circles if the activation
is NMDAR-dependent. Suppressors are depicted in red, activators in green and positive or
negative regulators in yellow. CaRE1-3 are found on the 5’ end of the exon IV. CaRF has been
shown to act as a repressor or activator of Bdnf transcription dependent on its mode of activation
(Zheng et al. 2012; Lyons et al. 2016).  The cis-elements E-box and NF-κB which regulate a
further transcription start, overlap on one base pair. NF-κB is needed for an intact NMDAR
response. It is suggested that it plays a role in Bdnf transcription, by regulating histone acetylation
(Federman et al. 2013), and DNA methylation (Lyons et al. 2016). Also, upregulation of the
nuclear factor of activated T cells (NFAT) increases NMDAR-dependent transcription of the exon
IV mRNA. Figure adapted from Zheng et al. 2012.
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BDNF signalling
Biochemical, physiological as well as histochemical data suggest that BDNF is released
from presynaptic terminals (but see (Harward et al. 2016)) to activate TrkB receptors
expressed both pre- as well as post-synaptically (Gartner et al. 2006; Dieni et al. 2012).
The TrkB receptor is a single transmembrane domain protein and dimerises upon binding
of mature BDNF (Chao 2003), phosphorylating tyrosine residues within the intracellular
kinase domain and activating downstream pathways, including ERK, PI3K, as well as
PLCγ pathway (Reichardt 2006). Presynaptic TrkB activation seems to enhance synaptic
transmission by activating the ERK pathway and increasing intracellular Ca2+ levels (Xu
et al. 2000), while post-synaptic activation of TrkB results in the phosphorylation of
voltage-gated potassium and sodium channels (Tucker and Fadool 2002; Ahn et al. 2007),
as well as NMDARs (Suen et al. 1997). BDNF thereby induces morphological changes,
including increased dendritic arborisation as well as cell body area, changes that are most
readily observed in inhibitory neurons (Ventimiglia et al. 1995; Marty et al. 1996;
Rauskolb et al. 2010). In neurons of the peripheral nervous system, BDNF is thought to
elicit its actions in cell bodies following the retrograde transport of the BDNF/TrkB
complex in endosomes (Ito and Enomoto 2016). In the central nervous system,
BDNF/TrkB signalling may occur primarily in dendrites following the presynaptic
release of BDNF from excitatory nerve terminals (Dieni et al. 2012). Prolonged exposure
of the receptor to its ligand BDNF decreased the expression of TrkB at the neuronal cell
surface leading to rapid desensitisation reflected by loss of TrkB phosphorylation
(Haapasalo et al. 2002). Interestingly, TrkB receptors can also be transactivated by
GPCRs such as the adenosine receptor, known to activate downstream pathways by
phosphorylating tyrosine residues on TrkB even in the absence of BDNF (Lee and Chao
2001; Lee et al. 2002; Swift et al. 2011). So far, no interaction have been reported between
the sphingosine receptors and TrkB, but further investigations are warranted following
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the observation that the NGF receptor TrkA is transactivated by the lysophosphatidic acid
1 (LPA1) receptor (Pyne et al. 2007), a receptor which as noted above shares around 30
% of its amino acid sequence with the S1P1R (Zhang et al. 1999). BDNF also binds to a
TrkB splice variant designated the truncated TrkB receptor. Its transmembrane, as well
as extracellular domain is identical to full-length TrkB, but it lacks the tyrosine kinase
residue (Klein et al. 1990). Upon binding of BDNF, truncated TrkB may form a
heterodimer with the full-length receptor thus exerting a dominant-negative inhibition by
blocking the ERK, PI3K, as well as PLCγ pathways. Additionally, truncated TrkB may
act to sequester BDNF to then trigger its internalization and degradation. In addition to
its binding to TrkB, BDNF has also long been known to bind to the neurotrophin receptor
p75NTR (Rodriguez-Tebar et al. 1990). This receptor is a member of the tumour necrosis
factor receptor family and often exerts biological effects that counteract those resulting
from TrkB activations, including the induction of programmed cell death (Roux et al.
1999; DeFreitas et al. 2001). Interestingly, pro-BDNF when released under pathological
conditions seems to bind to p75NTR with an affinity that is even higher than that of mature
BDNF (Taylor et al. 2012). However, pro-BDNF is not secreted under normal conditions
(Dieni et al. 2012), the only reports postulating the contrary were conducted in cells
overexpressing the protein, which presumably saturated the pro-BDNF processing
capacity (Nagappan et al. 2009; Yang et al. 2009).
Roles of BDNF in the nervous system
BDNF is perhaps best known for promoting the survival of peripheral sensory neuron –
indeed its ability to prevent the death of chick dorsal root ganglion neurons was used to
monitor its purification from brain tissue (Barde et al. 1982). While later studies revealed
that mouse dorsal root ganglion neurons are less responsive to BDNF than their chick
counterparts, gene targeting experiments revealed that the absence of BDNF leads to the
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loss of various cranial sensory neurons in the mouse (Ernfors et al. 1994). Bdnf-/- mice die
shortly after birth as a result of their inability to efficiently compete for milk with their
littermates due to lack of balance following the loss of essentially all vestibular neurons
(Ernfors et al. 1995). The loss of neurons in nodose and petrosal ganglia most likely also
contribute to the early death of the animals following an impaired ability to adequately
regulate blood pressure and oxygenation (Jones et al. 1994). While the pro-survival role
of BDNF is evident in the peripheral nervous system, this is not the case in the CNS as
the generation of a conditional mutation sparing the expression of BDNF in structures
essential for the survival of peripheral sensory neurons failed to reveal significant cell
losses in the CNS when the analyses were performed 2-month postnatal (Rauskolb et al.
2010). A slight decrease of total brain volume was detected, with the striatum being most
affected in terms of size reduction amongst the main brain regions. Random cell filling
indicated that striatal neurons are much smaller in BDNF-deprived animals, a reduction
of dendritic complexity including branching as well as the number of spines in dendrites.
In vitro experiments performed with the dissociated embryonic striatum revealed that
these neurons show a strong growth response to the addition of BDNF, whereby this was
not the case with neurons isolated from the embryonic hippocampus (Rauskolb et al.
2010). Further experiments suggest that in general, the growth promoting effects of
BDNF are more marked on inhibitory, GABA-ergic neurons including interneurons in
the developing cortex (unpublished results). Long-term more localised BDNF deprivation
experiments in the mouse did reveal that the lack of BDNF does eventually lead to
neuronal losses. Thus at 12 months the number of striatal neurons in mice carrying a
specific BDNF deletion in the cortex is significantly reduced compared to WT mice,
which is indicative of a long-term survival role of BDNF on striatal neurons (Baquet et
al. 2004). Furthermore, these mice also revealed a phenotype reminiscent of the one seen
in a mouse model of HD (Baquet et al. 2004). The importance of BDNF in the CNS
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especially during aging is shown by the decreased life expectancy of only 8 months in
mice with a deletion of BDNF in the entire CNS (Rauskolb et al. 2010). Additionally,
contrasting with the modest morphological effects of BDNF on hippocampal neurons (but
see (Harward et al. 2016)), BDNF has long been known to play a crucial role in functional
plasticity, including in particular long-term potentiation. In particular, animals lacking
even only one copy of Bdnf show reduced response in CA1 to high-frequency stimulation
of Schaffer collaterals (Korte et al. 1995). While there is general agreement that this is
best explained by a pre-synaptic release of BDNF, a recent study on structural plasticity
of spines in CA1 suggest that there may be a post-synaptic component as well, resulting
from the release of BDNF from spines (Harward et al. 2016). However, some of the key
experiments performed by Harward et al. involve over-expression of Bdnf constructs
targeting the protein to dendrites where it is not present under physiological conditions
(Dieni et al. 2012). In addition, the biological activity of Bdnf constructs fused with
reporters such as GFP remains to be convincingly demonstrated (Matsuda et al. 2009).
Irrespective of remaining uncertainties about the sites of release of BDNF, resulting from
the difficulties of working with proteins expressed at very low levels, it is known that
decreased levels are associated with behavioural deficits in learning and memory (Hall et
al. 2000; Heldt et al. 2007). Related to these findings in rodents, the discovery of a
nucleotide polymorphism in the BDNF gene in humans leading to an amino acid
replacement in pro-BDNF (valine for methionine) supports the notion that BDNF is
required for episodic memory (Egan et al. 2003). How an amino acid substitution in pro-
BDNF may affect its cell biology remains unclear though there have been suggestions
that the mutant protein may be released at lower levels (Egan et al., 2003). The so-called
Wilms tumour, Aniridia, Genitourinary anomalies, mental Retardation (WAGR)
syndrome also illustrates the role of BDNF in humans. This syndrome results from
deletions of various lengths on chromosome 11p13. All deletions including the BDNF
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gene cause cognitive impairments in heterozygotes (Han et al. 2013). In addition, patients
with BDNF haploinsufficiency have a higher incidence of childhood-onset obesity
compared to subjects with an intact BDNF gene (Gray et al. 2006; Han et al. 2008). In
line with this, animal experiments have revealed a crucial role for BDNF in the control
of food intake. BDNF released from the ventro-lateral hypothalamic nucleus is known to
have profound anti-orexic effects (Pelleymounter et al. 1995) and animals lacking one
Bdnf copy show progressive obesity as they age (Kernie et al. 2000).
With regard to diseases of the nervous system and neurodegeneration, BDNF has been
implicated in HD following suggestions that the mutant form of huntingtin may either
decrease BDNF transcription in cortical neurons and/or interfere with the anterograde
transport of the protein to the striatum (Zuccato et al. 2001; Gunawardena et al. 2003;
Strand et al. 2007; Liot et al. 2013). In AD, the possible role of BDNF is less clear beyond
observations that its serum levels may be decreased in patients and the levels of RNA
transcripts decrease in the pre-frontal cortex of individuals affected by the disease
(Nagahara et al. 2009; Laske et al. 2011; Qin et al. 2016). Beyond neurodegenerative
diseases, depression is one of the most discussed condition where BDNF is thought to
play an important role. Not only has been observed that animals lacking BDNF in the
CNS show dramatically reduced activity (Rauskolb et al. 2010), but also serum levels of
BDNF are decreased in depressed patients (Molendijk et al. 2014). The link between
depression and BDNF levels in humans takes its origin with work in rodents that has
indicated that BDNF injections into the brain exerts antidepressant effects followed by a
series of experiments indicating that blocking the activity of BDNF or reducing its activity
increases depressive symptoms in animal models (Lindholm and Castrén 2014).
Interestingly, antagonising BDNF’s effects has been suggested to block the actions of
drugs typically used to treat depression, themselves shown to increase Bdnf transcription
(Saarelainen et al. 2003). Importantly, BDNF has clear effects in supporting neurogenesis
 Chapter 1
36
in the adult brain and this is significant given reported anti-depressive effects of physical
exercise and numerous reports indicating that exercise increases neurogenesis and BDNF
levels in the brain (van Praag et al. 1999; Scharfman et al. 2005; Ernst et al. 2006;
Erickson et al. 2012; Szuhany et al. 2015). Indeed, the generation of new neurons has
been proposed to be a major component of the mode of action of antidepressants
(Santarelli et al. 2003). Regarding animal models of diseases affecting the function of the
developing nervous system, one of the best documented genetic link is with Rett
syndrome, a progressive neurodevelopmental disorder caused by a mutation in the
MeCP2 gene (Amir et al. 1999). Not only do Mecp2 mutant animals have reduced BDNF
levels in several brain areas (Chang et al. 2006; Deogracias et al. 2012), but also the
severity of the disease has been shown to be a function of BDNF levels. Thus, increasing
BDNF levels by overexpressing it in the forebrain retards the development of symptoms
in animals lacking MeCP2 (Chang et al., 2006). These results encouraged our laboratory
to inject FTY720 into animals lacking Mecp2 following the realisation that this drug
increases BDNF levels (Deogracias et al. 2012). It turned out that FTY720 injections not
only increase BDNF levels in animals lacking Mecp2 but also that the drug markedly
improves the locomotor symptoms of mutant animals and counteracts the effects of the
Mecp2 deletion on structures such as the striatum (Deogracias et al. 2012). These results
are the foundation of the present work as major questions regarding the mode of action
of FTY720 in the brain remain unresolved.
1.5 Aims and Hypothesis
The main goal of this PhD project was to understand the mechanisms of action of FTY720
on neurons. The key hypothesis was that FTY720 acts through the S1P1R. Accordingly,
a major aim was to establish a system allowing to test the hypothesis using a previously
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published protocol which allows the generation of excitatory, BDNF-expressing neurons
from either wild-type or S1p1r-/- ES cells. The following aims were formulated:
1. Generation and characterisation of S1p1r-/- ES cell-derived neurons
2. Investigation of the effects of FTY720 on BDNF levels in WT and S1p1r-/- ES
cell-derived neurons in vitro
3. Delineating the pathways activated by FTY720 in WT and S1p1r-/- ES cell-
derived neurons in vitro
4. Validate the in vitro findings in vivo with WT and conditional S1p1r-/- mice
38
Materials and Methods
2.1 Animal Husbandry
Mice were kept and handled according to the Animal Scientific Procedures Act (ASPA,
Home Office 1986). They were held under a 10/14 h light cycle and received food and
water ad libitum. Mice were weaned at four weeks and up to five mice were kept per cage.
2.2 Generation of the Mouse Line S1p1r loxP/loxP/CreERT2
A mouse line carrying the S1p1r gene, where exon 2 of the S1p1r gene is flanked by two
loxP sites (B6.129S6(FVB)-S1pr1tm2.1Rlp/J), was obtained from Jackson Laboratory
(Bar Harbor, ME, USA). This allows the removal of S1P1R conditionally (Figure 2.1A
and 3.1). These mice were maintained on a C57BL/6J background (Jackson Laboratory).
In order to generate a line, where the S1p1r gene can be conditionally removed in neurons
only, the mouse line mentioned above was crossed with the STOCK Tg(Thy-1- CreERT2,
-EYFP)HGfng/PyngJ mouse line (Jackson Laboratories) and maintained on a mixed
CD1;C57BL/6J background (Jackson Laboratory). This line expresses a construct
containing two copies of an altered mouse Thy-1 promoter preceding either the transgene
for the expression of the CreERT2 recombinase or the enhanced yellow fluorescent protein
(EYFP) (Figure 2.1B). Both copies of the Thy-1 promoter are needed to allow the
expression of CreERT2 recombinase and EYFP in the same neuron, as one copy drives the
expression of CreERT2 fusion gene, while the other drives the expression of the EYFP
sequence (Young et al. 2008). In the CNS, Thy-1 is only expressed by neurons. No
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expression can be detected in oligodendrocytes, astrocytes, or non-neuronal cells (Gordon
et al. 1987; Kollias et al. 1987). The CreERT2 stands for a Cre recombinase fused to a triple
mutation of the human estrogen receptor ligand binding domain. This inhibits the binding
of the endogenous estrogen to the receptor, but allows binding of 4-hydroxytamoxifen (4-
OHT), the metabolite of tamoxifen. After binding of 4-OHT the Cre recombinase will be
transported from the cytoplasm into the nucleus, where it will excise the genes flanked
by two loxP sites (Figure 3.1). This mouse line is also widely known under the name of
“single-neuron labelling inducible Cre-mediated knockout”, short SLICK. There are a
variety of different mouse lines, referred to as SLICK-3, -A, -H, -I, -P, -V and –X.
Characteristic for these lines is the expression of the transgene in limited number of
neurons within certain neuronal populations. For example, the SLICK-V line mainly
expresses the transgene in hippocampal dentate granule cells. However, this is not the
case for the SLICK-H line, where a widespread neuronal expression of transgenes can be
found (Young et al. 2008). This is desirable for this project, as a general deletion of S1P1R
is required. Therefore, the generation of the new mouse lines was undertaken using the
SLICK-H mouse model.
The newly created lines (designated as S1p1rloxP/loxP/CreERT2) were bred until a line
carrying the CreERT2 gene and being homozygous for the floxed S1p1r gene was
established. Due to the random insertion of the Thy-1/CreERT2 construct, it was not
possible to determine whether the mouse carried two copies or just one copy of the
construct.
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Figure 2.1 Floxed S1p1r gene and construct for neuron-specific CreERT2 expression
A Exon 2 of the S1p1r gene is flanked by two loxP sites allowing the conditional deletion of
S1P1R as exon 2 contains the entire coding region of S1p1r. B This construct was used by Young
and colleagues to generate the SLICK-H mouse line. The two copies of the Thy-1 promoter allow
a comparable expression of EYFP and CreERT2 in the same cell and therefore enables the detection
of CreERT2 positive neurons using fluorescence. Figure adapted from (Young et al. 2008).
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2.3 Genotyping of Animals and ES Cells
2.3.1 DNA extraction
To genotype the animals, ear notches were obtained and processed on the same day. To
genotype ES cells, the cells were trypsinised and centrifuged, and the pellet either
processed immediately or stored at -20°C. For both animals and ES cells, the tissue/pellet
was resuspended in 500 μl deoxyribonucleic acid (DNA) extraction buffer (10 mM Tris-
HCL pH 8.0, 1 mM CaCl2, 100 mM NaCl, 0.5 % sodiumdodecylsulphate (SDS))
containing 0.5 μg/μl proteinase K. Proteinase K stock was prepared as a 20 mg/ml stock
solution in 50 mM Tris-HCL pH 8.0, 10 mM CaCl2 and 40 % glycerol. After incubation
overnight on a shaker at 50°C at 300 rpm, 500 μl phenol-chloroform-isoamyl alcohol was
added and the mixture vortexed thoroughly for 30 sec and incubated on ice for 15 min.
Samples were centrifuged at 4°C at full speed for 30 min to separate the two phases. The
upper phase was collected and mixed with the same volume of isopropanol and 0.1 %
sodium acetate 3 M. Samples were incubated at -20°C for 1 h and centrifuged thereafter
at full speed and 4°C for 15 min. The supernatant was removed and the pellet washed
with 70 % ethanol by further centrifugation. The dry pellet was resuspended in 30 μl
ultrapure water and the DNA concentration was quantified using a BioSpectrometer®
(Eppendorf).
2.3.2 Polymerase Chain Reaction
For the polymerase chain reaction (PCR) of amplicons below 1000 bp the following mix
was prepared (2.5 µl Standard Taq Buffer (New England Biolab) + 0.5 µl 10 mM of
deoxynucleotide (dNTP) mix (Promega) + 0.5 µl primer sense 10 µM (Table 2.1) + 0.5
µl primer antisense 10 µM (Table 2.1) + 0.12 µl Taq polymerase 5000 U/ml (cat.no.
M0273S, New England Biolab) + 100 ng cDNA + H2O ad 25 µl). For the long-range
PCR which was used to amplify PCR products above 1000 bp the following SequalPrep™
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Long Range PCR kit (Thermo Fisher Scientific) was used (2 µl Buffer + 2 µl Enhancer
A + 0.4 µl DMSO + 1 µl primer sense 10 µM + 1 µl primer antisense 10 µM (Table 2.1)
+ 0.36 µl Long polymerase + 100 ng cDNA + H2O ad 20 µl). If an internal control was
required additional primers were added to the same mixture as the probe analysed.
Internal control genes were used when no PCR product was expected, so that the
amplification of the internal control gene would confirm that the lack of product was due
to no template being present and not simply due to an inhibition or failure of the PCR
reaction. PCR inhibition can occur because of several reasons including for example
contamination by organic substances (Schrader et al. 2012). The PCR was performed
using the BIORAD T100 Thermal Cycler with the corresponding programme (Table 2.1).
The first step of the programme is used for the initial denaturation of the genomic DNA,
followed by the indicated cycles of step two to step four. Step two allows yet again the
separation of the two DNA strands after every synthesis. In step three the primers anneal
to the DNA and the temperature which is chosen in this step is primer-dependent. Finally,
during step four, which is typically at 72°C, the product between the two primers is
synthesised (Table 2.1). After the amplification process the PCR mixture was loaded onto
a 1.5 % (for detection of Thy-1/CreERT2, -EYFP, exon 2 and sex determination) or 3 %
(for detection of S1p1rloxP/loxP) agarose gel for electrophoresis and visualised by ethidium
bromide.
2.3.3 Genotyping of Thy-1/CreERT2, -EYFP transgene
If the mice/cells were carrying the Thy-1/CreERT2, -EYFP transgene a band at 300 bp was
detected (The Jackson Laboratory). At the same time a reaction for the internal control
was run. This reaction detected a band at 200 bp for the T-cell receptor delta constant
(Trdc-C) gene (Figure 2.2 and Table 2.1). If the transgene was absent, only a band for the
internal control was detected.
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Figure 2.2 Primer binding sites to Thy-1/CreERT2 transgene and internal control Trdc-C
A The sense primer is located in the Thy-1 promoter and is paired with the antisense primer having
its binding site in the EYFP gene. The expected size of the PCR product is 300 bp. B The Trdc-C
internal control gene was detected with the two primers depicted in the figure. The PCR using
these primers generated a product of 200 bp.
A
B
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2.3.4 Genotyping of S1p1rloxP/loxP transgene
To detect the loxP site on the 5’ end of exon 2 of the S1p1rloxP/loxP transgene the primer
pair #1 and #2 was used (Figure 2.3). This primer pair amplified a PCR product of
216 bp if the loxP site was not present (WT cells/mice) and 250 bp in the mutant
cells/mice carrying the loxP site. Therefore, in the case of a homozygous cell/mouse line
only the product of the mutant allele was detected at 250 bp (Figure 2.3).
To confirm the excision of exon 2 in S1p1rloxP/loxP cell lines the primer pair #1 and #3 was
used (Figure 2.3). The PCR reaction using these primers led to a specific product of
200 bp when exon 2 was excised. For this reaction, an internal control primer pair was
used, detecting a sequence of 275 bp in the Rosa26 locus (Figure 2.5). To confirm the
excision a further primer pair #1 and #5 was used. The binding site of primer #5 is located
on the 5’ end of exon 2. In the event of no excision, a product of 1462 bp was amplified
in WT mice/cells which was 34 bp longer in the mutant S1p1rloxP/loxP mice/cells due to
the loxP site at the 5’ end of exon 2 (Figure 2.3). After a successful excision of exon 2 no
product was amplified by the primer pair #1 and #5 as primer #5 lost its binding site and
the primer pair used for the internal control gene Trdc-C led to a product of 200 bp (Figure
2.3).
2.3.5 Genotyping for the X and Y chromosome gene Jarid1d
A primer pair detecting a sequence in the Jarid1d gene was used to determine the sex of
the ES cells isolated (Clapcote and Roder 2005). The PCR product detected on the X
chromosome was 331 bp long, which is longer than the 302 bp amplicon detected on the
Y chromosome (Figure 2.4).
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Figure 2.3 Illustration of the primer sites in the S1p1rloxP/loxP gene
Primer #1 and #2 were used to detect the loxP site at the 5’ end of exon 2. In WT mice, the
generated PCR product was 216 bp and due to the loxP site the product was expected at 250 bp
in mutant mice.
The primer pair #1 and #3 was used to detect the excision of exon 2. An amplicon of 200 bp was
detected in the event of a successful excision.
Primer #5 was designed to detect exon 2. The primer was combined with primer #1 to amplify a
PCR product of 1462 bp in WT mice and 1496 bp in mutant cell lines still carrying exon 2.
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Figure 2.4 Sex determination by PCR
The Jarid1d gene was used to determine the sex of the ES cells isolated. The intron between exon
9 and exon 10 of the Jarid1d gene is 29 bp longer (depicted in orange) on the X chromosome
compared to the Y chromosome. This allows for the generation of a 302 bp long product in male
ES cells (depicted in black) and 331 bp product in female ES cells (depicted in green). Figure
adapted from (Clapcote and Roder 2005).
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Table 2.1 Primers to genotype S1p1rloxP/loxP/CreERT2mouse line and ES cells
 S stands for sense; AS stands for antisense; Ø stands for control
Transgene Sequence 5’ to 3’ Programme
Thy-1-CreERT2, -EYFP
Primer S
Primer AS
Internal Ø Trdc-C S
Internal Ø Trdc-C AS
TCTGAGTGGCAAAGGACCTTAGG
CGCTGAACTTGTGGCCGTTTACG
CAAATGTTGCTTGTCTGGTG
GTCAGTCGAGTGCACAGTTT
1. 94°C 3min
2. 94°C 30sec
3. 60°C 1min
4. 72°C 1min
5. go to step 2 34x
6. 72°C 2min
7. 4°C ∞
loxP site at 5’ end of
S1p1r
Primer # 1 S
Primer # 2 AS
GAGCGGAGGAAGTTAAAAGTG
CCTCCTAAGAGATTGCAGCAA
1. 94°C 3min
2. 94°C 30sec
3. 55°C 30sec
4. 72°C 30sec
5. go to step 2 34x
6. 72°C 2min
7. 4°C ∞
Detection of exon 2
excision of S1p1r
Primer #3 AS
Internal Ø Rosa26 S
Internal Ø Rosa26 AS
GATCCTAAGGCAATGTCCTAGAATGGGACA
AAGGGAGCTGCAGTGGAGTA
GTCCCTCCAATTTTACACC
1. 94°C 3min
2. 94°C 30sec
3. 60°C 30sec
4. 72°C 15sec
5. go to step 2 34x
6. 72°C 2min
7. 4°C ∞
Detection of exon 2
excision of S1p1r
Primer #5 AS
Internal Ø Trdc-C S
Internal Ø Trdc-C AS
TAAGCCACGCCTGCTAATAGGTC
CAAATGTTGCTTGTCTGGTG
GTCAGTCGAGTGCACAGTTT
1. 94°C 3min
2. 94°C 30sec
3. 61°C 30sec
4. 72°C 90sec
5. go to step 2 34x
6. 72°C 5min
7. 4°C ∞
Sex determination
Primer S
Primer AS
CTGAAGCTTTTGGCTTTGAG
CCACTGCCAAATTCTTTGG
1. 94°C 5min
2. 94°C 30sec
3. 54°C 1min
4. 72°C 40sec
5. go to step 2 39x
6. 72°C 5min
7. 4°C ∞
Rosa26/CreERT2
Rosa26 S
Rosa26 AS
CreERT2 S
CreERT2 AS
AAGGGAGCTGCAGTGGAGTA
GTCCCTCCAATTTTACACC
GGTTATGCGGCGGATCCGAAAAGAAA
ACCCGGCAAAACAGGTAGTTATTCGGATCA
1. 94°C 5min
2. 94°C 30sec
3. 55°C 30sec
4. 72°C 30sec
5. go to step 2 34x
6. 72°C 5min
7. 4°C ∞
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2.4 Isolation of Mouse ES Cells from S1p1r loxP/loxP/CreERT2
Mice
A day before the mating took place, S1p1rloxP/loxP/CreERT2 female mice were exposed to
male’s pheromones by putting them in contact with male bedding material. This
procedure induces the natural oestrous cycle in females and no injections with the
hormone gonadotropin are needed.
The next day male and female mice were crossed overnight. Females carrying a plug were
sacrificed after two days and the oviducts were dissected and flushed using a mouth
pipette. Obtained embryos were cultured in 35 mm dishes containing different drops of
KSOM medium (cat.no. MR-020P-5D, Millipore) with 1 μM of the MEK inhibitor
PD0325901 (cat.no. 1408-B5, Axon Medchem) and 3 μM of the GSK3 inhibitor
Chir99021 (cat.no. 1386-B8, Axon Medchem). About four embryos were placed in each
drop. Drops were covered with mineral oil to avoid evaporation and were incubated at
37°C and a concentration of 7 % CO2.
After two days, the embryos were transferred into drops of N2B27 + 2i + LIF medium
(1 part Neurobasal + 1 part DMEM/F12 + 0.5% N2 supplement + 1% B27 supplement
without retinoic acid + 1% L-GlutaMAX™ + 50μM β-mercaptoethanol + 1μM
PD0325901+ 3μM Chir99021, and 100 Units/ml leukemia inhibitory factor (LIF) (~100
ng/ml LIF, cat.no. ESG1106, Millipore)) by using the mouth pipette, and after covering
with mineral oil incubated at 37°C and 7% CO2.
As soon as the embryos hatched by themselves (usually one or two days) the inner cell
mass was separated from the trophoblastic cells by following a previously described
protocol with few modifications (Solter and Knowles 1975; Batlle-Morera et al. 2008).
Embryos were placed into a drop of N2B27 containing 20% of rabbit anti-mouse serum
antibody (cat.no. M5774, Sigma) for 1 h. In case they did not hatch, they were placed for
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1-2 sec into a drop of acid tyrode solution, which removes the zona pellucida, followed
by two washing steps in phosphate buffered saline (PBS) and further anti-mouse serum
treatment.
Embryos were then subsequently transferred for 10 min to a drop of N2B27 containing
20 % of rat serum (produced in-house) as a source of the complement system, and after
that they were incubated for 1 h in a drop of fresh N2B27 for recovery. The treatment
with anti-mouse serum antibodies and subsequent rat serum is used to induce apoptosis
of the outer trophoblastic cell mass and to keep the cells of the inner cell mass alive at the
same time. This is enabled by the fact that the anti-mouse antibodies cannot reach the
inner cell mass due to a lack of penetration. The rat serum provides the complement
system to enhance the apoptotic process of anti-mouse antibody bearing cells. This
procedure facilitates the isolation of the inner cell mass without the need for microsurgical
procedures (Solter and Knowles 1975). During this time a 96-well plate was coated with
0.2 % gelatine. After 1 h incubation, it was possible to easily remove the trophectoderm
mechanically and each isolated epiblast was placed into a separate well of the gelatine-
coated 96-well plate with N2B27+2i+LIF medium.
The plate was incubated at 37°C and 7 % CO2 until colonies could be detected. At that
time the medium was changed every second day. As soon as the colonies were visible
they were trypsinised with 200 µl of 0.05 % trypsin for 5 min at 37°C. Trypsin treatment
was stopped by diluting it with N2B27+2i+LIF medium containing 10 % serum.
Resuspended cells were transferred into a gelatine-coated 24-well plate, containing
N2B27+2i+LIF and incubated for 2 h. As soon as the cells settled down, the medium was
replaced by N2B27+2i+LIF without any serum. From a 24-well plate, the cells were
subsequently passaged when they reached 80-90 % confluency. For these passages, the
cells were centrifuged after trypsinisation to get rid of the serum used for stopping the
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trypsin action. The ES cells were tested for mycoplasma using the ‘LookOut®
Mycoplasma PCR Detection Kit’ from Sigma (cat.no. MP0035) by following the
manufacturer’s instruction. Subsequently, the cells were frozen at -80°C in N2B27
containing 10 % fetal bovine serum (FBS) and 10 % DMSO.
During the expansion of the ES cells, DNA was extracted from the different clones as
indicated before and genotyped to determine the sex (section 2.3.5). The PCR primers
and protocol used are indicated in Table 2.1 and Figure 2.4.
  Chapter 2
51
2.5 ES Cell Lines used in the Study
2.5.1 J1 ES cell line
The WT J1 ES cell line (kindly provided from the Biozentrum, University of Basel,
Switzerland), was first described by the Jaenisch group in 1992 (Li et al. 1992) and has
been derived from a male agouti 129S4/SvJae (Stevens 1973; Simpson et al. 1997).
2.5.2 Rosa26/CreERT2 cell line
The Rosa26-CreERT2 mouse ES cell line (kindly provided by the research group of Meng
Li) was generated by targeted homologous recombination. E14Tg2a ES cells were
targeted with a vector containing 1 kb 5’ arm, a 4.3 kb loxP-puro-loxP-CreERT2-polyA
cassette and a 4 kb 3’ arm (Figure 2.5). Subsequently the Puro selection cassette (not
shown in Figure 2.5) was removed by transient transfection with a Cre expression
construct. The targeting event was screened by Southern Blot with external probes (not
shown). Genotype is verified by PCR using primers which are depicted by green arrows
for Rosa26 and red arrows for CreERT2 transgene (Table 2.1). Sal 1 represents the location
of the sequence recognised by the Sal 1 restriction enzyme (Dr. Xinsheng Nan, personal
communication).
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Figure 2.5 Rosa26/CreERT2 cell line
Figure shows map of the Rosa26/CreERT2 cell line which was provided by the research group of
Meng Li. Green arrows depict the location of the primers used to detect a 275 bp long amplicon
on the WT Rosa26 locus. The primers used for the detection of the CreERT2 transgene are shown
in red and amplify a 381 bp long PCR product. Figure adapted from Dr. Xinsheng Nan,
unpublished.
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2.6 Isolation of Mouse Embryonic Fibroblasts
A pregnant WT female mouse was culled 14 days’ post coitum. Embryos were harvested
and kept on ice in 1 x Hank’s Balanced Salt Solution (HBSS). Using dissection tools the
internal organs of the embryos were removed. The embryos’ cadavers were rinsed with
HBSS and trypsinised with 400 μl of 10 mg/ml trypsin (Worthington Biochem) in 3.6 ml
1 x HBSS (to reach an end concentration of 1 mg/ml trypsin) in a water bath of 37°C for
20 min. The tube was vortexed every 5 min during this step. The trypsinisation was
stopped by adding 1 mg/ml soybean trypsin inhibitor (Sigma) in 1 x HBSS. Suspension
was pipetted up and down with 1000 µl pipette, while DNAse (Roche) at a final
concentration of 0.05 mg/ml was added to the mixture. Tissue was left to settle down and
supernatant was passed through a 40 µm strainer (BD Falcon) before centrifugation at
1200 rpm for 10 min. Pellet was resuspended in cellular aggregates (CA) medium
(Dulbecco’s Modified Eagle Medium (DMEM) + 10 % FBS + 1 % L-GlutaMAX™ + 1
% non-essential amino acids (NEAA) + 0.00001 % ß-mercaptoethanol). MEFs were
counted using a NucleoCounter® NC-100™ (Chemometec) and 1x106 cells were cultured
on a 100 mm diameter Petri dish coated with 0.2 % gelatine (Sigma). As soon as the cells
reached confluency they were passaged again. Before storage in liquid nitrogen in CA
medium + 10 % DMSO, the cells were tested for mycoplasma using the ‘LookOut®
Mycoplasma PCR Detection Kit’ from Sigma (cat.no. MP0035) by following the
manufacturer’s instruction.
2.7 MEF and ES Cell Culture
The MEFs were cultured on 60 mm Ø dish (Nunc) until they reached confluency.
Subsequently, the proliferation of MEFs was inhibited by 10 µg/ml Mitomycin C (Sigma)
in CA medium for 2 h. The medium was then removed and the MEFs were washed twice
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with PBS. CA medium was added and the cells were left in the incubator for at least 1 h
before the ES cells could be cultured on them. ES cells were cultured in ES cell medium
(DMEM + 15 % FBS + 1 % GlutaMAX™ + 1 % NEAA + 100 Units/ml leukemia
inhibitory factor (LIF) (~100 ng/ml LIF) + 0.00001 % ß-mercapto-ethanol) and were kept
on MEF until homogenous colonies were formed and cells proliferated at a high rate.
Typically, this required four to five passages on MEFs. Only then ES cells were cultured
on 0.2 % gelatine.
2.8 Electroporation
The principle of the electroporation is summarised in Figure 2.6. The ES cells which were
harvested from S1p1rloxP/loxP/CreERT2 mice were transfected with the Cre-IRES-GFP
plasmid (kindly provided by I. Martinez-Garay, (Martinez-Garay et al. 2016)) using the
Biosystems Microporator MP-100 with the Neon® Transfection System Kit (Thermo
Fisher Scientific). Three pulses of 1400 volts were applied for 10 ms. After transfection,
ES cells were plated onto 0.2 % gelatine dishes at various concentrations. Five days later
colonies were picked. Every colony was resuspended in 100 µl of 0.01 % trypsin and
0.01 % ethylenediaminetetraacetic acid solution (EDTA, Thermo Fisher Scientific) in
PBS in a well of a 96-well plate. After 3 min, trypsinisation was stopped by adding
100 µl of ES cell medium. The cell suspension was transferred to a well of a 12-well
plate, where inactivated MEFs were precultured (see above, section 2.7). The different
clones were expanded and subsequently genotyped (see above, section 2.3). For short-
term storage cell lines were kept at -80°C and subsequently moved to liquid nitrogen for
long-term storage. For the subcloning, cell line #43 was split 1:1000 and kept in culture
for 10 days. Medium was exchanged every second day. On day 10 colonies were picked
and same procedure was followed as elaborated above.
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Figure 2.6 Principle of electroporation and transient expression of Cre-IRES-GFP plasmid
Cre-IRES-GFP plasmid is added to the cell suspension and an electrical pulse forms transient
gaps into the cell membrane which allows the plasmid to enter the cell. Once in the cytoplasm the
plasmid is translocated into the nucleus where it is transcribed followed by the subsequent
translation of the mRNA. The Cre expressing cells can be identified by the GFP signal (green).
The DNA of the plasmid is not integrated in the genome and its expression will therefore steadily
decrease.
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2.9 Differentiation of Mouse ES Cells into Neurons
The original protocol for the generation of glutamatergic-like neurons from mouse ES
cells was taken from Bibel and colleagues (Bibel et al. 2007). The protocol was optimised
by introducing minor changes which are elaborated in this paragraph. J1 ES cells were
cultured on MEF in ES cell medium. Multiple passages of the cells were conducted to
obtain high and synchronised proliferation. After reaching this point the cells were
cultured on gelatine-coated dishes for 3-4 passages to get rid of the remaining MEFs.
Subsequently, the ES cells were cultured on non-adherent plates in cellular CA medium,
allowing them to aggregate together. Every second day the medium was replaced. On day
four of culturing CAs, retinoic acid at a concentration of 5 μM was added to the cells. On
day eight of CA culture, the CAs were dissociated using 0.05 % trypsin from bovine
pancreas for 3 min at 37°C. Adding CA medium inactivated the trypsin and by pipetting
up and down they were dissociated entirely. At this point it was possible to halt the
protocol by freezing the CAs in 1 part ES cell medium and 1 part cryo medium (DMEM
+ 5% DMSO + 3.2% FBS). Otherwise the protocol continued by centrifuging and
resuspending them in commercial N2 medium (DMEM/F12 + 1 % NEAA + 1 % N2
supplement + 1 % Penicillin/Streptomycin (Pen/Strep) + 25 μg/ml Insulin + 1 mM L-
GlutaMAX™ + 50 µM ß-mercaptoethanol) or handmade N2 medium (50 % DMEM +
50 % F-12 + 2 mM GlutaMAX™ + 25 µg/ml Insulin + 50 µg/ml Transferrin + 20 nM
Progesterone + 100 nM Putrescine + 30 nM Sodium Selenite + 1 % Pen/Strep). The
neuronal progenitors were then plated on a 12-well plate at a density of 1 million cells
per well (2.85x105 cells/cm2) in 1.5 ml N2 medium per well. Plates were coated two days
in advance. A poly-ornithine stock solution of 0.5 mg/ml in borate buffer (150 mM
BH3O3, pH 8.3 adjusted with NaOH) was prepared and diluted 1:5 with ddH2O. Each
well was covered with 500 µl of the solution and left at 37 °C overnight. Plates were
incubated at 37 °C overnight. Two hours after plating, the medium was replaced
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completely, as well as after 24 h. On day 2 of the neuronal culture the medium was
replaced by complete medium (Figure 2.7 and as previously described in (Bibel et al.
2007)) with or without 5 µg/ml 5-Fluorodeoxyuridine (5-FdU). Treatment with 5 µg/ml
5-FdU was stopped after two days. The 1.5 ml complete medium per well was then again
completely changed on day 4, 8 and 12 and never again thereafter. On day 18, only 500
µl of fresh complete medium was added.
At the beginning, it was not possible to culture the S1p1rloxP/loxP/CreERT2 cell line on MEF,
with FBS containing medium. Therefore, these cells had to be cultured on gelatine-coated
dishes with the N2B27+2i+LIF medium. As soon as they were growing at a faster rate
they were transferred onto MEF coated dishes. The rest of the protocol remained
unchanged.
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Figure 2.7 Preparation of complete medium
A Once every 12 months a 100 x concentrated ingredients mix was prepared, which then was
stored in 5 ml aliquots at -80°C. B Complete medium was prepared fresh and was kept for up to
one month at 4°C. BSA, transferrin and insulin had to be weighed and dissolved in 30 ml before
the other ingredients were added. Immediately before use 2 nM L-GlutamaxTM was added to the
medium.
B
A
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2.10 Isolation of Primary Cortical Neurons
Mouse E16-16.5 embryos were harvested and brains isolated. During the entire procedure
the tissue was kept on ice-cold 1 x HBSS (Thermo Fisher Scientific). Cortices were
dissected and minced thoroughly with a scissor. To trypsinise the tissue, a stock solution
of 10 mg/ml trypsin (Worthington Biochem) was prepared in 1x HBSS just before use.
The tissue was distributed into 50 ml tube so that only tissue of six cortices was added to
one 50 ml Falcon tube in 9 ml of 1x HBSS. One ml of the trypsin stock solution was
added to get an end concentration of 1 mg/ml. Tissue was trypsinised for 20 min at 37 °C.
Every 5 min the solution was gently stirred to allow optimum exposure of the tissue to
the trypsin. Just before use a 10 mg/ml stock solution of trypsin inhibitor from soybean
(Sigma) was prepared and 1.1 ml was added to each 50 ml tube containing 10 ml of cell
suspension to reach an end concentration of approximately 1 mg/ml. The trypsin inhibitor
binds with high affinity to trypsin thereby blocking its active site (Blow et al. 1974). This
mixture was gently mixed and 100 μl of 1 mg/ml DNase (Roche) in H2O was added. After
mixing the cell suspension yet again it was passed through a strainer (BD Falcon) before
a centrifugation step for 10 min at 900 rpm. The supernatant was carefully removed and
the pellet was resuspended in primary culture medium (Figure 2.8 and (Chen et al. 2008)).
Cell number was counted using a NucleoCounter® NC-100™ (Chemometec) and primary
cortical neurons were plated at a density of 2.85 x105 cells/cm2. 12-well plates were
prepared the night before by coating each well with 500 μl of 0.5 mg/ml poly-L-lysine
(Sigma). Just before use, the wells were washed two times with H2O and dried. Cortical
neurons were cultured in 1 ml primary culture medium (Figure 2.8). Every third day until
9 DIV, 200 μl fresh medium was added per well.
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Figure 2.8 Preparation of primary culture medium
A The supplement NS21 was prepared as described by Chen et al. 2008 at a 100x concentration
and stored at -20°C for up to 12 months. The compounds in yellow must be prediluted in EtOH
to ensure their solubility at the concentration indicated in the column “stock solution”. B Primary
culture medium was prepared fresh by adding L-Glutamax at an end concentration of 0.5 mM, as
well as Pen/Strep and NS21 supplement to Neurobasal medium. Medium was kept at 4°C for up
to one month. Figure adapted from Chen et al. 2008.
B
A
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2.11 Treatment of Cultured Neurons
Stock solutions of 10 mM (Z)-4-OHT (Sigma) were diluted in ethanol (EtOH, cat.no.
02860, Sigma) and stored at -20°C. Before use, 4-OHT was diluted to a concentration of
0.1 mM in EtOH and 1.5 µl were added directly to the neurons which were in 1.5 ml
complete medium to get an end concentration of 0.1 µM. Control neurons were treated
with EtOH only.
Stock solutions of 1 mM pFTY720 (kindly provided by Novartis AG, Basel Switzerland)
were prepared by dissolving the powder in DMSO + 0.1 M HCl, aliquoted and stored at
-80°C. Dilutions were prepared with DMSO and kept at -20°C for maximum a week.
ES-cell derived neurons or primary cortical neurons were treated by adding pFTY720
directly to the neurons in a 1:1000 dilution (e.g. in 1.5 ml medium 1.5 µl of pFTY720
were added). Wells were immediately agitated to mix the DMSO well. For the long-term
treatment, fresh compound was added with fresh medium. In these cases, the pFTY720
dilution was prepared in a separate tube and directly added to the neurons during the
medium exchange. Long-term treatments started on day two and lasted for three weeks.
Fresh pFTY720 was added during each entire complete medium exchange (see above)
and again on day 18. However, on that day no entire complete medium exchange was
conducted, but 500 µl of medium containing pFTY720 in the relevant concentration was
added to each well.
For experiments including pre-treatment of J1 ES cell-derived neurons with monoclonal
anti-BDNF #9 (mAb#9, Developmental Studies Hybridoma Bank), neurons were
exposed to 10 μg/ml from 14 DIV until the end of treatment at 21 DIV. Monoclonal
Ab #9 (3 ng/ml) was directly added to the well in a dilution of 1:300. Treatment with
pFTY720 at 21 DIV was as described above.
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Stock solutions of potassium chloride (KCl) and sodium chloride (NaCl) were prepared
at a concentration of 3 M in DMEM. To get an end concentration of 60 mM the stock
solution was directly added to the neurons in a 1:500 dilution (e.g. to 1.5 ml medium
30 µl of 3 M KCl or NaCl solution were added). NaCl was used as a control to ensure
equimolarity of the solution.
2.12 Electrophysiology
Neuronal progenitors were cultured on 24-well Multiwell Micro Electrode Array (MEA)
plates (Multichannel System). Wells were coated as previously described (Bibel et al.
2007). At 14 DIV neuronal electrical activity was measured using the Multiwell-MEA
system. Measurements were taken over a period of 2 min. At each time point three
measurements were performed. During the recording cells were kept in a temperature
controlled chamber at 37 °C.
2.13 In vivo Experiments
For the in vivo experiments, only adult male mice of the age of 12 – 16 weeks were used.
Female mice were excluded of the study due to the treatment with an oestrogen receptor
modulator and the unknown consequences resulting of it in females. To activate the
CreERT2 recombinase, mice received an intraperitoneal (i.p). injection of 75 mg per kg
bodyweight (BW) of tamoxifen for five consecutive days. Corn oil was used as a vehicle.
Mice were left untreated for 7-12 days for the recombination to take place. Subsequently,
the consecutive treatment was started.
For the long-term treatment, mice were i.p. injected every fourth day in the course of one
month with either 0.1 mg FTY720 (Novartis) per kg BW or with vehicle saline. The
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experiment was terminated 24 h after the last injection. Mice were culled by a “schedule
1” procedure and brains were immediately harvested. To increase the reproducibility of
the dissection, the brains were cut into identical slices using a brain matrix (Acrylic Brain
Matrix Adult Mouse, World Precision Instruments; Figure 2.9). The different regions of
interest (cortex and hippocampus) were then isolated and snap frozen in liquid nitrogen.
The tissue was kept at -80°C until it was further processed (section 2.14 and 2.15).
For the 30 min treatment, every mouse was injected with either FTY720 (0.1 mg/kg BW)
or saline and placed into a new cage. Thirty minutes later, mice were culled using a
“schedule 1” procedure, brains were harvested and immediately snap frozen in liquid
nitrogen. They were stored at -80 °C. The different brain regions were dissected as
described above just before the lysis.
In vivo experiments were performed under UK Home Office approval according to the
Animal Scientific Procedures Act (ASPA, Home Office 1986).
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Figure 2.9 Coronal mouse brain sections obtained using a brain matrix
Brain sections were obtained using a brain mould. Section were 1.5 mm thick. Arrows indicate
the different brain regions, which were dissected (Scale bar 5 mm.):
1: caudate putamen and nucleus accumbens (Striatum)
2: prefrontal cortex
3: caudate putamen and nucleus accumbens (Striatum)
4, 6, 8: cortex
5, 7, 9: hippocampus
10: cerebellum
7 91
2 4 6 8 10
3
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2.14 RNA Isolation
2.14.1 ES cells and neurons
For RNA extraction from ES cells or neurons, cultures were washed with PBS and lysed
with 350 µl of RLT RNA lysis buffer (RNeasy Mini Kit, QIAGEN) containing 1 % β-
mercaptoethanol. Lysate was either immediately frozen at -80°C or processed with the
‘RNeasy Mini Kit’ (QIAGEN), following the manufacturer’s instructions and including
a DNase treatment for 15 min at room temperature.
2.14.2 Tissue
For RNA extraction from tissue TRIzol® reagent (Thermo Fisher Scientific) was used.
Briefly, tissues were mixed with 1 ml of reagent and cut into small pieces using scissors.
Samples were then sonicated and 200 µl of chloroform were added. After vortexing for
15 sec, an incubation step of 3 min at room temperature was performed. Samples were
centrifuged at maximum speed for 15 min at 4°C. The upper aqueous phase was removed
and 500 µl of isopropanol were added. The mixture was loaded into a RNeasy Mini Kit
(QIAGEN) column and the manufacturer’s instructions were followed.
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2.15 Protein Isolation
2.15.1 Neurons
Sample lysis for the detection of BDNF, pERK1/2 and pCREB by Western blot was
performed as follows. Neurons were washed twice with PBS. For a well of a 12-well plate
100µl of RIPA buffer (50 mM Tris base, 150 mM NaCl, 1 mM EDTA, 1 % Triton X-
100, 0.2 % sodium deoxycholate, 0.1 % SDS, adjust pH to 7.4 with HCl and inhibitors
(1 % phosphatase inhibitor cocktail 3 (Sigma), 1 % protease inhibitor cocktail (Sigma),
100 mM 6-aminohexanoic acid, 1.5 mM aprotinin, 1 mM dithiotreitol (DTT), 100 mM
1,10-phenanthroline, 1 mM phenylmethylsulfonyl fluoride (PMSF)) was used. Using a
cell scraper, the cells were detached from the dish and transferred into an Eppendorf tube.
Cell lysates were sonicated for 10 seconds at a pulse of 5 and 50 % amplitude if used for
BDNF Western blot, otherwise this step was omitted. Lysates were vortexed every 5 min
while they were kept on ice for 30 min. This was followed by a centrifugation step at 4°C
and 15,000 rpm for 10 min. Lysates were then transferred into a fresh Eppendorf tube,
protein concentrations were analysed (see below) and stored at -80°C.
Lysis of neurons for the analysis of Arc in Western blots was performed with the
following lysis buffer (50 mM Tris base, 150 mM NaCl, 1 mM EDTA, 1 % Igepal® CA-
630 (Sigma), adjust pH to 7.4 with HCl and phosphatase and protease inhibitors (see
above). This lysis buffer was found to facilitate the extraction of Arc and used on the
recommendations of Clive Bramham, an expert in the Arc field. The rest of the procedure
was identical.
For BDNF enzyme-linked immunosorbent assay (ELISA) quantification in neurons, cells
were lysed using RIPA buffer without SDS (50 mM Tris base, 150 mM NaCl, 1 mM
EDTA, 1 % Triton X-100, 0.2 % sodium deoxycholate, adjust pH to 7.4 with HCl),
followed by the lysis procedure stated above.
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To quantify protein the PierceTM BCA Assay Protein Kit for cell samples (cat.no. 23235,
Thermo Fisher Scientific) was used. The standard curve of the kit was adjusted to be able
to analyse protein in cell lysates (Figure 2.10). Cell lysates were diluted 1:50 with ddH2O
and 100 µl of bicinchoninic acid (BCA) reagent was added to the samples as well as the
standard curve. Plate was incubated at 37°C for 30 min and the absorbance was analysed
at 562 nm using the plate reader (FLUOstar® Omega Microplate Reader).
2.15.2 Tissue
For Western blot analyses in tissue the exact amount of RIPA buffer with protease and
phosphatase inhibitors was determined by weighing the tissue. For every mg of tissue 1µl
of lysis buffer was added. Subsequently, the tissue was macerated by drawing it with a
1 ml syringe attached to a 25-gauge needle. After homogenization of the tissue, the
samples were kept on ice for 30 min and vortexed every 5 min, centrifuged at 4°C and
15,000 rpm for 30 min. Lysates were then transferred into a fresh Eppendorf tube and
centrifuged again at the same settings for 10 min to get rid of any tissue residues. After
transferring the lysates into fresh tubes, they were kept at -80°C. After thawing and before
using the samples in the ELISA, they were centrifuged at 4°C and 15,000rpm for 30 min.
Protein was quantified using the PierceTM BCA Protein Assay Kit (Thermo Fisher
Scientific) according to the manufacturer’s instruction.
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Figure 2.10 Standard curve for protein quantification in cell lysates
Standard A was prepared by diluting the 2 mg/ml stock bovine serum albumin (BSA, Sigma)
solution with water. Subsequently, a dilution series was performed. Standard I is the blank and
therefore only contains water. Concentration indicates the BSA concentration of each standard.
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2.16 Primary Rat Megakaryocytes
Two eight weeks old Wistar male rats were culled by a “schedule 1” procedure (Animals
(Scientific Procedures) Act 1986) and tibias as well as femurs were removed from the
hind limbs and placed in 1 x HBSS. Using a 25-gauge needle with a 5 ml syringe, bones
were flushed with CATCH buffer (4.6 mM sodium acetate, 1 mM adenosine,
1 mM theophylline, 5 % FBS, 1 x HBSS) until they were transparent. Cell suspension
was mixed and passed through a 40 µm strainer (BD Falcon) before it was centrifuged
for 5 min at 1800 rpm at 4°C.  The pellet was resuspended in hypotonic solution (H2O)
for 30 sec to lyse the red blood cells and 1.8 % NaCl solution was immediately added to
keep cells in an isotonic condition. The suspension was centrifuged again at 1800 rpm for
5 min at 4°C and resuspended in CATCH buffer before it was centrifuged for the third
and last time (as above). Pellet was resuspended in ‘megakaryocyte complete medium’
(IMDM (Thermo Fisher Scientific) + 5 % BSA + 2 mM GlutaMAX™ + 100 U/ml
Pen/Strep + 25 ng/ml rat thrombopoietin (TPO) + 25 mg/ml rat stem cell factor (SCF)
(both R&D Systems) and cells were distributed in nine non-adherent 100 mm Ø plates
(Greiner). Per plate 8 ml complete medium was used and cells were incubated at 37°C
and 4 % CO2. After two days in culture plates were changed and 2 ml fresh complete
medium was added per plate. After another four days in culture (six days in total) cells
were harvested and centrifuged (as above). Pellet was resuspended in 10 ml of PBS. For
the BSA gradient 2ml of 3 % BSA in PBS was added to a 15 ml Falcon conical tube.
Subsequently, 2 ml of 1.5 % BSA in PBS was slowly added to the tube ensuring that the
two phases did not mix. Finally, 2 ml of the cell suspension was slowly pipetted on top
of the gradient and again being careful not to mix the different phases. Tubes were kept
in a rack for up to 40 min to let the cells pass through the gradient. The upper 4 ml were
harvested and centrifuged (as above) and the pellet was resuspended in complete medium
and cultured for another two days. To the bottom phase 2 ml of PBS were added and the
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cell suspension was centrifuged (as above). The pellet was resuspended in CellGro®
SCGM (CellGenix) medium containing 100 U/ml Pen/Strep. Cells were equally
distributed in three 25 mm Ø dishes, each containing 2 ml of medium. Treatment was
immediately started by either adding 2 μl of 10 μM pFTY720 to reach an end
concentration of 10 nM or by adding 2 μl of DMSO as a vehicle control. Megakaryocytes
were harvested by centrifugation (as above), washed with PBS and subsequently lysed by
addition of RNA RLT lysis buffer containing 0.1 % β-mercaptoethanol from the RNeasy
Mini Kit (Qiagen). RNA extraction was followed according to the manufacturer’s
instruction. Primers used for the RT-qPCR are listed in Table 2.4 and 2.5.
2.17 ELISA
The principle of a two-site ELISA is elaborated in Figure 2.11. For the detection of BDNF
in ES cell-derived neurons a MaxiSorp white polystyrene 96-well plate (cat.no. 436110,
VWR) was coated with the monoclonal antibody anti-BDNF #1 (Ab #1, Developmental
Studies Hybridoma Bank). To each well 200 µl of 3 µg/ml Ab #1 diluted in coating buffer
(50 mM NaHCO3, 50 mM Na2CO3, pH 9.7) was added. After overnight incubation, the
plate was washed once with PBS and blocked for 2 h at 30°C with blocking solution
(4 % BSA in PBS). The plate was washed again just once with PBS and 150 µl of
incubation buffer (0.1 M KH2PO4, 0.1 M Na2HPO4, pH 7.6) were added to each well. The
standard curve was prepared using recombinant BDNF protein starting at a concentration
of 25 ng/ml, followed by eight subsequent 1:2 dilutions. Triplicates of 50 µl of standard,
blank or sample were added to each well. The samples were then incubated at room
temperature on a rotating platform. After 3 h the samples were removed and the wells
were washed five times with PBS. The secondary antibody anti-BDNF #9 conjugated
with horseradish peroxidase (HRP) (Ab #9-HRP, Developmental Studies Hybridoma
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Bank) using HRP-linkage kit (Thermo Fisher Scientific). was prepared at a concentration
of 1:4000 in incubation buffer containing 4 % BSA. To each well 200 µl of the mixture
was added and incubated for 3 h at room temperature. The wells were then washed five
times with PBS before 100 µl of developing solution (BM chemiluminescence ELISA
Substrate POD, cat.no. 11582950001, Roche) were added to each well. Luminescence
was measured using the plate reader (FLUOstar® Omega Microplate Reader).
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Figure 2.11 Principle of two-site ELISA
Two specific antibodies are used to detect and quantify BDNF. The first antibody (Ab #1)
attached to the surface of the well via covalent bonds. Lysate containing BDNF is then incubated
in the well and BDNF will therefore be immobilised. During subsequent washing steps unbound
BDNF is removed and the secondary antibody which is linked to the enzyme HRP (Ab #9-HRP)
detects the immobilised BDNF. After removal of any excessive Ab#9, the substrate, containing
hydrogen peroxide and luminol is added and the chemiluminescent reaction is started, which
results in oxidisation of luminol and subsequent light emission.
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2.18 Western Blot
Lysates were mixed with 1x lithium dodecyl sulphate (LDS) buffer (1 M Glycerol,
140 mM Tris Base, 106 mM Tris HCl, 0.5 mM EDTA, 0.22 mM Brilliant Blue G-250,
0.175 mM Phenol Red, 74 mM LDS, pH 8.5) and 50 mM DTT and boiled at 70ºC for 10
min. Subsequently they were loaded on a NuPAGETM NovexTM 4-12 % Bis-Tris gel
(Thermo Fisher Scientific) and run at 120 V for 90 min in 2-(N-
morpholino)ethanesulfonic acid (MES) running buffer (50 mM MES, 50 mM Tris base,
0.1% SDS, 1 mM EDTA, pH 7.3). Proteins were then transferred to a nitrocellulose
membrane, by applying 80 V for 1 h at 4°C, using the wet transfer technique. The gel and
the membrane were placed between two blotting papers and put in a cassette which was
completely immerged in transfer buffer (25mM Bicine, 25mM Bis-Tris, 1mM EDTA,
20% MeOH). Following transfer, the membrane was blocked using blocking solution for
at least 30 min. The blocking solution used for BDNF Western blots consisted of 3 %
Amersham ECL Prime blocking reagent (GE Healthcare) + 3 % BSA in TBS-T (24.7 mM
Tris base, 137 mM NaCl, 2.6 mM KCl, 0.1 % Tween-20, pH 7.5). For all the other
Western blots 5 % blotting-grade blocker (Bio-Rad) in TBS-T was used (Table 2.2). The
membrane was incubated at 4°C overnight with primary antibody diluted in blocking
solution (Table 2.2). The next morning the membrane was washed three times 15 min
with TBS-T, before it was incubated with an either HRP- or Alexa 647-conjugated
secondary antibody for 1 h at room temperature (Table 2.3). The membrane was washed
again three times 15 min in TBS-T. For development of the membrane LumiGLO®
ReserveChemiluminescent Substrate kit (seracare) was used. Membrane was covered
with 1 ml of substrate and incubated at room temperature for 1 min. The substrate was
removed and the signal was detected using the ChemiDoc™ MP system together with the
Image Lab™ software (Bio-Rad). This camera system allows the detection of
chemiluminescent and fluorescence signal and to control for saturation. Exposure times
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was adjusted to avoid saturation. For the analysis of the signal refer to section 2.19. After
development, the membrane was washed three times for 10 min with TBS-T and blocked
with blocking solution at 4°C for 30 min (Table 2.2), before primary antibody of the
internal control was incubated overnight at 4°C. The next morning the membrane was
washed three times for 15 min with TBS-T and secondary antibody of the internal control
was incubated for 1 h at room temperature. In the case of βIII-tubulin, the secondary
antibody was always conjugated to the Alexa-647 fluorophore. Membrane was washed
again three times 15 min with TBS-T and developed as above. If the Alexa-647
fluorophore was used the signal was detected by using red epi-illumination as the
excitation source and a 695/55 emission filter. Thereafter, the membrane was only
stripped if an incubation with another primary antibody apart from βIII-tubulin was
desirable. The membrane was stripped for 30 min with stripping buffer (Thermo Fisher
Scientific) and then washed three times for 15 min with TBS-T. Subsequently, standard
procedures like those specified above were followed. Finally, to control the loading with
a second method, all the protein on the membrane were stained with the Pierce™
Reversible Protein Stain Kit (Thermo Fisher Scientific). This was to verify that the
internal control was representative of the loading and not affected by subsequent
treatments. Then in the case of a total protein stain, one did not just control for one specific
protein but for all the detectable protein. The principle is similar to a Ponceau Red staining
with the advantage that the staining does not fade and pictures can be taken without the
loss of signal. The staining was not performed according to the manufacturer’s
instruction, as only 1 ml per membrane was used and the membrane was incubated for 5
min on the shaker. Subsequently, the membrane was washed three times for 5 min with
water and pictures were taken (Figure 2.12).
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Table 2.2 Primary antibodies used for Western blot applications
Antibody Type Dilution
End Conc.
Species Blocking
Solution
Distributor
anti-Arc  mAb 1:250
1 µg/ml
mouse 5 % Blotting
Grade
Blocker
BD Bioscience
cat.no. 612603
anti-β-actin pAb 1:5000
0.2 µg/ml
chicken 5 % Blotting
Grade
Blocker
Abcam
cat.no. ab13822
anti-βIII-tubulin  mAb 1:10000
0.1 µg/ml
mouse 5 % Blotting
Grade
Blocker
Biolegend
cat.no. 801202
anti-BDNF mAb 1:2000
0.5 µg/ml
mouse 3 % ECL
3 % BSA
Icosagen
cat.no. 3C11
anti-BDNF N-20 pAb 1:750
0.13
µg/ml
rabbit 3 % ECL
3 % BSA
Santa Cruz
cat.no. sc-546
anti-Cre mAb 1:1000 rabbit 5 % Blotting
Grade
Blocker
Cell Signaling
cat.no. 15036S
anti-GAPDH  pAb 1:5000
0.2 µg/ml
chicken 5 % Blotting
Grade
Blocker
Abcam
cat.no. ab83956
anti-pCREB
(Ser111)
mAb 1:1000
-
rabbit 5 % Blotting
Grade
Blocker
Cell Signaling
cat.no. 9198S
anti-pERK1/2
(Thr202/Tyr204)
mAb 1:10000
-
rabbit 5 % Blotting
Grade
Blocker
Cell Signaling
cat.no. 4370
anti-S1P1R pAb 1:500
2 µg/ml
rabbit 5 % Blotting
Grade
Blocker
Cayman
Chemicals
cat.no.
10005228
anti-S1P1R mAb 1:1000
-
mouse 5 % Blotting
Grade
Blocker
Millipore
cat.no. MABC94
anti-synaptophysin mAb 1:1000
10 µg/ml
mouse 5 % Blotting
Grade
Blocker
Sigma
cat.no. S5768
anti-GFAP mAb 1:1000
-
mouse 5 % Blotting
Grade
Blocker
Cell Signaling
cat.no. 3670S
anti-vGlut2 mAb 1:1000
1µg/ml
mouse 5 % Blotting
Grade
Blocker
Synaptic System
cat.no. 135421
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Table 2.3 Secondary antibodies used for Western blot applications
Antibody Dilution
End Conc.
Species Distributor
anti-mouse HRP 1:7500
0.13 µg/ml
goat Promega
cat.no. W4021
anti-rabbit HRP 1:7500
0.13 µg/ml
goat Promega
cat.no. W4011
anti-chicken HRP 1:7500
0.27 µg/ml
goat Abcam
cat.no. ab6877
anti-mouse Alexa 647 1:5000
0.4 µg/ml
donkey Thermo Fisher Scientific
cat.no. A31571
Figure 2.12 Pierce™ Reversible Protein staining
Illustration of a total protein staining using the Pierce Reversible Protein Stain kit. Four different
neuronal lysates were loaded and it is apparent that from lysate #4 less protein was loaded. In
such a case the lysates were reloaded and protein amounts were adjusted.
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2.19 Densitometric Analysis
Western blot data were quantified using ChemiDoc™ MP system together with the Image
Lab™ software (BioRad). Manually, a square was matched around each lane, making
sure that each band was surrounded (Figure 2.13A). With the help of the software the lane
was automatically detected. Next, each peak which was generated was analysed to make
sure that the lane was detected completely and that the area under the curve correlated to
the density of the band (Figure 2.13B). The software then subtracted the background and
calculated the area under the curve (AUC). This value was now used to compare the
intensity of the signal from the different groups. The AUC of the target of interest, was
divided by the AUC of the internal control. To determine changes in percentage versus
the control, each sample value was divided by the value obtained from the control
treatment (e.g. DMSO).
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Figure 2.13 Densitometric analysis of a BDNF Western blot
A BDNF Western blot analysed with secondary anti-mouse HRP. ImageLab™ Software was used
to detect bands on the Western blot. Blue squares were placed by hand and software then detected
the band automatically. B From these bands the software calculated the intensity of the signal and
blotted the intensity against the relative front (Rf). The software first substracted the background
and then specified the AUC, which corresponds to the entire intensity of the band specified as
volume. In this particular case the volume for lane 1 was 2,378,090, for lane 2 it was 1,092,366,
for lane 3 it was 392,898 and for lane 4 it was 190,124, corresponding to the decrease of signal.
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2.20 RT-qPCR
The real-time quantitative poly chain reaction (RT-qPCR) was performed to analyse the
relative expression of different genes. RNA was extracted as mentioned in section 2.14.
RNA was quantified using a BioSpectrometer® (Eppendorf), which apart from the
concentration of RNA also quantifies the 260/280 nm absorbance ratio. This value was
supposed to be in the range of 1.8 to 2.0 to be free of protein contamination. If this was
not the case the samples were discarded.  Between 500 ng – 1000 ng of total RNA were
reverse transcribed using the SuperScript® III reverse transcriptase (Thermo Fisher
Scientific). First, 1 mM of dNTP mix (Promega) and 0.025 µg/µl of Random Hexamer
Primers (Promega) were mixed with the RNA and diluted with ddH2O to a final volume
of 13 µl. The mixture was heated to 65°C for 5 min, while the master mix (4 µl 5x First-
Strand Buffer (Thermo Fisher Scientific) + 1 µl of 0.1 M DTT (Invitrogen) + 1 µl 20 –
40 U/µl RNasin® Ribonuclease Inhibitor (Promega) +1 µl 200 U/µl the SuperScript® III
reverse transcriptase) was prepared. The 7 µl of master mix were then added to the
RNA/dNTP/Random Primer mix and was incubated at 50°C for 2 h. Subsequently, the
reaction was inactivated by heating the mixture to 70°C for 15 min. The complementary
DNA (cDNA) was then either directly used for a qPCR or stored at -80°C. Primers were
either manually designed, using the primer design software
https://www.genscript.com/ssl-bin/app/primer with a subsequent analysis of the primers
using clone manager software (version 7) and a specificity test using the BLAST
homepage (https://blast.ncbi.nlm.nih.gov/Blast.cgi) or TaqMan® probes were acquired
from Thermo Fisher Scientific. Primers for the detection of S1pr mRNA in the rat
megakaryocytes were taken from a recent publication which looked at the expression of
S1pr in the rat dorsal root ganglia and sensory neurons (Kays et al. 2012). The manual
designed primers had to fulfil the following criteria: They had to be between 17-25 bp
long, have a GC content of minimum 55 – 65 % and a melting temperature around 60 –
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70°C. Although a genomic DNA digestion step with DNase enzyme was performed,
primers were still designed to span an intron sequence where applicable to avoid genomic
DNA amplification.
For each RT-qPCR between 25-50 ng of cDNA was used which corresponded 1.5-2.5 µl
of final reverse transcription mix. For each reaction on the 96-well plate, the same amount
of cDNA was used. For one sample of the FAST SYBR® Green RT-qPCR 12.5 μl FAST
SYBR® Green master mix (Thermo Fisher Scientific) + 0.625 μl of 10 µM oligo sense +
0.625 μl of 10 µM oligo antisense + 1.5 – 2.5 μl cDNA + H20 ad 25 μl were mixed. Each
reaction was prepared in triplicates in one tube, mixed well and distributed in a
MicroAmp® Fast Optical 96-well plate (Thermo Fisher Scientific). For each sample a
reaction for the internal control was performed at the same time (Table 2.4). For the PCR
reaction, the StepOnePlus™ Real-Time PCR system (Thermo Fisher Scientific) was used
with the following programme. In the first 10 min, the temperature was raised to 95°C,
the reaction then started by denaturation of the DNA at 95°C for 30 sec. The temperature
dropped to 57°C for 30 sec to allow the annealing of the probe and then increased again
to 70°C for 1 min to allow amplification. The last three steps were repeated for 39 times.
Subsequently, a melting curve was generated to identify if unspecific fluorescence signal
was detected as the SYBR® dye detects any double-stranded DNA. The melting curve
was generated by increasing the temperature slowly at a rate of 1°C per minute up to 99°C
to detect the fluorescence signal released by the now denatured products which
incorporated the fluorescent dye during the PCR reaction. The obtained values by the RT-
qPCR were analysed using Word Excel.
For a TaqMan® RT-qPCR the mix included 12.5μl FAST TaqMan® master mix (Thermo
Fisher Scientific) + 1.25 μl of TaqMan® primer/probe set (Thermo Fisher Scientific) +
1.5-2.5 μl cDNA + H2O ad 25 μl. For each sample, a reaction for the internal control was
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performed at the same time (Table 2.5). In the first 20 secs, the temperature was risen to
95°C, the reaction then started by denaturation of the DNA at 95°C for 1 sec. The
temperature dropped to 60°C for 20 secs to allow the annealing of the probe and to extend
the product. The last two steps were repeated for 39 times.
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Transgene Oligonucleotide Species Primer 5’ to 3’
Thy-1 sense
antisense mus musculus
CCAGAATCCAAGTCGGAACT
GGACACCTGCAAGACTGAGA
CreERT2 senseantisense mus musculus
TCCATATTGGCAGAACGAAA
CAGCTACACCAGAGACGGAA
vGlut1 senseantisense mus musculus
GGAGGAGCGCAAATACATTGAGG
CATAGACGGGCATGGACGTAAAG
vGlut2 senseantisense mus musculus
TGCAAAGCATCCTACCATTACAG
GCAGAAGTTGGCAACAATTATCG
Tbr1 senseantisense mus musculus
ACAACAAGGGAGCATCAAACAAC
TCTGTGCCATCCTCATTCACTTC
S1p1r senseantisense mus musculus
TCGCCGACAGCAGCAAGATG
AACCTCCGGGATGCTAGTGG
S1p2r senseantisense mus musculus
ACCGAGCACAGCCAACAGTC
GAGGTGGTCTCCTGCATGTC
S1p3r senseantisense mus musculus
GATGCGCCTTGCAGAACGAG
CCATGGCTTCCTAGAGACAG
S1p4r senseantisense mus musculus
TGGTGGTCTTCGCCCTCATC
TGAGTAGCCTGCGGGACTTG
S1p5r senseantisense mus musculus
TCTGGAGTGCCGGTTACAGG
GGAGCTTGCCGGTGTAGTTG
β-actin senseantisense mus musculus
CAATAGTGATGACCTGCCGT
AGAGGGAAATCGTGCGTGAC
S1p1r senseantisense rattus norvegicus
TTCAGCCTCCTTGCTATCGC
AGGATGAGGGAGATGACCCAG
S1p2r senseantisense rattus norvegicus
GACGCTGGACATGCAGGAG
TACATGGCTGAGTGGAACTTGC
S1p3r senseantisense rattus norvegicus
GCCACCCGCCAGTCTTG
GCCAGCTTCCCCACGTAAT
S1p4r senseantisense rattus norvegicus
CGTTTCCAGCATCCGCAG
CCAGTCCCTTCTCACCTCTCCT
S1p5r senseantisense rattus norvegicus
CCTATGTGCTCTTCTGCGTGCTG
CGCACCTGACAGTAAATCCTTG
Hprt senseantisense rattus norvegicus
GCAGACTTTGCTTTCCTTGG
TACTGGCCACATCAACAGGA
Table 2.4 Primers used for SYBR® Green RT-qPCR.
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Transgene Species Product Size Primer
Bdnf mus musculus 92 bp Mm04230607_s1
S1p1r mus musculus 133 bp Mm00514644_m1
Vegfd mus musculus 57 bp Mm01131929_m1
18s rRNA mus musculus 61 bp Mm03928990_g1
Bdnf rattus norvegicus 142 bp Rn02531967_s1
Gapdh rattus norvegicus 174 bp Rn01775763_g1
Table 2.5 Protocols and primer/probe sets used for TaqMan® RT-qPCR.
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2.21 Analysis of Ct values
The RT-PCR was repeated three times for each sample and the values from each reaction
were averaged. The RT-PCR data was analysed using the 2-ΔΔCt method (Schmittgen and
Livak 2008). The ΔCt values were calculated by subtracting the Ct values of the reference
gene from the gene of interest. When analysing the gene expression changes relative to a
calibrator, the ΔCt value of the calibrator was further subtracted from any other value to
obtain the ΔΔCt value for each condition. The calibrator was typically the untreated
control. The fold-change difference was calculated by converting the ΔΔCt to a linear
form using 2-ΔΔCt. In the absence of a calibrator the ΔCt values were compared to each
other by plotting the 2-ΔCt value, as this value represents the variation between samples
more accurately than the Ct values (Schmittgen and Livak 2008).
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2.22 Immunocytochemistry
Cells were cultured and differentiated as described earlier. They were cultured on glass
coverslips, which were pre-treated with pure nitric acid overnight and washed with
ultrapure water until neutral pH is attained. The water was removed and the coverslips
were washed in 1 M HCL at 40-50°C for 4 h. Coverslips were then washed again with
ultrapure water until neutral pH was attained, before washing them for 1 h with pure
ethanol. This was followed by drying the coverslips on a filter paper and autoclaving
them. The staining was performed according to a previously published protocol with
slight modifications (Ippolito and Eroglu 2010). In brief, cultured cells were washed with
PBS and fixed for 15 min with 4 % paraformaldehyde (PFA). The cells were then washed
three times with 0.1 % Triton X-100 in PBS (PBS-T) and blocked for 30 min with
blocking solution (50 % antibody buffer (150 mM NaCl, 50 mM Tris Base, 1 % BSA,
100 mM L-Lysine) + 50 % donkey serum containing 0.2 % Triton X-100). The primary
antibody (Table 2.6) was diluted in antibody solution (90 % antibody buffer + 10%
donkey serum). Cells were incubated with primary antibody overnight in a humidified
chamber at 4°C. Cells which were used for the no primary control were incubated with
antibody solution (see above) only. The next morning the cells were washed three time
for 10 min each with PBS-T. The secondary antibody (Table 2.7) was also diluted in
antibody solution (see above) and cells were incubated for 1 h in a dark chamber. Four
washes with PBS-T for 15 min each were carried out and nuclei were stained with 4',6-
diamidino-2-phenylindole dihydrochloride (DAPI) (cat.no. D9542, SIGMA) at a
concentration of 1:10,000 in PBS for 5 min. Cells were washed with ultrapure water and
coverslips were mounted with Dako mounting medium (Dako North America, USA). For
detection of S1P1R no Triton X-100 was used at any point to avoid permeabilization of
the membrane and all washing steps were performed with PBS only.
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Table 2.6 Primary antibodies used for immunocytochemistry
Table 2.7 Secondary antibodies used for immunocytochemistry
Antibody Type Dilution
End Conc.
Species Distributor
anti-S1P1R pAb 1:250
4 µg/ml
rabbit Cayman Chemicals
cat.no. 10005228
anti-Cre mAb 1:1000
-
rabbit Millipore
cat.no. ab5392
Antibody Dilution
End Conc.
Species Distributor
anti-rabbit Alexa 647 1:1000
2 µg/ml
donkey Thermo Fisher Scientific
cat.no. A31573
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2.23 Imaging
Images were acquired at 63x magnification using a confocal microscope (LSM 780, Carl
Zeiss) together with the ZEN Black software (version 2.0, Carl Zeiss).
2.24 Analysis
Image Lab™ software (BioRad) was used for densitometry analysis on Western blots.
MARS software (BMG labtech) was used to analyse the luminescence data from ELISA
measurements as well as data acquired from protein quantification assays.
The StepOne™ Software was used to analyse the Ct values obtained in the RT-qPCR.
ImageJ was used to perform colocalization analysis.
For further analyses Word Excel software was used.
2.25 Statistical Analysis
For statistical analysis GraphPad Prism software (version 7.02) was used. Only in cases
where a normality test had to be performed was SPSS software (version 23) consulted. If
only three independent experiments were undertaken a non-parametrical t test, also
known as Mann-Whitney test, was performed or when two or more groups were to be
compared a Kruskal-Wallis test was considered. If the Kruskal-Wallis test showed a
significant difference, the test was followed up by the Dunn’s multiple comparison post-
hoc test. Data from experiments which were repeated more than three times were analysed
for Gaussian distribution, via performing a Q-Q-Plot. When the z values of the skewness
and kurtosis (mean/standard deviation) was in the range of -1.96 and +1.96, the p value
of the Shapiro-Wilk test was greater than 0.05 and the Q-Q-Plot indicated normality, the
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data was considered normally distributed and an Unpaired t-test was performed or where
two or more groups were to be compared a One-way analysis of variance (ANOVA)
which was followed up by a Bonferroni post-hoc test if it showed a significant difference
was considered. Unless otherwise stated, the number n stands for the number of
independent experiments conducted.
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Generation and Characterisation of the S1p1r-/- ES
Cell Line B2
3.1 Introduction
Currently there is a high degree of uncertainty as to the distribution of the S1P1R in the
brain, not least because of the lack of reliable, specific antibodies and the limited cellular
resolution of in situ hybridisation in the CNS. While there is agreement that several
different cell types express the receptor, including vascular endothelial cells and
astrocytes based on work with transgenic animals the suggestion has been made that
neurons may not express S1P1R (Choi et al. 2011). This conclusion has been
subsequently challenged following the discovery that FTY720 increases BDNF levels in
the brain and the knowledge that neurons are the primary site of Bdnf expression in the
CNS (Deogracias et al. 2012). As the germline deletion of S1p1r causes early embryonic
death as blood vessels fail to develop normally an alternative is to generate genetically
modified embryonic stem (ES) cells and to differentiate them into neurons. Indeed,
protocols have been developed allowing the in vitro generation of highly enriched
populations of excitatory neurons (Bibel et al. 2004), which unlike inhibitory neurons,
express the Bdnf gene (Baquet et al. 2004). As detailed in “Materials and Methods” a new
mouse line S1p1rloxP/loxP/CreERT2 was generated by crossing mice carrying floxed S1p1r
alleles with animals expressing a tamoxifen-inducible form of Cre placed under the
control of a randomly inserted Thy-1 promoter (Figure 3.1). This strategy allows the
conditional excision of the S1p1r in neurons. Subsequently, ES cells were harvested from
the inner cell mass of S1p1rloxP/loxP/CreERT2 blastocysts to differentiate them into neurons.
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Figure 3.1 Scheme of S1p1r excision following 4-OHT addition
All cells of this mouse line carry two floxed S1p1r alleles as well as a randomly inserted
Thy-1/CreERT2 construct. After activation of the Cre recombinase with 4-hydroxytamoxifen
(4-OHT) exon 2 of the S1p1r can be excised from neurons.
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3.2 ES Cell Harvest
S1p1rloxP/loxP/CreERT2 mice were bred and female mice sacrificed after two days to harvest
the blastocysts (Materials and Methods, section 2.4). A total of eight blastocysts were
isolated and cells cultured either until the blastocysts spontaneously hatched or following
the manual removal of the zona pellucida. The “embryo proper” or epiblast was separated
from the trophectoderm and subsequently cultured in a 96-well plate (Figure 3.2). From
these eight blastocysts, eight epiblasts were cultured and four cell lines were viable, which
equals a success rate of 50 %. In female mouse, unlike human ES cells, both X
chromosomes are active and are therefore not suitable for their use in the differentiation
protocol. Typically mouse XX ES cells eventually die with time in culture as the process
of X inactivation cannot be readily recapitulated in vitro (Barakat and Gribnau 2010).
Male ES cells were selected by genotyping and the ES cell lines #1 - #4 used in
subsequent experiments (Figure 3.3). These cell lines were expanded until a high enough
number of cells could be obtained to allow their storage in liquid nitrogen. ES cells were
initially cultured using the N2B27 + 2i + LIF protocol introduced by Ying and colleagues,
a procedure that eased the isolation of ES cells from blastocysts (Ying et al. 2008). The
ES cell line #1 was kept in culture and was subsequently cultured on MEF (Figure 3.4)
and differentiated into neurons using the protocol from Bibel et al. 2007 (Materials and
Methods, section 2.9).
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Figure 3.2 Scheme of ES cells harvest
The bright field pictures illustrate early mouse embryos and the scale bar is 50 µm.
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Figure 3.3 Sex determination by PCR
Amplicons were separated by electrophoresis on a 1.5 % agarose gel labelled with ethidium
bromide. Genomic DNA isolated from S1p1rloxP/loxP/CreERT2 ES cell lines #1 - #4 were analysed.
Positive control samples (male (♂) and female (♀)) and negative control sample without DNA
(H2O) were used. 331 bp and 302 bp amplicons represent a sequence found on the X or Y
chromosome, respectively.
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Figure 3.4 Culture of ES cells
A ES cells cultured with the
N2B27 + 2i + LIF protocol
(Materials and Methods, section
2.4).
B ES cells of the mutant cell line
#1 after transfer from the N2B27
+ 2i + LIF system to the culture on
MEF with DMEM/FBS and LIF.
C ES cells from the WT ES cell
line J1 cultured on MEF.
Scale bar 100 µm
100 µm
100 µm
100 µm
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3.3 ES Cell-Derived Neurons
ES cells were cultured for at least four and for up to seven passages on MEFs. Multiple
passages markedly improved the quality of the differentiation procedure and greatly
helped generating homogeneous populations of ES cells by selecting the most rapidly
dividing cells (Bibel et al. 2007). This simple procedure turned out to select for
pluripotent cells as asymmetric cell division slows down the cell cycle. The last two
passages on MEFs were conducted with a lower number of MEFs, i.e. less than 1 x 106
cells were plated per 60-mm dish to decrease the number of MEFs as these interfere with
the formation of cellular aggregates. Subsequently, two rounds of passages onto gelatine-
coated dishes was found to be optimal for the complete elimination of MEFs from the
culture. Following dissociation of the cellular aggregates, neuronal progenitors were then
cultured in commercial N2 medium (Materials and Methods, section 2.9) which appeared
to improve the general quality of the neurons when compared to handmade N2 medium
as described by Bibel and colleagues (Figure 3.5, Materials and Methods section 2.9).
After two days, the cells were cultured in complete medium (Materials and Methods,
Figure 2.7). Other attempts with primary culture medium (Material and Methods, Figure
2.8) led to a high number of non-neuronal cells, as well as neuronal aggregation. Apart
from the medium, the density at which the neurons were cultured was also found to make
a significant difference regarding the quality of the cultures. While higher densities
improved the survival rate, they also markedly increased the degree of neuronal
aggregation that eventually compromised the long-term survival of the cultures. The
optimal cultures density was determined to be 2.85x105 cells per cm2.
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Figure 3.5 Neurons cultured with handmade and commercial N2 medium
Neuronal progenitors 1 DIV were cultured with handmade N2 (A and C) and
commercial N2 medium (B and D). When cultured with N2 commercial medium more
cells appeared to have a round neuronal like profile compared to cells cultured with
handmade N2 medium. Observations are from four independent experiments. Scale bar
50 μm.
A
C
B
D
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3.4 S1p1r Excision
3.4.1 Tamoxifen treatment
To excise S1P1R specifically on neurons, S1p1rloxP/loxP/CreERT2 ES cell-derived neurons,
referred to thereafter as #1 neurons, were treated with 4-OHT at different time points. In
parallel, Thy-1 as well as CreERT2 expression was analysed to identify potential optimal
time points of 4-OHT addition (Figure 3.6 and 3.7). ES cell-derived neurons were treated
overnight with 0.1 µM 4-OHT due to the results obtained from pilot experiments
indicating that concentrations above 0.1 µM 4-OHT were toxic for ES cell-derived
neurons. In addition, the quality and efficiency of 4-OHT was analysed using a control
cell line expressing CreERT2 under the control of the Rosa26 promoter expressed in ES
cells. Overnight exposure of these cells to 0.05 µM 4-OHT was shown to be effective to
induce Cre-mediated excision of a transgene flanked by two loxP sites in ES cells
(Appendix, Figure A.1).
As expected, Thy-1 mRNA levels increased with the maturation of the neurons. At 6 DIV,
following the start of differentiation, Thy-1 mRNA levels already reached a seven-fold
increase compared to 3 DIV and then increased further to reach significance at 13 DIV
with a 50-fold increase (* p (day 3 vs. day 13) < 0.05, Figure 3.6). In line with this, CreERT2
mRNA was detectable at 6 DIV though it was noted that unexpectedly, mRNA levels
failed to increase further with the maturation of the neurons (Figure 3.7A).
Unsurprisingly, CreERT2 mRNA levels did not change after exposure to 0.1 μM 4-OHT
(Figure 3.7B). The expression of the S1p1r gene was then determined in neurons treated
either with 4-OHT or the vehicle EtOH at 6 DIV, as well as 13 DIV (Figure 3.8). At both
time points excision of S1p1r could not be achieved. The possible reasons for the failure
of excision was investigated by looking at the nuclear translocation of CreERT2 after 4-
OHT treatment in #1 neurons via immunostaining.
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Figure 3.6 Thy-1 mRNA levels increased during the maturation of #1 neurons
At 3 DIV Thy-1 mRNA was detected in #1 neurons and its expression increased
significantly over the next 10 days (Kruskal-Wallis test followed by a Dunn’s multiple
comparison test, * p (day 3 vs. day 13) < 0.05, n = 3). Data are represented as mean of
2-ΔΔCt ± SEM.
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Figure 3.7 CreERT2 mRNA expression stayed constant after 6 DIV in #1 neurons
A CreERT2 mRNA was expressed in #1 neurons at 6 DIV. CreERT2 did not increase further
during the maturation of #1 neurons (Mann-Whitney test, p > 0.05, n = 6 repeats from 3
independent experiments). J1 ES cells served as a negative control. B At both time points
CreERT2 mRNA levels were unaffected by the 4-OHT treatment (Mann-Whitney test, p >
0.05, n = 3). Data are represented as mean of 2-ΔΔCt ± SEM. Ø: vehicle (EtOH) treated
cells.
B
A
  Chapter 3
101
Figure 3.8 4-OHT treatment unexpectedly failed to decrease S1p1r mRNA
expression in mutant #1 neurons.
#1 neurons were treated with 0.1 μM 4-OHT or vehicle overnight and lysed at the
indicated days. S1p1r mRNA levels were analysed using a TaqMan® RT-PCR assay.
S1p1r mRNA levels remained unchanged after tamoxifen treatment (Mann-Whitney
test, p > 0.05, n = 3). Data are represented as mean of 2-ΔΔCt ± SEM.
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3.4.2 CreERT2 immunostaining and Western blot
The possible reasons for the unsuccessful S1p1r excision in the #1 neurons was further
investigated. To identify if the 4-OHT treatment used would induce the expected nuclear
translocation of CreERT2, #1 neurons were treated with 0.1 μM 4-OHT or vehicle (EtOH)
overnight and an immunostaining was performed. In six days old #1 neurons a staining
for CreERT2 could be detected with its highest intensity found in the cytoplasm (Figure 3.9
and 3.10). However, no difference was detected when comparing the CreERT2 staining
intensity in the nucleus of 4-OHT and vehicle treated neurons (Figure 3.10). This is in
contrast to the obvious translocation seen in the ES cell line Rosa26/CreERT2 (Materials
and Methods, section 2.5.2), which was used as a positive control to validate the
immunostaining (Figure 3.11) and activity of 4-OHT (Figure 3.12). This indicates that
while 4-OHT was active, 4-OHT treatment did not activate nuclear translocation of
CreERT2 in #1 neurons 6 DIV. To investigate if treatment with 4-OHT would lead to
CreERT2 activation in more mature neurons the experiment was repeated in 14 days old #1
neurons (Figure 3.13). These neurons express higher levels of Thy-1 mRNA compared to
less mature neurons (Figure 3.6), and although the CreERT2 mRNA levels were similar in
six days old neurons compared to 13 days old neurons (Figure 3.7A), it was unclear if
CreERT2 protein levels would follow the same pattern. However, CreERT2 could not be
detected in cultures of #1 neurons 14 DIV (Figure 3.13), and the staining was similar to
that seen in the cell line used as a negative control, J1 (Figure 3.14).
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Figure 3.9 CreERT2 immunostaining in #1 neurons 6 DIV
#1 neurons 6 DIV were treated with 0.1 μM 4-OHT or vehicle overnight and fixed
thereafter. Cells were stained for CreERT2 (Alexa-647, red). Brightfield image illustrates
a single plane scan to facilitate identification of neurons. Nuclei were stained with
DAPI (blue). CreERT2 staining was mainly detected in the cytoplasm. Right panel shows
neurons stained with no primary antibody. Scale bar 20 μm.
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Figure 3.10 Colocalisation analysis of CreERT2 with DAPI in #1 neurons 6 DIV
#1 neurons 6 DIV were treated with A vehicle (EtOH) or B 0.1 μM 4-OHT overnight,
followed by an immunocytochemistry staining for CreERT2. Staining was analysed for
nuclear translocation of CreERT2 (Alexa-647, red). 4-OHT did not induce nuclear
translocation of CreERT2 as no colocalisation of the CreERT2 staining with DAPI could
be observed. Scale bar 10 μm.
B
A
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Figure 3.11 Positive control for CreERT2 immunostaining
Rosa26/CreERT2 ES cells were treated with 0.1 μM 4-OHT or vehicle overnight and
fixed thereafter. Cells were stained for CreERT2 (Alexa-647, red). Brightfield image
illustrates a single plane scan. Nuclei were stained with DAPI (blue). CreERT2 staining
was detected in the nucleus after 4-OHT treatment. Right panel shows neurons stained
with no primary antibody. Scale bar 20 μm.
  Chapter 3
106
Figure 3.12 Nuclear translocation of CreERT2 in Rosa26/CreERT2ES cells
Rosa26/CreERT2 cells were treated with A vehicle (EtOH) or B 0.1 μM 4-OHT
overnight, followed by immunocytochemistry staining for CreERT2. Staining was
analysed for nuclear translocation of CreERT2 (Alexa-647, red). 4-OHT induced nuclear
translocation of CreERT2 which is represented by the overlay of the DAPI and CreERT2
fluorescence signal in B compared to weak CreERT2 signal in the nucleus in A. Scale bar
10 μm.
B
A
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Figure 3.13 CreERT2 was not detectable in #1 neurons 14 DIV
#1 neurons 14 DIV were treated with vehicle (EtOH) or 0.1 μM 4-OHT overnight,
followed by immunocytochemistry staining for CreERT2. Cells were stained for CreERT2
(Alexa-647, red). To identify neuronal cells bodies a single plane brightfield image is
shown. Nuclei were stained with DAPI (blue). No staining for CreERT2 could be
detected. The signal obtained is close to the no primary control and is similar to the
staining found in the negative control cell line J1 (see below). Right panel shows
neurons stained with no primary antibody. Scale bar 20 μm.
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Figure 3.14 Negative control for CreERT2 immunostaining
J1 neurons 14 DIV were stained for CreERT2 (Alexa-647, red). A single plane brightfield
image is shown to identify neurons. Nuclei were stained with DAPI (blue). Only
background signal can be detected which is similar to that detected in #1 neurons
14 DIV. Right panel shows neurons stained with no primary antibody. Scale bar 20 μm.
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3.4.3 CreERT2 Western blot
A Western blot analysis was performed to verify CreERT2 expression. These experiments
were complicated by the very low expression levels of CreERT2 whereby surprisingly, it
seemed that 14 days old #1 neurons expressed even slightly lower levels of CreERT2
(Figure 3.15B). Additionally, #1 neurons clearly expressed less CreERT2 than the positive
control cell line Rosa26/CreERT2 where 4-OHT treatment led to a clear translocation of
CreERT2 (Figure 3.12) and induced successful target excision (Appendix, Figure A.1).
  Chapter 3
110
Figure 3.15 CreERT2 Western blot
Western blot for CreERT2 was performed. Rosa26/CreERT2 cell line served as a positive
control alongside J1 neurons and #1 ES cells as negative control. A While high levels
of CreERT2 could be readily detected in the Rosa26/CreERT2 lysates, barely detectable
levels could be observed in #1 lysates at 5 DIV that hardly seem to increase at 14 DIV.
Note that to ensure CreERT2 detection in these #1 lysates, comparatively higher levels of
proteins were loaded at 14 DIV B Quantification of the corresponding Western blot by
densitometry. It appears that the levels of CreERT2 expression seemed to even decrease
between 6 DIV and 14 DIV.
B
A
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3.4.4 Cre electroporation
Given the lack of detectable excision of the S1p1r gene following 4-OHT treatment, #1
ES cells were electroporated with a Cre-IRES-GFP plasmid to ease the detection of Cre
in transfected ES cells (Materials and Methods, section 2.8). Forty-eight clones were
picked between five and seven days after electroporation and cultured on a 24-well plate.
Eighteen turned out to be viable and were used for genotyping using primer #1 and #2
(Figure 3.16A). Primer #1 and #2 detect the loxP site at the 5’ end of exon 2 (Figure 3.16).
If the excision of exon 2 was successful, primer #2 will have lost its binding site and no
product will be amplified. In WT ES cells, no loxP site is in place and the exon 2 is still
present. Therefore, primer #1 and #2 will amplify a product of 216 bp (Materials and
Methods, section 2.3 and Figure 3.16). It is smaller than the band found in mutant ES
cells carrying the loxP site where a PCR product of 250 bp will be amplified (Figure
3.16A and B). In clone #43 and #46 a band of approximately 200 bp was amplified. The
signal was considerably weaker in clone #43. This band corresponded to the same one
detected in WT J1 ES cells (Figure 3.16B). As the mother cell of clone #43 and #46 was
a mutant cell carrying the loxP site it is not possible to detect a WT band even after the
excision. Therefore, this band can only be explained by the presence of WT MEF in the
culture at the time of genomic DNA extraction. Clone #48 represents a cell line where the
excision was not complete and the loxP site is still present (Figure 3.16B).
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Figure 3.16 Successful excision of exon 2 of the S1p1r in cell line #43 and #46
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Figure 3.16 Successful excision of exon 2 of the S1p1r in cell line #43 and #46
A Schematic of the binding sites of primer #1 and #2, as well as loxP sites on the S1p1r gene.
B Different clones were analysed using primer #1 and #2, which detect the loxP site at the 5’
end of the exon 2 and generates a product of 216 bp in WT cells and 250 bp in cells carrying
the loxP site. Note that in clone #43 and #46 a band of 200 bp was amplified, identical to the
band found in WT J1 ES cells. This suggests that the loxP site was successfully excised in
clone #43 and #46, but that genomic DNA contamination with MEF cell DNA was occurring.
In clone #48 a product of 250 bp is amplified, as the loxP site is still present.
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Another primer was used to further confirm the excision (Figure 3.17A). Primer #1 and
#3 flank the exon 2. Those primers were chosen to detect a product of 200 bp length
which will only be amplified if exon 2 was removed (Figure 3.17A). As expected in clone
#43 the amplicon of 200 bp is detected, which proved the excision of the exon 2 (Figure
3.17B). The genotyping results suggested that the excision of the S1p1r exon 2 was
successful in clone #43. However, a contamination of the clone with cells still carrying
the S1p1r is possible due to the nature of colony picking. If the number of ES cells still
expressing the S1p1r is low, the PCR may fail to detect it. Therefore, a subcloning
procedure was undertaken to ensure clone purity. This resulted in another 12 colonies
which were genotyped using the same techniques and clone B2 was chosen due to a clear
detection of the product generated with primer #1 and #3 at 200 bp (Figure 3.17B). This
PCR was performed with an internal control (Rosa26) generating an amplicon of 275 bp
to demonstrate that a lack of bands is not due to an inhibition of the PCR reaction (Figure
3.17B and Materials and Methods, section 2.3).
To further confirm the excision, another primer pair #1 and #5 was tested (Figure 3.18).
In the event of a successful excision, primer #5 would lose its binding site and no product
is expected in S1p1r-/- cell lines. Without an excision of exon 2 however, primer #1 and
#5 will amplify a PCR product of 1462 bp in WT cell lines and 1496 bp in cell lines
carrying the S1p1rloxP/loxP gene. Indeed, no product around 1400 bp was detected in cell
line #43 and B2 and the expected PCR products were amplified in the J1 and #1 cell line
(Figure 3.18B)
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Figure 3.17 Exon 2 was successfully removed in cell lines #43 and B2
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Figure 3.17 Exon 2 was successfully removed in cell lines #43 and B2
A Schematic of the binding sites of primer #1 and #3 as well as loxP sites on the S1p1r gene.
B The #43 clone was sub-cloned to generate clone B2. Genotyping with primer #1 and #3
detected a PCR product of 200 bp in cell line #43 and B2 which proves the excision of
exon 2. The amplicon detected at 275 bp reflects the amplification of the internal control
detecting the Rosa26 locus and demonstrates that the PCR reaction was not inhibited. The
 200 bp amplicons were extracted from the gel and sequenced (see below).
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Figure 3.18 PCR with primer #1 and #5 confirmed exon 2 excision in cell line B2 and #43
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Figure 3.18 PCR with primer #1 and #5 confirmed exon 2 excision in cell line B2 and #43
A Schematic representation of the binding sites of primer #1 and #5, as well as loxP sites on
the S1p1r gene. B PCR was performed with primers for the internal control Trdc-c. In the J1
cell line exon 2 was detected which is represented by the amplicon at 1462 bp. In the #1 cell
line the loxP site at position 19540 is detected with primer #1 and #5 and therefore a bigger
PCR product of 1496 bp was amplified. In cell line #43 and B2 only the amplicon for the
internal control at 200 bp was detected which confirms the excision of exon 2.
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The amplicons detected by the primer #1 and #3 in clone #43 and B2 (Figure 3.17C),
were sequenced to affirm the excision. The sequence of clone #43
(AGTATGTGTTTCTAGGATTAATGTACCTGAAGTTAAAACAAAGTGGCGTGC
TTCGTTATCGCTAGCGCTGCAGGATAACTTCGTATAATGTATGCTATACAAA
GTTATCTAGGCCGCCACCGCGGTGGAGCTCCATCTCCAGCCTCTAAGTTGTC
CCATTCTAGGACATTGCCTTAGGATCAAA) and B2 (CGTATGTGTTTCTGGAT
TAATGTACCTGAAGTTAAAACAAAGTGGCGTGCTTCGTTATCGCTAGCGCTG
CAGGATAACTTCGTATAATGTATGCTATACAAAA) matched part of the sequence
of the S1p1r gene and contained the loxP site at the 5’ end of exon 2 (Figure 3.19). These
results therefore confirmed the successful excision of exon 2 of the S1p1r gene in the #43
and B2 cell line.
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Figure 3.19 Alignment of the S1p1r sequence with PCR amplicon of #43 and B2 cell lines
Amplicons of the #43 and B2 cell line which were generated with primer pair #1 and #3 were
sequenced and aligned with the S1p1r sequence. Both sequences aligned from position 19473
shortly after primer #1 (highlighted in blue) until 19540 with the S1p1r sequence. At 19540
the full loxP sequence (highlighted in red) could be detected in cell line #43. Only part of it
was detected in the B2 cell line as the sequencing was aborted, shown by the polyadenylation
tail (highlighted in dark green). The sequence of #43 continued shortly before primer #3
(highlighted in purple) at position 23822 and ended with a polyadenylation tail (highlighted
in dark green) after primer #3. Part of the sequence of the 200 bp amplicon in #43 and B2 ES
cells therefore corresponded to the S1p1r gene and confirmed the excision of exon 2.
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3.4.5 Analysing S1p1r excision using Western blot
To explore whether the removal of S1p1r could also be documented at protein level,
Western blots were performed using two frequently used and commercially available
antibodies targeting S1P1R. Specifically, the membrane was first incubated with the
polyclonal antibody from Cayman Chemical (Figure 3.20), then stripped and incubated
with the monoclonal antibody from Millipore (Figure 3.21). The polyclonal antibody
revealed a main band of about 50 kDa expressed at similar levels in both WT and B2
neurons. The monoclonal antibody showed a single band of about
43 kDa with again similar intensity in B2 neurons (Figure 3.21). According to the
literature murine S1P1R is detected at around 47 kDa (Crousillac et al. 2009; Brizuela et
al. 2014; Efstathopoulos et al. 2015) or 37 kDa (Silva et al. 2017). Additionally, a range
between 35 kDa to 75 kDA has been reported when the S1P1R was tagged with a human
influenza hemagluttinin (HA) or Flag epitope and recognised by the corresponding
antibodies (Kohno et al. 2002; Shiow et al. 2006). This range can be explained by the
glycosylation of the receptor and other possible posttranslational modifications (Kohno
et al. 2002).
3.4.6 Analysing S1p1r excision using immunocytochemistry
Further analysis was performed using an immunocytochemistry staining with the same
polyclonal antibody from Cayman Chemical. In line with the data obtained in Western
blot, a signal for the S1P1R was detected in J1 as well as B2 neurons. The staining
intensity was similar in all neurons and lacked specificity, indicated by the ubiquitous
signal detection which was close to background levels (Figure 3.22 and 3.23).
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Figure 3.20 Polyclonal antibody detected S1P1R in both cell lines by Western blot
A Western blot representing S1P1R expression in J1 and B2 neurons between 2 and 21 DIV.
The polyclonal antibody from Cayman Chemical detected a protein around 50 kDa. 20 μg of
protein were loaded per lane. B Graph shows densitometric analysis. S1P1R expression was
similar in both cell lines (Kruskal-Wallis test, p > 0.05, n = 4). βIII-tubulin was used as internal
control. Graph represents values of the mean ± SEM.
A
B
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Figure 3.21 S1P1R detection by Western blot using a monoclonal antibody
A Western blot representing longitudinal S1P1R expression in J1 and B2 neurons between 2
and 21 DIV. The monoclonal antibody from Millipore detected a protein around 43 kDa.
20 μg of protein were loaded per lane. B Graph shows densitometric analysis. S1P1R
expression was similar in both cell lines (Kruskal-Wallis followed by a Dunn’s multiple
comparison, p > 0.05, n = 4). βIII-tubulin was used as internal control. Graph represents values
of the mean ± SEM.
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Figure 3.22 S1P1R antibody detected a weak signal in J1 neurons
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Figure 3.22 S1P1R antibody detected a weak signal in J1 neurons
J1 neurons 14 DIV were stained with anti-S1P1R (Alexa Fluor 647 – red). Brightfield picture
illustrates a single plane scan to allow identification of neurons. The rest of the images
illustrate maximum intensity projections. Nuclei were stained with DAPI. In J1 neurons a faint
staining for the S1P1R could be detected throughout the culture at the same intensity as high
background staining, indicative of a lack of antibody specificity. Right panel corresponds to a
control staining with no primary antibody. Scale bar 20 µm.
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Figure 3.23 S1P1R antibody detected unspecific signal in B2 neurons
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Figure 3.23 S1P1R antibody detected unspecific signal in B2 neurons
B2 neurons 14 DIV were stained with anti-S1P1R (Alexa Fluor 647 – red). Brightfield picture
illustrates a single plane scan to allow identification of neurons. The rest of the images
illustrate maximum intensity projections. Nuclei were stained with DAPI. In B2 neurons a
staining for S1P1R of a similar intensity to that found in J1 neurons was detected throughout
the culture. Right panel corresponds to a control staining with no primary antibody. Scale bar
20 µm.
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3.4.7 Analysing S1p1r excision using RT-qPCR
Next, the mRNA was extracted of 14 days old J1 and B2 neurons and analysed using a
TaqMan® RT-PCR Assay. These experiments revealed that no S1p1r mRNA could be
detected in the B2 S1p1r-/- cell line, further confirming receptor excision (Figure 3.24).
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Figure 3.24 RT-PCR confirmed the successful S1p1r excision in B2 neurons
No S1p1r expression was detected in the S1p1r-/- cell line B2. As a positive control WT J1 neurons
were used. Threshold cycle numbers are presented.
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3.5 Differentiation of B2 ES Cells into Neurons
In contrast to the differentiation of J1 ES cells, known to give rise to essentially pure
cultures of glutamatergic-like neurons (Bibel et al. 2004), the differentiation of the mutant
B2 ES cells while also generating neurons (see below), gave rise to large numbers of non-
neuronal cells alongside neurons. In addition, mutant B2 neurons did not survive for
longer than 12 DIV using the standard cell culture protocol, possibly as a result of being
outcompeted by the rapidly growing non-neuronal cell population (Figure 3.25 and 3.26).
To reduce the number of non-neuronal cells, the mitotic inhibitor 5-FdU was added to the
culture. To determine the best time point for, as well as duration of drug treatment,
different protocols were tested and it turned out that the addition of 5 µg/ml 5-FdU from
2 DIV to 4 DIV of the neuronal culture gave the best results.
Glial fibrillary acidic protein (GFAP), a widely used marker for astrocytes (Middeldorp
and Hol 2011), was used to demonstrate the successful reduction of GFAP-expressing
cells after 5-FdU treatment in the J1 and B2 cultures (Figure 3.27). Indeed, after 5-FdU
treatment GFAP was not detectable anymore by Western blot in J1 and B2 cultures
(Figure 3.27). GFAP levels were normalised to β-actin. The neuronal marker βIII-tubulin
could not be used as a loading control as its levels varied significantly between the
different conditions. Expression levels of βIII-tubulin were significantly reduced in
untreated B2 cultures compared to treated J1 neurons (*p (Ø B2 vs. 5-FdU J1) < 0.05,
Figure 3.27D). This also shows that 5-FdU selectively kills proliferating cells and as
neurons are post-mitotic this treatment should not and did not detectably affect them
under the conditions used here (Figure 3.27).
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Figure 3.25 Survival and purity of J1 neurons with and without 5-FdU treatment
J1 neurons treated with 5 µg/ml 5-FDU at 2 DIV (E – G) were not different with regard to
survival or apparent number of non-neuronal cells compared with untreated controls (A – D).
White scale bar 50 μm. Yellow scale bar 20 μm.
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Figure 3.26 Survival and purity of B2 neurons with and without 5-FdU treatment
The survival of B2 neurons was dramatically improved following the addition of 5 µg/ml 5-
FdU from 2 DIV – 4 DIV (compare D and G). At 12 DIV hardly any neurons are visible in
the untreated B2 culture (note the lack of neuronal processes in D). Arrows point to non-
neuronal cells (C and D). White scale bar 50 μm. Yellow scale bar 20 μm.
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Figure 3.27 5-FdU treatment depleted cultures of GFAP-expressing cells
D
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Figure 3.27 5-FdU treatment depleted cultures of GFAP-expressing cells
A Western blot reflects the expression of GFAP in 5-FdU treated and untreated J1 and B2
neurons. 20 μg of protein loaded per lane. B GFAP was no longer detectable in J1 and B2
neurons treated with 5-FdU. Levels were normalised to β-actin as C β-actin (Kruskal Wallis
test, p > 0.05, n = 3) were similar between conditions opposed to D βIII-tubulin. In untreated
B2 neurons βIII-tubulin levels were significantly reduced compared to 5-FdU treated J1
neurons (Kruskal Wallis test followed by Dunn’s multiple comparison, *p (Ø B2 vs. 5-FdU
J1) < 0.05, n = 3). Untreated samples are three different samples of one differentiation,
whereas treated samples are of three independent differentiations. All graphs represent
densitometric analysis. Data are represented as mean ± SEM. Ø: untreated cells.
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3.6 Characterisation of J1 and B2 Neurons
The differentiation of mouse ES cells into neurons using the protocol of Bibel and
colleagues is known to lead to the generation of excitatory neurons, as previously
established using antibodies to the glutamate vesicular transporters (Bibel et al. 2004;
Bibel et al. 2007) as well as other neuronal markers such as synaptophysin and the AMPA
receptor subunit GluR1 (Bibel et al. 2004).
3.6.1 Synaptophysin expression in J1 and B2 neurons
To test whether the excision of the S1P1R from ES cells would influence the
differentiation process, neuronal markers were used to monitor neuronal maturation in B2
neurons compared with J1 WT neurons. This is an important point as S1P1R has been
previously shown to be somehow involved in neurogenesis. Indeed, the receptor is
expressed in the mouse brain during embryogenesis and S1p1r-/- mice show severe cell
loss in the forebrain (McGiffert et al. 2002; Mizugishi et al. 2005). To investigate whether
maturation of WT and B2 mutant neurons would proceed similarly, the levels of the
synaptic protein synaptophysin were quantified by Western blot (Figure 3.28).
Synaptophysin expression levels followed a similar expression pattern in J1 and B2
neurons resulting in no statistically significant difference detected at any time point
measured (p > 0.05, Figure 3.28). Synaptophysin was not detectable in J1 and B2 cultures
before 10 DIV (Figure 3.28). These results suggest that S1P1R may not be required for
synaptophysin expression by excitatory neurons.
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Figure 3.28 J1 and B2 neurons matured at similar rates as assessed by synaptophysin expression
Synaptophysin levels were analysed in J1 and B2 neuronal cultures at different time points. A Western
blot for synaptophysin showed expression after 10 DIV and subsequent increase during maturation of
the neurons. 20 µg of protein were loaded per lane. B Graph represents densitometric analysis. Both
cultures expressed similar levels of synaptophysin (Kruskal-Wallis test followed by Dunn’s multiple
comparison test, p > 0.05, n = 3). Data was normalised to internal control βIII-tubulin. Graphs represent
values of the mean ± SEM.
A
B
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3.6.2 BDNF expression levels in J1 and B2 neurons
Given that a main goal of the project is to investigate the role of the S1P1R in the
regulation of BDNF levels by FTY720, it was essential to establish that BDNF is
detectable in B2 neurons. BDNF levels were barely detectable at early time points but
higher levels were detectable over time, in both J1 and B2 neurons (Figure 3.29). These
results suggest that the lack of S1P1R may not directly affect BDNF protein levels in ES
cell-derived neurons.
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Figure 3.29 BDNF expression levels were similar in J1 and B2 neurons
Longitudinal BDNF protein expression levels were investigated in J1 and B2 neurons
from 2 – 21 DIV. A Western blot represents BDNF expression in J1 and B2 neurons.
20 μg of protein were loaded per lane. BDNF levels were barely detectable before
10 DIV. B Graph represents densitometric analysis. No difference between the BDNF
expression in J1 and B2 neurons was detected at any time point during the maturation of
the neurons (Kruskal Wallis test followed by Dunn’s multiple comparison, p > 0.05, n =
3). Data was normalised to internal control βIII-tubulin. Graph represents values of the
mean ± SEM.
B
A
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3.6.3 vGlut1 and vGlut2 mRNA expression in J1 and B2 neurons
To further compare the maturation of J1 and B2 neurons, the expression of the vesicular
glutamate transporters 1 and 2 (vGlut1 and 2) were analysed using RT-qPCR. RNA was
extracted from two and 14 days old neurons and the levels of vGlut1 mRNA found to be
identical in both cultures, with no significant changes during neuronal maturation (Figure
3.30A). Likewise, the expression levels of vGlut2 mRNA were identical in J1 and B2
neurons. Levels of vGlut2 mRNA increased significantly during the maturation of the J1
neurons (2 DIV vs. 14 DIV: 51-fold increase) as well as B2 neurons (2 DIV vs. 14 DIV:
33-fold increase, Figure 3.30B).
3.6.4 vGlut2 protein expression in J1 and B2 neurons
To investigate if the mRNA levels reflect the expression levels of vGlut2 on protein levels
in J1 and B2 neurons a Western blot was performed. The analysis was focused on vGlut2
only as our group has previously shown that vGlut1 could not be reliably discriminated
from vGlut2 in Western blot and immunocytochemistry (Schrenk-Siemens et al. 2008).
Unexpectedly, vGlut2 protein levels were significantly higher expressed in B2 neurons
compared to J1 neurons (*p < 0.01) after 14 days in culture (Figure 3.31).
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Figure 3.30 vGlut1 and vGlut2 expression levels were similar in J1 and B2 neurons
Expression pattern of vGlut1 (One-way ANOVA, p (J1 vs. B2) > 0.05, n = 5) and vGlut2
(Kruskal Wallis test, p (J1 vs. B2) > 0.05, n = 5) mRNA was identical in J1 and B2
neurons at both time points. A vGlut1 expression stayed constant over the course of 14
days, whereas B vGlut2 expression increased during maturation of the neurons (Mann-
Whitney test, **p (2 days vs. 2 weeks) < 0.01, n = 5). Data is presented as 2-ΔCtx104.
Data was normalised to internal control β-actin. Graphs represent values of the mean ±
SEM.
B
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Figure 3.31  vGlut2 protein expression in J1 and B2 neurons after 14 days in culture
Protein levels of vGlut2 were analysed in 14 days old J1 and B2 neurons. A Western blot
represents vGlut2 expression in J1 and B2 neurons 14 DIV. 20 μg total protein were
loaded per lane. B Graph shows densitometric analysis. Levels of vGlut2 were expressed
at significantly higher levels in B2 compared to J1 neurons after 14 days in culture
(Unpaired t test, *p < 0.05, n = 5). Data was normalised to internal control βIII-tubulin.
Graph represents values of the mean ± SEM.
  Chapter 3
142
3.6.5 Tbr1 mRNA expression in J1 and B2 neurons
To explore a possible cortical identity of J1 and B2 neurons, expression levels of the T-
box brain gene 1 (Tbr1) mRNA were analysed by RT-qPCR. Tbr1 is one of the markers
expressed in the cortical pre-plate as well as in cortical layer VI (Hevner et al. 2001).
Both cell lines showed an identical expression pattern. Tbr1 levels varied considerably at
14 DIV in both cultures and no increase during the maturation of the neurons was
observed (Figure 3.32).
3.6.6 Expression pattern of S1p1 – 5 receptors in J1 and B2 neurons
To explore the possibility of compensatory increases in expression of other S1P receptors,
expression levels were analysed using RT-qPCR. As expected S1p1r mRNA levels were
significantly different between the two cell lines after two days in culture (*p < 0.05 (2
days B2 vs. 2 days J1)), as well as two weeks (***p < 0.001 (2 weeks B2 vs. 2 weeks J1)).
As a positive control sample cDNA from mouse hippocampus was used and resulted in a
2-ΔCtx104 value of 11. This is close to the levels found in J1 neurons after 14 days in
culture (2-ΔCx104 = 10.2). It was also observed that S1p1r expression increased during the
maturation of J1 neurons (**p < 0.01 (2 days J1 vs. 2 weeks J1)). No significant
differences were found between the two cell lines when comparing the mRNA levels of
the other four S1P receptors, apart from S1p3r (Figure 3.33). While high levels of S1p3r
mRNA were found in J1 and B2 neurons, there was a clear trend towards decreased
expression levels during the maturation of the B2 neurons. In the J1 and B2 neurons the
S1p3r mRNA was expressed at significantly higher levels than the S1p2r mRNA (*p <
0.05). In both cultures, no expression of the S1p4r and S1p5r mRNA could be detected
(Figure 3.33).
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Figure 3.32 Tbr1 mRNA levels were comparable between J1 and B2 neurons
Expression levels of Tbr1 mRNA were similar between J1 and B2 neurons (One-way ANOVA,
p > 0.05, n = 5). In both cultures no difference in Tbr1 levels was observed during neuronal
maturation at 14 DIV. Data is presented as 2-ΔCtx104. Data was normalised to internal control
β-actin. Values are mean ± SEM.
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Figure 3.33 S1p1 – 5 receptor mRNA levels in J1 and B2 neurons
While in general, no significant differences were found between the expression levels of S1p2-
5r mRNA levels in J1 and B2 neurons (Mann-Whitney test, p > 0.05, n = 3), B2 neurons showed
a burst of high expression of S1p3r mRNA after 2 DIV that came back to WT levels after two
weeks (Kruskal-Wallis test, *p (S1p2r vs. S1p3r) < 0.05). S1p1r mRNA expression was
significantly reduced in the B2 neurons at two days (Unpaired t-test, *p (S1p1r 2 days vs. 2
days) < 0.05, n = 4) as well as 2 weeks (Unpaired t-test, ***p (S1p1r 2 weeks vs. 2 weeks) <
0.001, n = 4) compared to J1 neurons. In J1 neurons a significant increase of S1p1r levels was
observed after 2 weeks compared to 2 days (Unpaired t-test, **p (S1p1r 2 days vs. 2 weeks) <
0.01, n = 4). Data is presented as 2-ΔCtx104. Data was normalised to internal control β-actin.
Values are mean ± SEM.
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3.7 Discussion
The focus of this Chapter was on the generation of ES cell-derived neurons lacking the
S1P1R. The initial attempt to directly excise the S1P1R from neurons via the addition of
tamoxifen failed (Figure 3.8), possibly because of the lack of significant nuclear
translocation of CreERT2 after tamoxifen addition (Figure 3.9 and 3.10). The activity of
tamoxifen was tested on control cells expressing CreERT2 under a different promoter and
led to the expected positive results (Figure 3.11 and 3.12, Appendix, Figure A.1).
Therefore, it appears likely that under the culture conditions used, the activity of the
Thy-1 promoter may be too low to drive the expression of significant levels of CreERT2 in
these neurons (Figure 3.9, 3.13 and 3.15). Thy-1 mRNA data suggested that expression
levels would increase during maturation of the neurons (Figure 3.6). Hence, it is unclear
why CreERT2 mRNA levels stayed unchanged between 6 DIV and 13 DIV (Figure 3.7A)
and why CreERT2 expression levels in 14 days old #1 neurons were below detection limits
in the immunostaining (Figure 3.13). What this study does not address and what should
be investigated in the future, is the proportion of CreERT2 expressing cells in #1 cultures.
Then the presence of cells not expressing Thy-1 and therefore CreERT2 could also
contribute to the S1p1r levels quantified. Then the genomic analysis of S1p1r expression
(Figure 3.8), does involve the entire population of cultured cells. In view of these results,
a different approach was followed, namely the excision of exon 2 following
electroporation of the S1p1rloxP/loxP/CreERT2 ES cells with a Cre-IRES-GFP plasmid. This
strategy led to a successful excision, as confirmed by genotyping, sequencing and RT-
qPCR analysis, resulting in the generation of ES cells designated B2 (Figure 3.16 - 3.19
and 3.24). Confirmation of S1P1R deletion at the protein level was not possible as due to
the lack of specific antibodies, as neither of the two antibodies tested could specifically
detect S1P1R (Figure 3.22 and 3.23). Whether or not the signals detected both before and
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after Cre-mediated excision correspond to other members of this family remains unclear
(Discussion, section 8.2).
A close examination of the cultures by phase-contrast revealed that a high number of non-
neuronal cells were present in the culture of B2 neurons (Figure 3.25), a conclusion
supported by GFAP Western blot analysis (Figure 3.27B). This Western blot showed that
after 5-FdU treatment GFAP was no longer detectable. Similar levels of GFAP were also
detected in J1 neuronal cultures not treated with 5-FdU (Figure 3.27B). The
differentiation protocol used in this study normally gives rise to a very high proportion of
glutamatergic neurons and only few ramified astrocytes detected by GFAP antibodies
(Bibel et al. 2004). It does seem however that certain unknown conditions and the absence
of mitotic inhibitors led to an increase of this proportion of cells, explaining the results
presented in Figure 3.27. Furthermore, it seems conceivable that the relatively high levels
of S1p3r mRNA detected in B2 neurons at 2 DIV may derive from an increased number
of dividing cells in B2 compared to J1 cultures (Figure 3.25 and 3.26). Indeed, a marked
reduction of S1p3r mRNA levels was observed between 2 days and 2 weeks following
5-FdU treatment (Figure 3.33). The detection of GFAP in Western blot suggests that a
proportion of these dividing cells are likely to be astrocytes (Figure 3.27). It has been
shown that astrocytes express high levels of S1P3R (Dusaban et al. 2017); the lower levels
of S1p3r mRNA in J1 neurons might be due to differences in GFAP-expressing cells
between single differentiations or because additional non-neuronal cell types might
contribute to the high levels of S1p3r mRNA in B2 neurons. This is a real possibility
given the near ubiquitous expression of S1P3R (Blaho and Hla 2014). This result should
be followed up by a detailed analysis of the cellular composition of the cultures via
immunocytochemistry, including cell-type specific markers for microglia (Bennett et al.
2016) and oligodendrocytes (Bronstein et al. 1997). The RT-PCR experiment also
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revealed that there was no long-term compensatory expression of any of the other
sphingosine receptors following S1P1R excision.
With regard to the maturation of the neurons generated from J1 and B2 ES cells, it is of
note that the levels of synaptophysin and BDNF showed a similar expression pattern
(Figure 3.28 and 3.29). This was expected as firstly, BDNF is known to be regulated by
neuronal activity (West et al. 2002) and secondly BDNF also enhances functional and
morphological maturation of synapses (Park and Poo 2013). To follow the neuronal
maturation of the J1 and B2 neurons more closely the analysis of a number of additional
maturation markers could be investigated as well as synaptic activity via functional assays
including calcium imaging and/or patch clamp recordings as previously practiced with
these cultures (Barth et al. 2014). Directly supporting the notion that the neurons
generated from both J1 and B2 cells are excitatory and therefore express the Bdnf gene
(Baquet et al. 2004 and Introduction), the levels of the glutamate transporters vGlut1 and
vGlut2 were measured and found to be similar (Figure 3.30). The higher expression of
vGlut2 at 14 DIV seen in both cell lines, is due to its localisation to synaptic vesicles
which is in line with the increased number of synapses represented by the synaptophysin
levels (Figure 3.28; (Fremeau Jr et al. 2001; Todd et al. 2003). Surprisingly, B2 neurons
expressed significantly higher levels of vGlut2 protein levels at 14 DIV compared to J1
neurons (Figure 3.31), for reasons that are unknown. As this difference had no measurable
impact on BDNF protein levels between J1 and B2 neurons (Figure 3.29), the functional
significance of this observation remains unclear at this point.
To better define if the neuronal subtypes differ between B2 and J1 neurons, additional
neuronal markers to Tbr1 could be used, such as the chicken ovalbumin upstream
promoter transcription factor-interacting protein 1 and 2 (Ctip1, Ctip2). Ctip2 is found to
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be primarily expressed in the intermediate zone of the developing mouse cerebral cortex
at E18.5, whereas Ctip1 is distributed throughout the cerebral cortex (Leid et al. 2004).
In summary, the excision of the S1P1 receptor in ES cells appeared to have been
successful, allowing the generation of neurons with some similar characteristics to those
generated from the wild-type J1 ES cells. In particular, the degree of BDNF expression
seemed to follow a developmental time course which was similar in both neuronal
cultures (Figure 3.29). However, further detailed analysis is needed to make a conclusion
on the role of the S1P1R in the differentiation of ES cell-derived neurons into
glutamatergic-like neurons and their maturation. Future experiments should also involve
the characterisation of a cell line of the same background as the B2 ES cells which still
express S1P1R, like #48 (Figure 3.16). This would help to understand if certain
differences observed between J1 and B2 neurons, for example the expression of vGlut2
protein at 14 DIV is due to the lack of S1P1R or solely due to background differences.
This could be followed up by RNA sequencing analysis in all three cell lines to clearly
define if there is any compensatory gene expression due to the excision of the S1p1r gene.
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Quantifying BDNF Protein Levels in ES Cell-Derived
Neurons
4.1 Introduction
The next objective was to establish a method allowing the reliable quantification of BDNF
in ES cell-derived neurons. In principle, immunoassays of solubilized material represent
the method of choice to quantify the levels of cytokines and growth factors. Indeed, so-
called two-site ELISAs based on the use of antibodies have already been extensively used
in the BDNF field, especially with human serum as documented in many publications
linking BDNF levels with various conditions such as depression (Introduction, section
1.1 and (Lee and Kim 2010; Buckley et al. 2011; Bathina and Das 2015). However, a
recent publication comparing six commercially available BDNF ELISAs indicated
surprising variations in the results obtained with these ELISAs used to measure BDNF
levels in the serum of over 30 volunteers, raising questions about the suitability of such
assays (Polacchini et al. 2015). Our laboratory developed specific, well-characterized
antibodies to BDNF (Kolbeck et al. 1999; Heyden et al. 2011; Deogracias et al. 2012) so
that a major source of variability could be minimised, namely the quality of the antibody
reagents and the coating of the ELISA plates. Nonetheless, initially it was unclear if this
ELISA would be sensitive enough to detect the low levels of BDNF in neurons derived
from ES cells. As detailed in the following, this turned out not to be the case whereby an
alternative possibility arose during the project with the introduction of the first
monoclonal antibody suitable for the detection of BDNF by Western blots.
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4.2 BDNF ELISA
4.2.1 ELISA measurement of lysates from ES cell-derived neurons
To validate the reproducibility of the BDNF ELISA protocol, BDNF levels of the same
sample were measured twice. Two different lysates of ES cell-derived neurons were
loaded onto different ELISA plates and both experiments performed independently of
each other. Surprisingly, BDNF content varied between the two measurements (Mann-
Whitney test, actual difference between medians (sample 1 #1 vs. sample 1 #2) = -1.89
and (sample 2 #1 vs. sample 2 #2 = -4.31), n = 3 technical repeats) (Figure 4.1).
4.2.2 Background values varied between wells of the ELISA plate
To investigate the cause of this unexpected variability between identical samples, a
BDNF ELISA was performed to determine background values potentially caused by the
lysis buffer used to extract the material from cultured neurons, but this time in the absence
of cell lysates. Surprisingly, high background levels were measured (yellow highlighted
in Figure 4.2) as well as alarming variations between different wells of the ELISA plate
(red numbers in Figure 4.2). These background values are highly relevant not just because
they are variable but also because they are too close (theoretically calculated to
correspond to about 18 pg BDNF per ELISA-well) to the real BDNF values expected
from neurons derived from ES cells, i.e. in the range of 20-30 pg/well.
  Chapter 4
151
Figure 4.1 Variability of BDNF concentrations determined by ELISA
The exact same triplicates were analysed twice by BDNF ELISA. The only difference
being the position of the samples on the 96-well plate. When re-tested, the different
samples show different BDNF protein levels (Mann-Whitney test, actual difference
between medians (sample 1 #1 vs. sample 1 #2) = -1.89 and (sample 2 #1 vs. sample 2
#2 = -4.31), n = 3 technical repeats). Values are presented as pg of BDNF per μg total
protein. Data is represented as mean ± SEM.
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Figure 4.2 Different wells on ELISA plate gave different background values
A Only lysis buffer was loaded into the 96 -well plate (yellow highlighted wells) and amounts
of recombinant BDNF used for the standard curve are represented in pg of protein per well
(blue highlighted wells). B Background values differed up to 13-fold depending on their
position on the 96-well plate (red values). Blue highlighted wells represent the standard curve
as measured in the ELISA in pg of BDNF per well.
A
B
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4.2.3 High background values are caused by the detergents
contained in the lysis buffer
To identify the specific components of the lysis buffer causing high background signals
in the BDNF ELISA, different buffers were tested (Figure 4.3). Triton X-100 as well as
sodium deoxycholate (SDO) are typically included in the buffer used to solubilize the
cells and both turn out to be responsible for the elevated background values (Figure 4.3).
Of these two detergents, Triton X-100 seems to explain most of the background signal
and even 0.1% was sufficient to interfere with BDNF measurements. Intriguingly, a
cellular lysate from mouse ES cells known not to express the BDNF protein also added
to the background levels. To exclude the possibility that an interaction between the
detergents and the buffer itself caused these high background values, the incubation buffer
already used in the ELISA was tested. This phosphate buffer has a neutral pH and does
not contain any detergents (Materials and Methods, section 2.17). While it did not
generate a high background by itself it did so upon the addition of Triton X-100 (Figure
4.3). Unfortunately, detergents turned out to be the only way to extract BDNF from the
cells and at the same time keeping it in solution. As in the absence of carrier protein or
detergents, BDNF is known to be adsorbed by the wall of plastic tubes and by pipette tips
due to its physico-chemical properties. To prevent this phenomenon, bovine serum
albumin (BSA) was also tested to prevent unspecific adsorption of BDNF, but this
addition did not solve the problem of elevated background (Figure 4.3). The unsuitability
of the standard BDNF ELISA for reliable measurements of the very low levels of BDNF
generated by neurons derived from ES cells was finally confirmed by the observation that
the expected proportionality of the signal was not obtained when testing the same samples
at different volumes of lysate (Figure 4.4).
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Figure 4.3 Detergents in the lysis buffer identified as a cause of high background values
Different types of lysis buffers were tested to identify changes in background values in the
ELISA. Triton X-100 containing buffers generated the highest background, which were
further increased when cell lysate was present in the sample. Values show the mean of two
measurements in pg of BDNF per ELISA-well.
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Figure 4.4 Lack of proportionality in the BDNF ELISA
The same neuronal lysates were analysed at two different concentrations with the
ELISA. When adding double the amount of lysate, only 12 % (sample #1) or 25 %
(sample #2), instead of 50 % more BDNF was quantified. Two independent lysates (#1
and #2) confirmed these results. Values are presented as pg of BDNF per μg total
protein.
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4.3 Detection of BDNF using Western blot
At the beginning of the project only BDNF polyclonal antibodies of variable quality were
accessible. These antibodies typically detect multiple bands and made a reliable, let alone
quantitative detection of BDNF difficult (Figure 4.5A). Fortunately, a new antibody
became available very recently (Materials and Methods, section 2.18), the first
monoclonal antibody allowing a specific and sensitive detection of BDNF on Western
blot. Importantly, this new antibody also allows the detection of pro-BDNF as the
sequence of mature BDNF (against which the antibody has been raised) is contained in
pro-BDNF (Figure 4.5A and B; (Leibrock et al. 1989)).
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Figure 4.5 Monoclonal antibody improved BDNF detection and quantification
A BDNF detection using the long available polyclonal N-20 anti-BDNF antiserum
from Santa Cruz. Note the multiple unspecific bands, including the area where pro-
BDNF can be expected. B BDNF detection using the newly available BDNF
monoclonal antibody 3C11 from Icosagen. Recombinant BDNF (rBDNF) and pro-
BDNF (rpro-BDNF) confirmed specificity. GAPDH was used as internal control.
A B
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4.4 Discussion
BDNF levels in ES cell-derived neurons are low and sensitive methods are needed to
ensure reliable detection. RT-qPCR is an effective tool for quantifying Bdnf mRNA due
to the amplification of the target sequence, which enables the analysis of low abundance
mRNAs. However, information relating to the protein levels of BDNF is crucial to
determine the implications of a drug treatment, and therefore should not be overlooked in
investigations concerning the FTY720-dependent increase of BDNF in neurons.
Unfortunately, and for the reasons discussed in the above, the most straightforward
method, namely quantification by BDNF ELISA turned out not to be feasible. The main
reasons are the very low levels of BDNF coupled with elevated background values caused
by the use of detergents needed to extract and carry BDNF to the ELISA plates. It is
conceivable that detergents may disrupt the hydrophobic bonds formed between the first
antibody (Ab #1) used to coat the plates and the plastic surface of the ELISA plate, thus
possibly allowing direct binding of the HRP-conjugated secondary antibody
(HRP-Ab #9). This possibility was tested and made likely by the observation that the
ELISA procedure performed without the addition of Ab #1 did generate high background
values (data not shown). Strong variability was also observed between the different wells
which further complicated BDNF measurements by ELISA and while this variability may
not be a problem when the levels of BDNF are relatively high as is the case for example
in human serum or mouse brain, it did cause difficulties in the case of neurons generated
from ES cells. Despite the inherent imperfect nature of protein quantification by Western
blot techniques, the availability of a BDNF monoclonal antibody offered an alternative
possibility.
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Effects of pFTY720 on J1 and B2 Neurons
 Introduction
One of the most convincing ways of defining the role of a receptor in the mode of action
of a drug is to look at the effects of the drug after genetically deleting the receptor. In the
case of S1P1R, germ line deletion of the gene causes embryonic lethality (Introduction,
section 1.2). Mouse embryos carrying a germ line deletion of S1p1r die at around E13
due to massive bleeding, caused by a lack of vascular smooth muscles cells enveloping
the blood vessels (Liu et al. 2000). Deletion of floxed alleles of S1p1r using selective Cre
drivers is one possibility to circumvent the problem of early lethality and while this
strategy has been applied to S1p1r, it led thus far to some confusing results, including the
conclusion that S1P1R may not be expressed by neurons and that the effects of FTY720
would be mediated by S1P1R on astrocytes (Choi et al. 2011). This notion is tentatively
supported by immunohistochemical data using human brain tissue (Nishimura et al.
2010). However, subsequent studies indicating that FTY720 increases BDNF levels in
mouse models (Deogracias et al. 2012; Di Pardo et al. 2014; Fukumoto et al. 2014)
challenged these conclusions as neurons are the only cells in the intact brain expressing
significant levels of BDNF (Rauskolb et al. 2010). After establishing and characterising
the S1p1r-/- cell line B2 (Chapter 3) and validating the BDNF detection and quantification
method (Chapter 4), the aim of the work described in this Chapter was to explore the role
of the S1P1R in the pFTY720-dependent increase of BDNF levels in ES cell-derived
neurons. As the S1P1R is a GPCR, further downstream targets including the ERK
pathway, as well as CREB phosphorylation were investigated to gain further insights into
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the mode of action and to delineate possible compensatory mechanisms by other S1P
receptors in the S1p1r-/- cell line B2. Throughout the study the phosphorylated active form
of FTY720 (pFTY720) was used to avoid variability due to unknown levels of its main
phosphorylation enzyme, the kinase SphK2, in the culture system.
  Chapter 5
161
5.2 Investigating the Effects of pFTY720 on BDNF Levels
in J1 and B2 Neurons
5.2.1 Analysis of BDNF levels after long-term exposure to pFTY720
The effects of pFTY720 on BDNF protein levels were investigated in J1 and B2 neurons
treated with 10 nM and 100 nM pFTY720 from day two onwards (Materials and Methods,
section 2.9). These experiments were limited to three weeks and to concentrations lower
than 1 µM pFTY720 as pilot experiments indicated that prolonged exposure of J1 neurons
to pFTY720 1 µM was toxic for the cells (data not shown). After three weeks in culture,
neurons were lysed and BDNF levels were analysed using Western blot (Figure 5.1A and
B). Densitometric analysis revealed a 45 %, significant increase of BDNF levels in J1
neurons (p (Ø vs. 100 nM) < 0.05), whilst this was not the case in B2 neurons (p (Ø vs.
100 nM) = 0.36; Figure 5.1C). However, it is important to note that the results obtained
with J1 neurons also indicated a considerable variability with regard to the magnitude of
the effect. This was a major difficulty observed with this culture system when assessing
BDNF levels as well as those of other targets (see below and section 5.4 Discussion).
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A
B
C
Figure 5.1 Long-term exposure of ES-cell derived neurons to pFTY720
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Figure 5.1 Long-term exposure of ES cell-derived neurons to pFTY720
5-FdU-treated B2 and J1 neurons were exposed to pFTY720 10 nM or 100 nM from
2 DIV until lysis at three weeks. A/B Western blot of B2 and J1 neurons. 20 µl of lysate
were loaded per lane. C pFTY720 100 nM significantly increased BDNF levels in J1
neurons compared to controls (Mann-Whitney test, *p < 0.05, n = 6). This was not the
case in the B2 neurons treated with pFTY720 100 nM (Mann-Whitney test, p = 0.36,
n = 6). Data are represented as mean ± SEM relative to βIII-tubulin and changes are in
percentage vs. control. Ø: vehicle (DMSO) treated cells.
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5.2.2 BDNF protein levels are unaffected by short-term treatment
with pFTY720
Short-term treatment with pFTY720 10 nM has previously been shown to increase BDNF
levels significantly in primary mouse cortical neurons (Deogracias et al. 2012). To
investigate if this can also be observed in ES cell-derived neurons, short-term experiments
were performed with J1 neurons at 14 DIV. Neurons were treated with pFTY720 10 nM
for 8 h or 24 h, proteins extracted and BDNF levels analysed by Western blot (Figure
5.2A). pFTY720 was found not to increase BDNF levels significantly at either time point
(p > 0.05; Figure 5.2B). Due to a lack of significant effect in J1 neurons, primary mouse
cortical neurons at 12 DIV were also treated with pFTY720 10 nM at three different time
points (4 h, 8 h and 24 h). However, also in primary cortical neurons BDNF levels were
not affected by pFTY720 treatment (p > 0.05; Figure 5.2D). To investigate this further
additional experiments were performed in primary mouse cortical neurons. None of these
experiments led to a significant increase of BDNF levels (Appendix, Figure A.2 and A.3).
  Chapter 5
165
A
B
C
D
Figure 5.2 Short-term effects of pFTY720 on BDNF protein levels
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Figure 5.2 Short-term effects of pFTY720 on BDNF protein levels
A 14 DIV old J1 neurons were treated with pFTY720 10 nM for 8 h and 24 h. Western
blot represents BDNF expression of J1 neurons after short-term exposure to pFTY720
10 nM. 20 µl of neuronal lysate were loaded per lane. B pFTY720 at a concentration
of 10 nM did not increase BDNF protein levels in J1 neurons significantly compared
to controls (Kruskal-Wallis test, p > 0.05, n = 3). C 12 DIV old primary mouse cortical
neurons were treated with pFTY720 10 nM for 4 h, 8 h and 24 h. Western blot
represents BDNF expression of primary cortical neurons after short-term exposure to
pFTY720 10 nM. 20 µl of neuronal lysate were loaded per lane. D pFTY720 at a
concentration of 10 nM did not increase BDNF protein levels in primary cortical
neurons 12 DIV significantly compared to controls (Kruskal-Wallis test, p > 0.05,
n = 3 from 2 independent experiments). Data are represented as mean ± SEM relative
to the internal control βIII-tubulin. Changes are in percentage vs. control. Ø: vehicle
(DMSO) treated cells.
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5.2.3 Are BDNF levels modulated by the sphingosine kinase inhibitor
N,N-dimethylsphingosine in J1 neurons?
The moderate increase of BDNF levels in J1 neurons as well as the variability of the
results may potentially be explained by the endogenous production of the natural ligand
S1P of S1P1R. This hypothesis was tested by adding the sphingosine kinase inhibitor
N,N-dimethylsphingosine (DMS) to the culture. DMS inhibits both sphingosine kinases
(SphK1 and 2) and thus prevents the phosphorylation of sphingosine to S1P, leading to
decreased levels of endogenous S1P in the culture system (Yatomi et al. 1996; Edsall et
al. 1998).
Following a 16 h exposure of 14 DIV J1 neurons to DMS, the levels of BDNF were found
to be unchanged (Figure 5.3B). Co-treatment of pFTY720 with DMS 100 nM and
pFTY720 10 nM (Figure 5.4A) did also not lead to a change of BDNF levels (p > 0.05,
Figure 5.4B). To this date it is therefore not possible to draw a conclusion on the role of
endogenous S1P on BDNF levels in ES cell-derived neurons.
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Figure 5.3 Effects of DMS on BDNF levels in WT neurons
14 DIV old J1 neurons were treated with different concentrations of DMS for 16 h.
A Western blot of BDNF levels in J1 neurons after DMS treatment. 40 μg of protein
were loaded per lane. B Graph represents densitometric analysis. DMS did not decrease
BDNF protein levels in J1 neurons significantly (One-way ANOVA, p > 0.05, n = 4).
Data are represented as mean ± SEM relative to internal control β-actin and changes
are in percentage vs. control. Ø: vehicle (EtOH) treated cells.
A
B
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Figure 5.4 Effects of co-treatment of pFTY720 with DMS on BDNF levels
14 DIV old J1 neurons were treated with DMS 100 nM either alone or in combination
with pFTY720 10 nM for 16 h. A Western Blot of BDNF levels in J1 neurons after co-
treatment. 40 μg of protein were loaded per lane. B Graph represents densitometric
analysis. Co-treatment of pFTY720 10 nM with DMS did not increase BDNF protein
levels significantly (Mann-Whitney test, n.s. p > 0.05, n = 3). Data are represented as
mean ± SEM relative to internal control β-actin and in percentage change vs. control.
Ø: vehicle (EtOH) treated cells. The solid light blue bar represents cells treated with
EtOH and pFTY720 10 nM.
A
B
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5.3 Effects of pFTY720 on ERK1/2 and CREB
Phosphorylation
Although the ES cell-derived neuronal culture used here delivered variable results in
terms of BDNF induction by pFTY720, it is of interest to identify the possible mechanism
downstream of S1P1R. Especially due to the availability of the B2 neurons and the results
obtained with these cells (Figure 5.1). The enhancement of BDNF protein stability, an
increased Bdnf mRNA translation or transcription could be possible explanations. Even
though one report suggests that BDNF protein levels may be regulated by a rapid increase
in translation following ketamine injections (Autry et al. 2011), there are currently no
further indications that BDNF levels in neurons may be regulated by other mechanisms
than increased transcription. Therefore, the focus of the current study was to investigate
if pathways known to induce Bdnf mRNA transcription are affected by pFTY720
treatment in ES cell-derived neurons. GPCRs, including S1P1R are well known to act on
the ERK pathway, as well as cAMP pathway (Choi and Chun 2013; Eishingdrelo and
Kongsamut 2013). Importantly, there is considerable evidence that Bdnf transcription is
regulated by CREB phosphorylation and the levels of intracellular calcium (West et al.
2001).
5.3.1 ERK1/2 phosphorylation following short-term pFTY20 addition
to J1 and B2 neurons
To investigate the effects of pFTY720 on ERK1/2 phosphorylation, 14 DIV J1 and B2
neurons were exposed to different concentrations of pFTY720 (10 nM, 100 nM and
1 µM) for 10 min. Neuronal lysates were examined by Western blot and phosphorylation
of ERK1/2 was analysed by densitometry (Figure 5.5). ERK1/2 phosphorylation was
significantly increased in J1 neurons when treated with pFTY720 10 nM
(**p < 0.01) and 100 nM for 10 min compared to controls (**p < 0.01, Figure 5.5C).
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However, a One-way ANOVA analysis failed to reveal a statistically significant
difference between the two cell lines regarding phosphorylation of ERK1/2 after 10 min
(p > 0.05, Figure 5.5C). Importantly, whilst ERK1/2 phosphorylation was significantly
increased in B2 neurons after treatment with pFTY720 1 μM compared to controls
(**p < 0.01, Figure 5.5C), it should be noted that in a subsequent time course experiment,
these findings could not be reproduced (Figure 5.6).
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Figure 5.5 pFTY720 significantly increased pERK1/2 in J1 and B2 neurons
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Figure 5.5 pFTY720 significantly increased pERK1/2 in J1 and B2 neurons
14 DIV J1 and B2 neurons were exposed to different concentrations of pFTY720 for
10 min. A/B Western blot for pERK1/2 expression in J1 and B2 neurons, respectively.
20 μl of neuronal lysate were loaded per lane. C Graph shows densitometric analysis.
pFTY720 10 nM and 100 nM significantly increased the phosphorylation of ERK1/2 in
J1 neurons compared to controls (Mann-Whitney test, **p (Ø vs pFTY720 10 nM and
100 nM) < 0.01, n = 5). In B2 neurons treatment with pFTY720 1 μM for 10 min led to
a significant increase of ERK1/2 phosphorylation compared to controls (Mann-Whitney
test, **p (Ø vs pFTY720 1 μM) < 0.01, n = 5). However, this result needs to be
interpreted with caution as it could not be reproduced in a time course experiment
performed with B2 neurons (Figure 5.6B and C). One-way ANOVA showed no
differences between the phosphorylation of ERK1/2 in B2 and J1 neurons after
pFTY720 exposure for 10 min (One-way ANOVA, p > 0.05). Data are represented as
mean ± SEM relative to βIII-tubulin and changes are in percentage vs. control. Ø:
vehicle (DMSO) treated cells.
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5.3.2 Effects of pFTY720 on pERK1/2 in J1 and B2 neurons at
different time points
Next, pFTY720 1 µM was tested at different time points using 14 DIV J1 and B2 neurons.
Neuronal lysates were examined by Western blot (Figure 5.6A). As a result of the high
variability observed, especially with the B2 neurons, the significant difference which was
previously observed after 10 min exposure to pFTY720 1 μM (Figure 5.5) could not be
reproduced (p > 0.05; Figure 5.6C).
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Figure 5.6 Effects of pFTY720 1 μM on pERK1/2 in J1 and B2 neurons
  Chapter 5
176
Figure 5.6 Effects of pFTY720 1 μM on pERK1/2 in J1 and B2 neurons
14 DIV J1 and B2 neurons were exposed to pFTY720 1 μM for the indicated time points. A/B
Western blot for pERK1/2 expression in J1 and B2 neurons, respectively. 20 μl of neuronal
lysate were loaded per lane. βIII-tubulin was used as internal control. C Graph shows
densitometric analysis. No significant increase of ERK1/2 phosphorylation was observed in
either cell line (One-way ANOVA, p > 0.05, n = 4). Data are represented as mean ± SEM
relative to βIII-tubulin and changes are in percentage vs. control. Ø: vehicle (DMSO) treated
cells.
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5.3.3 Effects of pFTY720 on pCREB levels in J1 and B2 neurons
Next, 14 DIV ES cell-derived neurons J1 and B2 were exposed to different concentrations
of pFTY720 for 10 min to explore a possible role of S1P1R in CREB phosphorylation.
In both cell lines pFTY720 had similar effects after 10 min exposure (p > 0.05; Figure
5.7). After treatment with pFTY20 at a concentration of 1 µM CREB phosphorylation
was significantly increased in J1 neurons compared to controls (* p < 0.05; Figure 5.7).
However, when CREB phosphorylation was examined at different time points following
pFTY720 1 µM addition, the previously observed increase of pCREB after 10 min
exposure to the drug disappeared in J1 neurons (p > 0.05, Figure 5.8). Therefore, no
conclusion can be drawn from this experiment and the significant effect seen in J1
neurons (Figure 5.7) needs to be interpreted with caution. In B2 neurons the time course
experiment revealed a surprising and significant increase of CREB phosphorylation after
pFTY720 1 µM treatment for 1 h and 2 h compared to controls (* p < 0.05; Figure 5.8C).
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Figure 5.7 CREB phosphorylation following addition of pFTY720 to J1 and B2 neurons
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Figure 5.7 CREB phosphorylation following addition of pFTY720 to J1 and B2 neurons
14 DIV old J1 and B2 neurons were exposed to different concentrations of pFTY720 for
10 min. A/B Western blot for pCREB expression in J1 and B2 neurons, respectively. 20 μl
of neuronal lysate were loaded per lane. B Graph shows densitometric analysis. Although
pFTY720 1 µM increased CREB phosphorylation significantly in J1 neurons compared to
controls (Unpaired t test, *p < 0.05, n = 4), these results could not be reproduced in
subsequent experiments and therefore need to be interpreted with caution (Figure 5.8A and
C). No increase of pCREB levels was observed in B2 neurons with any concentration of
pFTY720 after 10 min exposure (Unpaired t test, p > 0.05, n = 4). A One-way ANOVA did
not reveal any significant differences between J1 and B2 neurons (One-way ANOVA, p >
0.05, n = 4). Data are represented as mean ± SEM relative to βIII-tubulin and changes are in
percentage vs. control. Ø: vehicle (DMSO) treated cells.
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Figure 5.8 Levels of pCREB following addition of pFTY720 1 μM to J1 and B2 neurons
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Figure 5.8 Levels of pCREB following addition of pFTY720 1 μM to J1 and B2 neurons
14 DIV J1 and B2 neurons were exposed to pFTY720 1 μM for the indicated time periods. A/B
Western blot for pCREB expression in J1 and B2 neurons, respectively. 20 μl of neuronal lysate
were loaded per lane. B Graph shows densitometric analysis. pFTY720 1 μM increased CREB
phosphorylation significantly after 1 h and 2 h in B2, but not J1 neurons compared to controls
(Mann-Whitney test, *p (Ø vs. pFTY720 1 μM 1 h and 2 h < 0.05, n = 4). The previously observed
significant effect in J1 neurons after 10 min exposure to pFTY720 1 μM (Figure 5.7) could not be
reproduced. No significant difference was found between J1 and B2 neurons (Kruskal-Wallis test,
p > 0.05, n = 4). Data are represented as mean ± SEM relative to βIII-tubulin and changes are in
percentage vs. control. Ø: vehicle (DMSO) treated cells.
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5.3.4 pFTY720 increased Bdnf mRNA significantly in B2 neurons
Given the effects of pFTY720 addition on CREB phosphorylation (Figure 5.8) and the
well-established role of the latter on BDNF transcription (Hong et al. 2008), J1 and B2
neurons were treated with pFTY720 at different concentrations for 8 h, RNA was
extracted and the levels of Bdnf mRNA determined. A trend, but no significant differences
were observed. Note however the variability between the individual values (Figure 5.9).
Shorter time points were examined next and 1 h after the addition of pFTY720, the levels
of Bdnf mRNA were significantly increased in B2 neurons compared to controls (*p (Ø
vs. 1 h) < 0.05, Figure 5.10), but not in J1 neurons (p > 0.05, Figure 5.10).
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Figure 5.9 Bdnf mRNA levels in J1 and B2 neurons 8 h after pFTY720 addition
14 DIV old neurons were treated with different concentrations of pFTY720 for 8 h. pFTY720
did not increase Bdnf mRNA levels significantly in J1 nor in B2 neurons (Kruskal-Wallis test,
p > 0.05, n = 3). Data are represented as mean of 2-ΔΔCt ± SEM relative to internal control 18S
rRNA. Ø: vehicle (DMSO) treated cells.
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Figure 5.10 pFTY720 significantly increased Bdnf mRNA levels in B2 neurons
14 DIV old neurons were treated with pFTY720 10 nM for 1 h, 4 h, 8 h and 16 h.
pFTY720 at a concentration of 10 nM increased Bdnf mRNA levels significantly in B2
neurons after 1 h compared to controls, but not in J1 neurons (Unpaired t-test, p > 0.05,
n = 4). A one-way ANOVA did not reveal a significant difference between the two cell
lines (One-way ANOVA, p > 0.05, n = 4). Data are represented as 2-ΔΔCt mean ± SEM
relative to internal control 18S rRNA. Ø: vehicle (DMSO) treated cells.
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5.4 Discussion
Long-term exposure of ES cell-derived neurons to pFTY720 suggested that the S1P1R
may be involved in the upregulation of BDNF levels, as no significant effect was observed
in the mutant cells lacking the receptor (Figure 5.1). Unfortunately, the high variability
encountered in the culture system used here makes it difficult to draw firm conclusions
as to an absolute requirement for S1P1R in mediating the effects of pFTY720 in neurons
or the pathways recruited following the activation of S1P1R. Short-term experiments
investigating the phosphorylation of ERK1/2 and CREB led to results that were even
more variable than those related to BDNF levels upon long-term exposure (Figure 5.5-
5.8). Significant effects which were found to occur after 10 min exposure to pFTY720
1 μM on pERK1/2 levels in B2 neurons and pCREB levels in J1 neurons could not be
replicated in subsequent time course experiments (Figure 5.5-5.8). The reasons for the
variability encountered in these experiments are unclear. Whilst this protocol was already
extensively used by a number of groups to investigate the function of various genes,
including p75NTR (Plachta et al. 2007), TrkA, TrkB and TrkC (Nikoletopoulou et al.
2010), Pax6 (Nikoletopoulou et al. 2007) and APP (Schrenk-Siemens et al. 2008), it
appears that it may not be the optimal system to study the regulation of genes such as
Bdnf. Bdnf is not only expressed at low levels but its expression also depends on the
degree of neuronal maturation (Thoenen 1991). In young ES cell-derived neurons the
levels of BDNF are barely detectable (Chapter 3, Figure 3.29), and it appears unlikely
that neuronal activity develops similarly in all neurons even from one differentiation.
Indeed, using the same differentiation protocol, a significant variability in terms of
neuronal maturation between single neurons of the same differentiation as well as
between cultures was reported using patch clamp recordings (Barth et al. 2014 and
Discussion, section 8.4). As the protocol used consists of several sensitive steps and
involves many different reagents (Material and Methods, section 2.9) multiple technical
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factors could also be accounted for this variability. The most crucial aspect for the
generation of a homogeneous population of neurons is the pluripotency of the ES cells
used (Bibel et al. 2007). While the skills of the operator to maintain the pluripotency of
the ES cells is one important aspect, culturing mouse ES cells in serum-containing
medium and on feeder layers, as in this study, has been shown to increase the number of
spontaneously differentiating cells compared to mouse ES cells cultured in serum-free
conditions (Marks et al. 2012; Tamm et al. 2013). To investigate if the pluripotency of
the ES cells may affect the variability observed in the neuronal cultures by generating
heterogeneous populations (Bibel et al. 2007), future experiments should explore the
expression pattern of different pluripotency markers, like the octamer-binding
transcription factor 4 (Oct4) and the homeobox protein Nanog in ES cells of both cell
lines (Loh et al. 2006). Additionally, the heterogeneity of ES cell-derived neuronal
cultures should be investigated by immunohistochemical analysis of neuroglia and
neuronal markers to facilitate the interpretation of the data obtained. Currently the results
do not allow firm conclusions to be drawn and it is evident that more detailed
characterisation studies of the J1 and B2 neurons are needed. What can be suggested due
to the significant effect on pCREB levels in B2 neurons after 1 h and 2 h pFTY720
exposure (Figure 5.8) is that pFTY720 may also have other targets in ES cell-derived
neurons apart from the S1P1R. This could be the S1P3R as the drug binds to it with
similar affinity (Sykes et al. 2014) and the HDAC enzyme (Hait et al. 2014). However,
other targets cannot be excluded at this preliminary stage as the significant increase of
Bdnf mRNA levels after pFTY720 exposure in only B2 neurons (Figure 5.10), could
possibly involve a modulation of intracellular Ca2+ levels by pFTY720 (Discussion,
section 8.3.3). More importantly, to delineate if these effects are due to the difference in
the background strain, the presence of the Thy-1/CreERT2 construct or indeed the lack of
S1P1R a different control cell line to J1 should also have been used. It has been shown
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that ES cells of different genetic background generated neurons of similar characteristics
with the protocol used in this study (Bibel et al. 2004) and the rationale behind using the
J1 cell line was to avoid any spontaneous recombination which could occur due to the
presence of a CreERT2 construct (Zhang et al. 1996). However, spontaneous loxP
recombination typically occurs at low level (Hayashi and McMahon 2002) and has been
mainly reported in vivo (Kristianto et al. 2017). Therefore, experiments should be
repeated with a cell line controlling for the different genetic background of the B2
neurons. A suitable cell line could be #48 (Chapter 3, Figure 3.16) which is of the same
genetic background as B2 but does express the S1P1R.
In contrast to the long-term effects of pFTY720 on BDNF protein levels in J1 neurons,
short-term exposure to 10 nM of pFTY720 did not induce any changes (Figure 5.2). This
was unexpected as it was previously reported that pFTY720 10 nM increases BDNF
protein levels after 24 h in primary mouse cortical cultures (Deogracias et al. 2012). To
identify if the lack of increase could be due to differences between ES cell-derived and
primary cortical neurons, the experiments performed by Deogracias and colleagues were
replicated (Figure 5.2 and Appendix Figure A.2 and A.3). Although the number of wells
investigated do not allow firm conclusions to be drawn, the current data suggests that also
in primary cortical culture pFTY720 may not induce a significant increase in BDNF
protein levels. To date it can only be speculated as to the reasons for the failure to
reproduce the published data. Discussions with Ruben Deogracias revealed that
differences in the experimental conditions, for example different media or the frequency
of medium changes are unlikely to explain differences in experimental results with
pFTY720. In the current study, fresh medium was added every third day until 9 DIV. In
the study of Deogracias et al. 2012 however, the medium remained unchanged (R.
Deogracias, personal communication). It is highly unlikely that the addition of medium
abolished the increase of BDNF protein levels as rather the opposite would be expected.
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Fresh medium appeared to induce increased spike counts and led to a significant increase
of Arc protein in ES cell-derived neurons (Appendix, Figure A.6 and A.10), which can
be predicted to occur in mouse primary cortical cultures in a similar fashion. Amongst
one of few plausible explanations may be differences in the activity of pFTY720. The
drug could have degraded into metabolites which would affect its potency. To investigate
if this was indeed the case different batches of pFTY720 should have been tested as well
as higher concentrations of up to 1 μM of pFTY720 for longer exposure times (e.g. 36 h,
48 h).
At present, it is not possible to draw a definite conclusion on the role of S1P1R in the
effects of pFTY720 on ES cell-derived neurons. Although it seems to be implicated in
the long-term effects of pFTY720 on BDNF protein levels (Figure 5.1) its role in
mediating short-term effects is still unclear and further experiments are needed.
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In vivo Effects of FTY720 in Mice Conditionally
Lacking S1P1R
6.1 Introduction
The S1p1rloxP/loxP/CreERT2 mouse line described in the context of the isolation of ES cells
(Chapter 3) was also used to investigate the role of the S1P1R on neurons in vivo. A
randomly inserted Thy-1/CreERT2 construct allows the specific expression of the inducible
recombinase in neurons only (Materials and Methods, section 2.2). The expression of
CreERT2 mRNA in the adult hippocampus and cortex were assessed to learn about the
potential of this mouse line designated SLICK-H (Young et al. 2008). The widespread
expression of the S1P1R by essentially all cell types in the CNS suggests that a detectable
decrease of S1p1r mRNA after tamoxifen injection may be unlikely (Choi and Chun
2013). This was tested in the cortex and compared to the hippocampus as it shows a
comparatively high density of neuronal cell bodies, even though it is vascularised and
endothelial cells are known to express the S1P1R at high levels.
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6.2 Characterisation of the S1p1r loxP/loxP/CreERT2 Mouse
Line
6.2.1 CreERT2 mRNA expression in two main adult brain areas
To identify the expression levels of CreERT2 mRNA the hippocampi and cortices of adult
S1p1rloxP/loxP/CreERT2 mice were dissected and RNA isolated (Materials and Methods,
section 2.14.2). RT-PCR experiments revealed that CreERT2 mRNA levels were higher in
the adult hippocampus compared to adult cortex (*p < 0.05, Figure 6.1).
6.2.2 S1p1r excision in the hippocampus and cortex
To test the efficacy of the tamoxifen treatment (75 mg/kg BW for five consecutive days),
S1p1r mRNA levels were determined in the hippocampus one week after the last
injection. A small, but significant reduction could be observed (**p < 0.01, Figure 6.2A),
suggesting that a proportion of neurons in the hippocampus are likely to express the
S1P1R. Also in the cortex S1p1r mRNA levels were analysed one week after the last
injection. However, no reduction of S1p1r mRNA levels was detectable in the cortex of
tamoxifen compared to corn oil injected mice (p > 0.05, Figure 6.2B).
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Figure 6.1 CreERT2 mRNA levels in the hippocampus and cortex
CreERT2 levels were found to be expressed at significantly higher levels in the hippocampus
compared to the cortex (Unpaired t test, *p (hippocampus vs. cortex) < 0.05, n = 6 mice). Data is
represented as 2-ΔCtx104. β-actin was used as internal control. Graph represents mean ± SEM.
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Figure 6.2 Tamoxifen injections decreased S1p1r mRNA levels in the hippocampus only
RNA extracted from the adult mouse hippocampus and cortex was used to analyse S1p1r mRNA
levels after five consecutive tamoxifen injections. A Receptor expression was found to be
significantly decreased in the hippocampus (Unpaired t-test, **p < 0.01, n = 6 mice). B In the
cortex the levels of S1p1r mRNA remained unchanged (Unpaired t-test, p > 0.05, n = 6 mice).
Data are represented as mean of 2-ΔΔCt ± SEM relative to internal control 18S rRNA.
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6.3 Molecular Changes in Various Brain Regions after
FTY720 Injections in vivo
6.3.1 Effects of FTY720 on BDNF levels
Adult mice were injected every day for five consecutive days with tamoxifen. After a
week FTY720 (0.1 mg/kg BW) injections started and were repeated every fourth day for
four weeks (Materials and Methods, section 2.13). Cortices and hippocampi were
dissected and BDNF levels analysed by Western blot (Figure 6.3). The effects of FTY720
on BDNF levels were relatively modest in the small cohort analysed. In the adult
hippocampus of both corn oil and tamoxifen treated animals FTY720 injections induced
only a trend towards an increase of BDNF levels compared to saline injected controls
(p = 0.054, Figure 6.3). In the cortex FTY720 treatment did not affect BDNF levels
whether in the corn oil nor in the tamoxifen treated mice (p > 0.05, Figure 6.4).
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Figure 6.3 BDNF protein levels in the hippocampus following FTY720 injections
Mice were injected for five days with tamoxifen. After another week, mice were injected with
FTY720 every fourth day for four weeks. BDNF levels showed overall a trend towards an
increase after FTY720 exposure which is independent of the tamoxifen treatment (One-way
ANOVA, p = 0.054, n = 5 mice). Ø: non-injected untreated mice. Graph represents change in
percentage vs. control.
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Figure 6.4 BDNF levels in the mouse cortex were unaffected by FTY720 injections
Mice were injected for five days with tamoxifen (75 mg/kg BW). Mice were allowed to
rest for one week to let recombination take place. Subsequently, mice were injected with
FTY720 (0.1 mg/kg BW) every fourth day for four weeks. BDNF levels remained
unchanged in the mouse cortex after FTY720 treatment. Additionally, BDNF levels were
not affected by tamoxifen treatment (One-way ANOVA, p > 0.05, n = 5 mice). Ø: non-
injected untreated mice. Graph represents change in percentage vs. control.
A
B
  Chapter 6
196
6.3.2 Effects of FTY720 on ERK1/2 phosphorylation
The effects of FTY720 following a single FTY720 injection were also investigated with
regard to ERK1/2 phosphorylation. Thirty minutes after FTY720 injections (0.1 mg/kg
BW) hippocampi and cortices were dissected and proteins extracted. The mice were
treated either with tamoxifen (75 mg/kg BW) or corn oil for five consecutive days, a week
before the FTY720 or saline application. Despite tamoxifen treatment, injection of
FTY720 led to a trend towards an increase of ERK1/2 phosphorylation compared to saline
injected controls in the hippocampus (difference between medians = 1.07, Figure 6.5). In
the cortex, no significant changes of ERK1/2 phosphorylation was induced by FTY720
treatment (Figure 6.6).
6.3.3 Effects of FTY720 on CREB phosphorylation
Using the same treatment regime as for the investigation of pERK1/2 levels, brain regions
were assessed for changes in CREB phosphorylation after FTY720 treatment. In the
hippocampus as well as the cortex of corn oil and tamoxifen treated adult mice no
significant changes of CREB phosphorylation were observed 30 min after a single
FTY720 injection of 0.1 mg/kg BW (p > 0.05, Figure 6.7 and 6.8).
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Figure 6.5 Short-term effects of FTY720 on ERK1/2 phosphorylation in the hippocampus
Corn oil or tamoxifen treated mice were injected with either FTY720 or the vehicle saline and
culled 30 min after the injection. A Western blot of pERK1/2. 40 µg of protein were loaded per
lane. B No changes of ERK1/2 phosphorylation was detected after FTY720 injections in corn oil
treated mice (Mann-Whitney test, p > 0.05, n = 5 mice). In tamoxifen treated mice a trend towards
an increase of ERK1/2 phosphorylation was observed after FTY720 injections (Mann-Whitney
test, actual difference between medians (saline vs. FTY720) = 1.07, n = 5 mice). Data are
represented as mean ± SEM relative to βIII-tubulin. Changes are in percentage vs. control.
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Figure 6.6 Short-term effects of FTY720 on ERK1/2 phosphorylation in the cortex
Corn oil or tamoxifen treated mice were injected with either FTY720 or the vehicle saline and
culled 30 min after the injection. A Western blot of pERK1/2. 40 µg of protein were loaded per
lane. B No changes in ERK1/2 phosphorylation were observed in the cortex of corn oil or
tamoxifen treated mice (Unpaired t-test, p (saline vs. FTY720) > 0.05, n = 5 mice). Data are
represented as mean ± SEM relative to βIII-tubulin. Changes are in percentage vs. control.
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Figure 6.7 Levels of CREB phosphorylation after FTY720 treatment in the hippocampus
Corn oil or tamoxifen treated mice were injected with either FTY720 or the vehicle saline and
culled 30 min after the injection. A Western blot of pCREB. 40 µg of protein were loaded per
lane. B CREB phosphorylation was not affected by FTY720 injection in the hippocampus of corn
oil or tamoxifen treated mice (Unpaired t-test, p (saline vs. FTY720) > 0.05, n = 5 mice). Data are
represented as mean ± SEM relative to βIII-tubulin. Changes are in percentage vs. control.
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Figure 6.8 Levels of CREB phosphorylation after FTY720 treatment in the cortex
Corn oil or tamoxifen treated mice were injected with either FTY720 or the vehicle saline and
culled 30 min after the injection. A Western blot of pCREB. 40 µg of protein were loaded per
lane. B No significant effect on CREB phosphorylation was found in the cortex of
tamoxifen or corn oil treated mice after a single FTY720 injection (Mann-Whitney test,
p (saline vs. FTY720) > 0.05, n = 5 mice). Data are represented as mean ± SEM relative to βIII-
tubulin. Changes are in percentage vs. control.
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6.1 Discussion
To begin to evaluate whether the newly generated mouse line S1p1rloxP/loxP/CreERT2 could
be used to excise S1P1R specifically in neurons and in brain regions of interest, the
expression levels of CreERT2 driven by the Thy-1 transgene were analysed prior to
tamoxifen treatment. In contrast to other extensively used Thy-1 lines expressing YFP in
small number of neurons, the Thy-1/CreERT2 SLICK-H line is characterised by a
widespread neuron-specific expression of CreERT2 in the brain (Young et al. 2008). In
theory, this line could help to delineate whether any effects of FTY720 in the brain may
be caused directly by the activation of S1P1R on neurons, as opposed to indirectly through
the activation of the receptor on other cell types, a major open question in the field. It was
found that tamoxifen injections did decrease the levels of S1p1r mRNA in the
hippocampus (Figure 6.2A). However, the level of reduction is only moderate and no
reduction was seen in the cortex (Figure 6.2). This may seem surprising considering the
fact that the Thy-1/CreERT2 SLICK-H line does show more than 90 % recombination
efficiency in neurons of the hippocampus and the neocortex (Heimer-McGinn and Young
2011). This unexpected result may be due to the limited knowledge on the relative
expression of S1P1R in neurons compared to non-neuronal cells (Blaho and Hla 2014).
In addition, it is unclear if the S1p1rloxP/loxP/CreERT2 mouse line used in this study shows
comparable levels of CreERT2 expression in the different brain areas to the mouse line
previously examined by Heimer-McGinn and Young. Indeed, one of the problems
encountered with lines based on random insertions of constructs such as Thy-1/CreERT2 is
that they do not show the same stability over generations due to variations in the transgene
copy number (Alexander et al. 2004). To more closely monitor CreERT2 expression in
neurons as well as nuclear translocation after tamoxifen, it will be important in future
experiments to monitor the efficiency of the process using sections of brain regions of
interest and to stain them with Cre antibodies. This could be completed by in situ
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hybridisation experiments to S1p1r mRNA in the hippocampus to identify the neuronal-
specific excision and to visualise the expression levels of S1p1r mRNA in non-neuronal
cells at the same time. In line with this, S1p1r mRNA levels would need to be normalised
to a neuron-specific mRNA, given that the Thy-1 promoter should drive a neuron-specifc
expression of CreERT2. The regime of tamoxifen administration also needs to be critically
considered as it is known to be problematic in the context of studies dealing with the adult
mouse brain. Here, mice were treated with tamoxifen (75 mg/kg BW) via intraperitoneal
injections for five consecutive days. Intraperitoneal injections were preferred over oral
administration by gavage to better control for the amounts of tamoxifen administered.
Others have used more radical approaches in Thy-1/CreERT2 SLICK-H mice, including
250 mg tamoxifen per kg BW for five consecutive days administered by oral gavage
followed by a rest of ten days and a final treatment of tamoxifen (same dosage) for another
five days (Heimer-McGinn and Young 2011). It is conceivable that this much more
extensive tamoxifen treatment may have led to significant reductions of levels in the
hippocampus and the cerebral cortex.
Still, a small reduction of S1p1r mRNA levels could be achieved in the hipppocampus
albeit not sufficient to prevent a trend towards an increase of BDNF levels following
FTY720 injection (Figure 6.3). It will be interesting to see in future experiments if a more
radical regime of tamoxifen treatment (see above) combined with the use of higher
numbers of animals may lead to statistically significant results. The rationale behind
investigating long-term effects of FTY720 on BDNF levels in vivo stems from the results
obtained with ES cell-derived neurons indicating that long-term treatment of these cells
led to a modest, albeit significant increase of BDNF protein levels in vitro provided
S1P1R was expressed (see Chapter 5). However, it has been previously reported that
BDNF levels already increased 48 h after a single FTY720 injection in the cerebral cortex,
the hippocampus and the striatum (Deogracias et al. 2012). These experiments should be
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replicated, especially as more recent results using the same long-term FTY720 injection
paradigm (one injection every fourth day for four weeks) failed to detect an increase in
BDNF protein levels in the hippocampus either (Miguez et al. 2015). Interestingely, in
the same study Bdnf mRNA levels were found to be increased after FTY720 injections
(Miguez et al. 2015), in line with another study where WT mice treated according to the
same protocol showed an increase of Bdnf mRNA levels in the cerebral cortex (Di Pardo
et al. 2014). In the current study no increase of BDNF protein levels in the cortex or
hippocampus of corn oil or tamoxifen treated animals was observed after FTY720
treatment (Figure 6.4). Although it was a central objective to analyse the effects of
FTY720 on BDNF protein expression levels (Introduction, section 1.4.4), it will be
necessary in future experiments to first determine the conditions under which Bdnf
mRNA levels may increase and the role of S1P1R in this effect. Additionally, considering
the expression levels of S1P1R in non-neuronal cells, experiments analysing long-term
effects of FTY720 on BDNF levels in animals lacking S1P1R expression in both neuronal
and non-neuronal cells should also be included.
With regard to the short-term effects of FTY720 no significant changes could be observed
whether in the cortex nor in the hippocampus (Figure 6.5-6.8). The high variability found
in the biochemical measurements after FTY720 treatment in the cortex as well as the
hippocampus, made it difficult to draw any conclusions and a higher number of animals
needs to be investigated (see also Discussion, section 8.5).
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Sphingosine Receptors and Megakaryocytes
4.1 Introduction
S1P is involved in a wide variety of cell-cell interactions, its S1P receptors are widely
distributed in tissues where they play a number of different roles ranging from the
promotion of cell survival to migration and proliferation (Pyne et al. 2016). This is also
the case in the vascular and hematopoietic system as illustrated by the results of germ line
deletion of S1P1R and the role of FTY720 in preventing the egress of lymphocytes from
lymph node (Introduction, section 1.2 and 1.3). The S1P gradient formed between the
relatively high concentration in both lymph and blood is read by the S1P1R and not only
directs lymphocytes out of the lymph nodes into the blood stream, but also helps guiding
proplatelet protrusions from megakaryocytes to facilitate the release of platelets into the
blood circulation (Hla et al. 2012; Zhang et al. 2012). As our laboratory recently reported
that human and rat megakaryocytes express BDNF/Bdnf mRNA transcripts similar to
neurons (Chacon-Fernandez et al. 2016), it was of interest to investigate which sub-type
of sphingosine receptors is expressed by megakaryocytes and to test whether pFTY720
regulates Bdnf mRNA levels.
  Chapter 7
205
4.2 Rat Megakaryocytes Express S1p receptor mRNAs
RNA was extracted from primary cultures of rat megakaryocytes after 6-10 days and RT-
qPCR was performed to analyse the expression of the five S1P receptors (Materials and
Methods, section 2.16). All five receptors were found to be expressed whereby S1p1r and
S1p2r mRNAs were found to be expressed at high levels with S1p3r being the least
abundant member, followed by S1p4r and S1p5r using the levels of Hprt as a reference
(Figure 7.1).
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Figure 7.1 Expression pattern of S1p receptors in rat megakaryocytes
S1p1r and S1p2r mRNAs were expressed at comparatively high levels with lower, but clearly
detectable expression of the three other members of the family. S1p2r mRNA is expressed at
significantly higher levels than S1p3r mRNA (Kruskal-Wallis test followed by Dunn’s
multiple comparison test, *p < 0.05, n = 3). Data are represented as mean of 2-ΔCtx104 ± SEM
relative to internal control Hprt.
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4.3 Bdnf mRNA Levels in Megakaryocytes after Different
Exposure Times to pFTY720
Primary megakaryocytes were treated for 6 and 16 h with pFTY720 10 nM, the cells
lysed, RNA extracted and Bdnf mRNA levels analysed. These experiments revealed a
significant decrease in Bdnf levels 6 h after treatment of megakaryocytes with pFTY720
10 nM (**p < 0.01). After 16 h exposure to pFTY720 a trend towards an increase of Bdnf
mRNA levels was observed (p = 0.06, Figure 7.2).
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Figure 7.2 Effects of pFTY720 on Bdnf mRNA levels in rat megakaryocytes
Cultured megakaryocytes were treated with pFTY720 10 nM for 6 h or 16 h. Bdnf mRNA
levels decreased significantly after 6 h exposure to pFTY720 10 nM (Unpaired t test, **p
< 0.01, n = 4). After 16 h a trend towards an increase of Bdnf mRNA levels was observed
(Unpaired t test, p (Ø vs. pFTY720 10 nM 16h) = 0.06, n = 4). Data are represented as
mean ± SEM relative to internal control Gapdh and normalised to the control. Ø: vehicle
(DMSO) treated cells.
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4.4 Discussion
While all five sphingosine receptors were found to be expressed by rat megakaryocytes,
it is of note that this seems not to be the case in mouse and human megakaryocytes where
only S1p1r, S1p2r and S1p4r are expressed (Zhang et al. 2012). It more resembles the
expression in immature megakaryocytes, where S1p1r and S1p2r are expressed at high
levels, whilst S1p3r is only barely detectable (Zhang et al. 2012). While Zhang and
colleagues used the same method to enrich the mature megakaryocytes, namely a BSA
gradient (Materials and Methods, section 2.16), they additionally isolated the immature
megakaryocytes by fluorescence activated cell sorting (FACS). It is therefore possible
that in the present study, a mixture of mature and immature rat megakaryocytes has been
investigated. This seems plausible given the observation that the rat megakaryocytes
showed S1p4r as well as S1p3r expression. Although it has been shown that Hprt seems
to be a stable reference gene for the detection of S1pr in three different tissues (Kays et
al. 2012), the results of the current study would need to be extended using additional
internal standards such as the attachment region binding protein Arbp (attachment region
binding protein) or Gapdh.
The interpretation of the results regarding Bdnf mRNA levels after pFTY720 addition is
complicated by the fact that towards the end of their in vitro maturation, cultured
megakaryocytes can be observed to generate platelets (as they do in vivo in the bone
marrow). This is relevant as our laboratory very recently demonstrated that not only
megakaryocytes, but also platelets contain Bdnf mRNA transcripts, including those
typically found in neurons (Chacon-Fernandez et al. 2016). As it remains unclear whether
all platelets are collected in those experiments in addition to megakaryocytes, it is difficult
at this point to interpret the results. The slight decrease seen at shorter time interval
suggests that some of the platelet-contained transcripts may have been lost during the
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extraction of the cells from the plate. The centrifugation step might not allow for all
platelets to be spun down as they are considerably smaller than megakaryocytes
(Materials and Methods, section 2.16). Also, the destruction of the megakaryocyte
nucleus through apoptosis after platelet release (Gordge 2005), could explain a further
loss of transcripts. Investigating the expression of a gene specifically found in
megakaryocytes and platelets like the von Willebrand factor would allow to clarify this
question and should be included in future experiments. Further, it will be interesting to
explore the role of pFTY720 after purifying megakaryocytes and to investigate the
supernatant separately as it is now clear that platelets are a complicating factor. Still, the
preliminary results illustrated here are intriguing, including the trend towards an increase
of Bdnf mRNA levels 16 h after pFTY720 addition show that investigating different time
points, higher pFTY720 concentrations and BDNF protein levels will be of major interest.
Finally, megakaryocytes may be additionally isolated by FACS using maturation-specific
markers to ensure that they are analysed at similar degrees of maturation.
211
Discussion
The main objective of this study was to explore the role of the S1P1R in mediating the
effects of pFTY720 on neurons. As FTY720 has long been known to diffuse into the brain
where it even accumulates there is a pressing need to understand how the drug may
interact with what is generally thought to be one of its main targets, namely S1P1R. To
this end, ES cells were isolated from the blastocysts of mutant animals carrying a
conditional mutation of the receptor. S1P1R was excised from these ES cells, neurons
generated and compared with those generated from WT ES cells. Using a modification
of an existing differentiation protocol, neurons lacking S1P1R were successfully
generated from these mutant ES cells and some of the biochemical changes following
exposure to FTY720 compared with WT neurons. Although the excision of S1P1R
affected the long-term effects of pFTY720 on BDNF levels in ES cell-derived neurons,
the high variability encountered in the system used does not allow firm conclusions to be
drawn about the role of S1P1R in these cells. Furthermore, some of the effects observed
with neurons lacking S1P1R, including a transient increase of Bdnf mRNA, cannot solely
be attributed to the lack of the receptor in the experimental setting used. This important
point will require further investigation using a S1P1R-expressing cell line of the identical
genetic background.
8.1 Generating Neurons Lacking S1P1R
As the role of sphingosine during early development only begins to be appreciated and
mice lacking S1p1r die at the time when the CNS begins to develop (Introduction, section
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1.2), it could not be assumed that neurons could be generated in the absence of S1P1R.
This concern is of special relevance as WT ES cells express S1P1R (data not shown), and
because the receptor has been suggested to play a role in neurogenesis (Liu et al. 2000;
McGiffert et al. 2002; Mizugishi et al. 2005). Indeed, the standard differentiation protocol
had to be modified due to the proliferation of non-neuronal cells observed with the
progeny of S1p1r-/- ES cells that affected long-term cultures of these neurons. While
neither the identity of the proliferating cells nor the reasons for this altered proportion
between neuron and non-neuronal cell progenitor could be investigated, these results
suggest that S1P1R, and by extension sphingosine signalling, may play a role during the
formation of cellular aggregate and the induction of neural commitment by retinoic acid.
Not much is known about this process in the first place except for the interesting
observation that the effects of the addition of retinoic acid can be replicated by interfering
with Wnt signalling (Aubert et al. 2002). Following a brief, early pulse of 5- FdU,
overgrowth of non-neuronal cells could be prevented and the phenotype of the resulting
neurons seemed to be similar to those of WT neurons for certain characteristics. In
particular, the extent as well as the developmental time course of synaptophysin and
BDNF expression turned out to be similar as was the development of more specific
markers such as two major glutamate transporters on mRNA level (Chapter 3). At the
protein level, a significant increase of vGlut2 expression was found in B2 neurons
compared to J1 neurons (Figure 3.31). The reasons for this increase are unclear at this
point and further experiments involving immunocytochemical analysis to define the
cellular composition of the cultures would be needed to understand the significance of
this observation.
During the course of these studies, it was noted that the yield of progenitors dissociated
from aggregates initiated with B2 ES cells (10x106 ± 1.3x106 cells/dish) was significantly
lower (Unpaired t test, **p < 0.01, n = 8) than the yield obtained with J1 ES cells (20x106
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± 1.1x106 cells/dish). While this observation is in line with a recent publication
demonstrating that FTY720 promoted neural progenitor survival as well as proliferation
in the adult mouse hippocampus (Efstathopoulos et al. 2015), it is more difficult to
reconcile with recent results indicating that endogenous S1P may maintain neural stem
cells quiescent in the sub-ventricular neurogenic niches (Codega et al. 2014). However,
an analysis of S1p1r mRNA levels during the 8-day course of cellular aggregation
revealed a progressive decrease of its expression in WT cells (data not shown). In the
complete absence of the receptor, it is conceivable that S1P1R-dependent regulatory
mechanisms may be missing thus hypothetically preventing an acceleration of progenitor
amplification. New insights into mechanisms regulating expansion of neural progenitors
may thus emerge from the use of mutant ES cells lacking S1P1R, a potentially valuable
tool given the observation that proliferation of non-neuronal cells following the plating
of these progenitors was considerably enhanced (see above). To better appreciate the
relevance of these in vitro observations, further in vivo work is needed whereby an
attractive possibility would be to cross the S1p1rloxP/loxP line with a lineage-specific line
such as the Glast/CreERT2 line allowing the excision of the receptor in radial glial cells as
well as in mature astrocytes following tamoxifen injections (Mori et al. 2006).
8.2 Using S1p1r-/- Neurons to Test Antibody Specificity
The availability of cells lacking S1p1r as evidenced by genomic DNA as well as RT-
qPCR analyses made it possible to test the specificity of commercially available
antibodies targeting this receptor. A widely used reagent is a polyclonal antibody from
Cayman Chemicals (Kohno et al. 2002; Crousillac et al. 2009; Nishimura et al. 2010;
Healy et al. 2013; Lukas et al. 2014). It detected S1P1R at a molecular weight slightly in
excess of 50 kDa while S1P1R has an estimated molecular weight of
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43 kDa (UniProtConsortium 2014), a discrepancy that may be explained by the N-
glycosylation consensus sequences in the extracellular domain of the receptor (Kohno et
al. 2002). Consistent with the mRNA data (Figure 3.33), the intensity of the Western blot
signal increased significantly with time in culture and was quite prominent after three
weeks (Figure 3.20-3.21). However, this is also the case with neuronal lysates prepared
from B2 ES cell-derived neurons, a result incompatible with the genomic DNA and
mRNA analyses. Further, a monoclonal antibody raised against S1P1R (Nakajima et al.
2014), detected a band at about 43 kDa that became more prominent during neuronal
differentiation and was also present in neurons derived from ES cells lacking the gene
encoding S1P1R. Hence, the specificity of both antibodies could not be confirmed, which
may explain in part the state of confusion in the field, especially regarding the important
question as to whether S1P1R is expressed at all by neurons (Chae et al. 2004; Nishimura
et al. 2010; Choi et al. 2011). In this regard, the results presented in Chapter 3 are
interesting as they indicate that the S1p1r gene is expressed in the cultures of ES cell-
derived neurons and that this expression increases during the differentiation (Figure 3.33).
Additionally, preliminary results in Chapter 5 suggest that S1P1R might be involved in
the long-term effects of pFTY720 on BDNF levels in ES cell-derived neurons. What this
study does not address, is the exact cellular composition of the cultures used. Preliminary
results on GFAP expression analysis by Western blot suggest that under suboptimal
culturing conditions and without mitotic inhibitor treatment, different cell types may be
present in these cultures (Figure 3.27). It is unclear if these cells would also express
S1P1R and thereby contribute to the effects seen in J1 cultures. As currently no specific
antibodies are available these additional investigations could involve in situ hybridisation
assays or fluorescence-activated cell sorting (FACS) with subsequent RT-PCR analysis
for S1p1r in the isolated cell types. There are published specificity tests of the S1P1R
polyclonal antibody showing an immunohistochemistry analysis of S1P1R expression on
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vascular endothelial cells in E12.5 mouse tissue, using S1p1r-/- tissue as control (Akiyama
et al. 2008). This prompted further investigations and an immunocytochemistry analysis
of J1 and B2 ES cell-derived neurons, thereby testing the possibility that the polyclonal
antibody might recognise the receptor on tissue sections, as opposed to Western blot.
However, these additional experiments revealed a weak granular-type of staining on
neuronal processes (Figure 3.22 and 3.23). While this staining pattern would as such be
compatible with the expression of a membrane protein it was of comparable intensity
using neurons derived from B2 ES cells not expressing S1P1R. Therefore, this staining
cannot be attributed to S1P1R, but possibly to another receptor such as S1P3R. This
would explain the discrepancy with the previous study by Akiyama et al. as the
developing mouse vasculature only expresses very low levels of S1P3R as revealed by in
situ hybridisation analysis (Ishii et al. 2001). Also, the germ line deletion of S1p3r does
not lead to embryonic lethality, unlike germ line deletion of S1p1r (Liu et al. 2000),
suggesting very low to no expression of S1P3R on E12.5 mouse endothelial cells.
Additional studies are needed to analyse a possible cross-reactivity of the polyclonal
antibody with S1P3R and to clearly define its specificity.
8.3 Effects of pFTY720 on J1 and B2 Neurons in vitro
8.3.1 Pathways activated upon prolonged pFTY720 exposure
After prolonged exposure of WT and mutant ES cell-derived neurons to pFTY720, a
significant increase of BDNF levels was observed in WT, but not in neurons lacking
S1P1R (Figure 5.1). This suggests that the increase may be a S1P1R-dependent effect.
The mode of action of FTY720 was originally described as that of a functional antagonist
due to its effect observed in lymphocytes. Indeed, long-term exposure of lymphocytes to
FTY720 and its phosphorylated form induce the internalisation of S1P1R, thereby
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hindering its activation by S1P (Graler and Goetzl 2004; Matloubian et al. 2004).
Subsequent studies reported on S1P1R internalisation in transfected Chinese hamster
ovary (CHO) (Mullershausen et al. 2009; Sykes et al. 2014), human umbilical vein
endothelial cells (HUVEC) (Mullershausen et al. 2009), and astrocytes (Choi et al. 2011;
Healy et al. 2013). These studies have shown that the drug’s action is complex and that
pFTY720 triggers a sustained cAMP signalling over S1P1R even after its internalisation
in HUVEC and astrocytes (Figure 8.1 and (Mullershausen et al. 2009; Healy et al. 2013)).
This persistent activation of the Gi/o protein leads to the continuous inhibition of adenylyl
cyclase and induction of ERK1/2 phosphorylation (Healy et al. 2013). If the
internalisation of S1P1R also occurs in neurons is unclear at this point. Should this indeed
be the case the induction of ERK1/2 phosphorylation could possibly be an explanation
for the reported increase of Bdnf transcription in vitro and in vivo (Deogracias et al. 2012).
By contrast, the increase in intracellular Ca2+, known to occur soon after S1P1R activation
is not sustained following prolonged exposure to pFTY720 in astrocytes (Healy et al.
2013), for reasons that are not well understood. It is possibly caused by a conformational
change of S1P1R elicited by its ligands and/or an uncoupling of the S1P1R from the PLC
pathway, known to induce intracellular Ca2+ release after its activation through the Gβγ
subunit (Figure 8.1 and (Werry et al. 2003; Healy et al. 2013)). This is important as it is
well known that Bdnf transcription in neurons is induced by rapid Ca2+ influx
(Introduction, section 1.4.2 and (West et al. 2014)). At this point, the continuous
activation of the ERK pathway seems to be the most likely explanation for the increase
of BDNF levels in WT neurons (Figure 5.1). In mutant neurons lacking S1P1R, the drug
will likely first bind to S1P3R, as the affinity of pFTY720 to S1P1R and S1P3R is similar
(Sykes et al. 2014) and the expression of the two receptors in cultured J1 and B2 neurons
at the mRNA level is comparable (Figure 3.33). S1P3R is also coupled to Gi/o protein and
the ERK pathway (Ishii et al. 2002). However, the results suggest that this does not occur
  Discussion
217
at significant levels in the B2 neurons as no BDNF increase could be observed after long-
term exposure to pFTY720 in these neurons lacking S1P1R (Figure 5.1). Also, the results
on the phosphorylation of ERK1/2 is difficult to interpret due to the high variability
encountered in the culture system used (Figure 5.5 and 5.6, Discussion Chapter 5).
Intriguingly, pFTY720 acts as a weak partial agonist on S1P3R by blocking the signalling
of S1P via the Gq protein and at the same time activating the Gi/o protein-dependent
pathways. This distinct activation of S1P3R by S1P and pFTY720 is thought to occur
because of different conformational changes of the receptor caused by pFTY720
compared to S1P (Sensken et al. 2008). Presumably, long-term exposure of mutant
neurons to pFTY720 may inhibit adenylyl cyclase and abrogate Ca2+ signalling while still
activating the ERK pathway. However, the activation of S1P1R by pFTY720 is more
efficient than activation of S1P3R as the intrinsic activity of pFTY720 on S1P1R (pEC50
= 9.32) is significantly higher compared to S1P3R (pEC50 = 8.44), as examined by a [35S]-
GTPγS incorporation assay (Sykes et al. 2014), possibly explaining the lack of an increase
in BDNF expression in B2 neurons compared to J1 neurons.
In addition to receptor-mediated mechanisms, it has recently been reported that FTY720
enters the cell to be phosphorylated in the nucleus where it acts as an HDAC inhibitor
(Hait et al. 2014). HDAC inhibitors have been known to induce Bdnf transcription (Chen
et al. 2006) and this was confirmed by the study of Hait et al., showing increased Bdnf
mRNA levels after FTY720 treatment (Hait et al. 2014). However, if the HDAC
inhibition by pFTY720 played a significant role following long-term exposure of neurons
to the drug, a BDNF increase would be expected in mutant neurons lacking S1P1R.
Although pFTY720 is unlikely to cross the cell membrane, due to its polar head groups,
it could still be entering through two different mechanisms. Either by binding S1P3R,
which also results in internalisation, followed by the release of pFTY720 in the
intracellular compartment and subsequent recycling of the receptor (Sykes et al. 2014) or
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after its dephosphorylation by the lipid phosphate phosphatase 3 (LPP3)
(Mechtcheriakova et al. 2007), which then enables its crossing of the cell membrane as
FTY720. However, this seems not to occur at a significant level as shown by the lack of
increase of BDNF in the mutant neurons (Figure 5.1). This was further confirmed by
exploring the vascular endothelial growth factor D (Vegfd) mRNA levels after a short-
term exposure to pFTY720. In the study of Hait et al. a significant increase of Vegfd levels
was observed in the hippocampus of FTY720-treated mice due to HDAC inhibition.
However, in ES cell-derived neurons Vegfd mRNA levels remained unchanged in J1 and
B2 neurons following pFTY720 treatment (Appendix, Figure A.11).
At this point it is very difficult to draw a final conclusion about the functional significance
of S1P1R expressed on neurons and its role in regulating BDNF levels, not least because
of the rather weak effects of long-term exposure of pFTY720 on BDNF levels (Figure
5.1). As such this is surprising considering previous effects in vivo of FTY720 in mice
lacking Mecp2-/-. It was shown that FTY720 treatment over the course of four weeks
significantly increased BDNF protein levels in various brain regions of Mecp2-/- mice
(Deogracias et al. 2012). It is conceivable that this increase may somehow be linked with
decreased levels of BDNF in the brain of Mecp2-/- mice. However, in the same study
exposure of WT mice to FTY720 for 48 h, also increased BDNF levels significantly in
the mouse brain (Deogracias et al. 2012), suggesting that other factors must play a role in
neuronal cultures. Whether BDNF accumulation in long-term neuronal cultures may
mask any increase of BDNF levels caused by pFTY720 treatment was investigated using
a monoclonal antibody (mAb #9) able to capture secreted BDNF. However, the addition
of this antibody to J1 neurons several days before experiments were conducted did not
affect BDNF levels following treatment of the cultures with pFTY720 (Appendix, Figure
A.14). Also, changing the density of the neuronal culture or treating the neurons earlier
than 14 DIV failed to induce a larger increase of BDNF levels following drug addition,
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although the steady state levels of BDNF were lower (Appendix, Figure A.15-A.17).
Possibly, neurons younger than 14 DIV may still be too immature to respond to pFTY720,
as suggested by the relatively low expression levels of the synaptic protein synaptophysin
(Figure 3.28). Indeed, previous work with primary cultures of neurons has indicated that
BDNF increase was dependent on active synaptic transmission (Deogracias et al. 2012).
Hence, effects of pFTY720 on ES cell-derived neurons were therefore not further
investigated in cultures before 14 DIV. More experiments are needed to understand the
lack of a significant increase of BDNF protein level. It is evident however, that the high
variability in the culture system, which will be discussed below (section 8.4) may remain
problematic. A promising strategy for future studies could be to try and accelerate the
maturation of ES cell-derived neurons, such that a robust synaptic activity may develop
sooner (see below section 8.3.2). Additionally, the synaptic activity should be monitored
by for example patch-clamp recordings to ensure comparable levels of basal activity in
all the conditions analysed.
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Figure 8.1 Proposed mechanism of action following long-term exposure to pFTY720
Gi/o coupled pathways can be activated through the internalised S1P1R, activating the ERK
pathway, which induces CREB phosphorylation with subsequent Bdnf mRNA transcription.
pFTY720 also binds S1P3R which is proposed to be the primary target in the mutant neurons
and thereby inhibits the binding of S1P. It activates the Gi/o coupled ERK pathway with a
lower intrinsic activity than over S1P1R (dotted green arrow) and inhibits activation of Gq
coupled pathways, thereby acting as a partial agonist. Original figure including information
from Ishii et al. 2004; Mullershausen et al. 2009; Healy et al. 2013; Park and Poo 2013; Sykes
et al. 2014; West et al. 2014.
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8.3.2 Short-term effects of pFTY720 on BDNF levels
ES cell-derived WT neurons treated at 14 DIV for 8 h or 24 h failed to increase BDNF
protein levels (Figure 5.2). The difficulties encountered in obtaining a significant and
reproducible increase of BDNF levels in ES cell-derived neurons were not only
unexpected in view of previous in vivo results (see above) but also in the face of what has
been reported with primary cultures derived from the embryonic mouse cortex. In primary
cortical cultures short-term exposure of neurons to 10 nM and 100 nM pFTY720 for
24 h increased BDNF protein as well as Bdnf mRNA levels significantly (Deogracias et
al. 2012). This discrepancy in BDNF levels observed in response to pFTY720 treatment
further underlines the difference between primary cortical and ES cell-derived neurons.
This includes the observation that ES cell-derived neurons do not seem to mature at the
same rate as neurons freshly isolated from the developing brain (Chuang et al. 2013;
Sadegh and Macklis 2014). As it was previously shown that primary cortical neurons
reach maturity between 10-20 DIV (Lesuisse and Martin 2002), it is possible that ES cell-
derived neurons need to be cultured for longer than 14 DIV to attain a similar level of
maturity. It has been noted that it is possible to enhance neuronal maturation in ES cell-
derived neurons by manipulating various conditions (for review see (Chuang et al. 2015)).
These involve among others the activation of the Wnt signalling pathway (Jing et al.
2011), or addition of a nitric oxide donor to the culturing system (Arnhold et al. 2002). In
spite of the limitations of ES cell-derived neurons, the inherent flexibility of this system
confers many advantages justifying its use. They bear the potential to generate an
unlimited number of post-mitotic cells and facilitate the generation of genetically
modified neurons (Bibel et al. 2004; Gordon et al. 2013). However, the failure to replicate
the data of Deogracias and colleagues in primary cortical culture demands for the
consideration of other factors. It seems plausible that the quality or stability of the drug
pFTY720 may have been affected. This could be further investigated by testing pFTY720
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using simpler biochemical assays based on cells transfected with S1P1R and the analysis
of downstream biochemical measurements (Sanna et al. 2004; Jo et al. 2005;
Mullershausen et al. 2009). An additional difficulty when studying the role of S1P1R in
transducing biological signals is likely to result from the endogenous production of the
receptor ligand, namely S1P (see Introduction, section 1.2). In an attempt to decrease the
concentration of endogenous S1P, neurons were exposed to the sphingosine kinase
inhibitor DMS. Surprisingly, a trend towards an increase in BDNF expression was
observed (Figure 5.4). This result may suggest that the chronic exposure of ES cell-
derived neurons to endogenous ligand, especially in the context of high density culture
may chronically desensitise the receptor. In view of this result, future experiments should
include measurements of endogenous S1P, especially in the context of dense cultures to
better understand not only the pharmacology but also the physiology of this signalling
system, the complexity of which only begins to be appreciated.
8.3.3 Effects of pFTY720 on ERK1/2 and CREB phosphorylation
In an attempt to simplify the analysis by decreasing the complexity resulting from
receptor internalisation caused by prolonged drug exposure, parameters thought to be
close to receptor activation were explored at short time intervals after exposure to
pFTY720. To this end, ERK1/2 and CREB phosphorylation were investigated as wells as
their possible impact on Bdnf mRNA levels. Due to the high variability encountered in
B2 neurons no conclusion can be drawn regarding the effects of pFTY720 on ERK1/2
phosphorylation and the significant increase seen in WT neurons following exposure to
10 nM and 100 nM pFTY720 must be interpreted with caution (Figure 5.5). Both S1P1R
and S1P3R activate the ERK pathway after binding pFTY720 (Sensken et al. 2008; Healy
et al. 2013), with the drug being more potent in its action through S1P1R compared with
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S1P3R (Sykes et al. 2014). This may explain a stronger response observed in J1 neurons
(see also above). pFTY720 has been shown to phosphorylate Akt a downstream target of
both receptors (Figure 1.2 and (Brinkmann 2007)), which is known to subsequently
increase pCREB (Du and Montminy 1998). In B2 neurons, pFTY720 seemed to induce a
significant increase of pCREB levels and significantly increased Bdnf mRNA levels
whereas this could not be consistently observed in J1 neurons (Figure 5.7-5.8 and 5.10).
The high variability encountered in the system used here might explain why previous
results in primary cortical cultures of WT mice report on an increase of pERK1/2, pCREB
and Bdnf mRNA levels after pFTY720 addition (Deogracias et al. 2012). Also, the fact
that Gi/o protein activation signals to the PI3K/Akt and ERK pathway implies that CREB
phosphorylation should also occur in WT neurons following S1P1R stimulation (Radeff-
Huang et al. 2004; McCubrey et al. 2007; Tao et al. 2009; Safarian et al. 2015). It has
been shown that in cells lacking both S1P2R and S1P3R, stimulation of S1P1R does not
induce an activation of the Akt pathway (Zhang et al. 2007; Means et al. 2008). In WT
cells however, the Akt pathway is activated in a Gi/o protein-dependent manner, indicative
of a possible interplay between the different receptors (Zhang et al. 2007; Means et al.
2008). How this complexity of S1P signalling affected the results obtained in this study
is unknown. But as this finding supports the notion that the phosphorylation of CREB
should still occur in the WT neurons through the activation of the Gi/o protein and its
downstream pathways (Figure 8.2), it is conceivable that pFTY720 may act on other
targets in B2 neurons. This may lead to a stronger Ca2+ increase, a notion supported by
the increase of CREB phosphorylation (Figure 5.8) and the significant increase of Bdnf
mRNA in the mutant neurons only (Figure 5.10). Activation of S1P1R does increase
intracellular Ca2+ levels in a Gi/o protein-dependent manner provided exposure to
pFTY720 is shorter than 1 h. Following this brief exposure time, significant number of
receptors may be internalised (Figure 8.1 and 8.2 and (Healy et al. 2013)). However, the
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increase of intracellular Ca2+ was not strong enough to induce CREB phosphorylation
consistently in J1 neurons as the pCREB increase seen after 10 min exposure to pFTY720
1 μM (Figure 5.7) could not be reproduced in subsequent experiments (Figure 5.8). This
could be further explored by measuring intracellular Ca2+ levels after pFTY720 addition
to B2 neurons with and without blocking S1P3R to investigate if another target may be
involved as predicted by previous studies. Indeed, pFTY720 has been shown not to induce
a Ca2+ response through S1P3R due to its inhibition of the Gq-dependent pathway (Ishii
et al. 2002; Sensken et al. 2008).
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Figure 8.2 Proposed mechanism of action following short-term exposure to pFTY720
pFTY720 stimulates S1P1R thereby activating the ERK pathway, as well as the PI3K/Akt
pathway, and inducing Ca2+ increase which all lead to CREB phosphorylation with subsequent
Bdnf mRNA transcription. pFTY720 binds S1P3R and thereby inhibits the binding of S1P. It
acts as a partial agonist as it has inhibitory actions on the Gq coupled pathway, while it
stimulates the Gi/o coupled ERK pathway but with a lower intrinsic activity compared to
S1P1R (dotted green arrow). It is suggested that pFTY720 binds another target (indicated by
the question mark), which is either a receptor or a direct mediator of intracellular Ca2+ increase.
Original figure including information from Ishii et al. 2002; Brinkmann 2007; Zhang et al.
2007, Means et al. 2008; Sensken et al. 2008 and Sykes et al. 2014.
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8.4 Variability in Culture System
While the generation of neurons from ES cells is an invaluable tool to neuroscientists as
exemplified by the clarification of various gene functions (see for example (Schrenk-
Siemens et al. 2008; Nikoletopoulou et al. 2010; Yazdani et al. 2012)), its use in the
context of quantitative biochemical measurements turned out to be significantly more
problematic than initially anticipated. Indeed, an unexpectedly large variability was
observed in all measurements performed, irrespective of the molecule under
investigation. One plausible reason at the core of the variability may be differences in the
temporal development of synaptic activity. This is not only supported by the data obtained
from extracellular recordings (Figure A.9 and A.10), but also by the results of other
investigators using the same basic differentiation protocol (Bibel et al. 2007; Barth et al.
2014). Intracellular recordings performed by Barth and colleagues revealed considerable
variations between cells in relation to the development of synaptic activity. The variability
was not due to the differences of one differentiation to the other, as already within one
differentiation changes were observed (Barth et al. 2014). Previous results on the activity
of pFTY720 on primary cultures of neurons have suggested that the effects of the drug
on BDNF levels where dependent on both pre-as well as postsynaptic mechanisms
(Deogracias et al. 2012). Therefore, it is likely that at least part of the variability observed
in the parameters investigated in this study may be a consequence of asynchronous
development of the connectivity between neurons and of synaptic activity. In line with
this, spike count measurements performed here using Micro Electrode Arrays (Materials
and Methods, section 2.12) revealed considerable differences between single wells
(Figure A.9). Despite the high variability encountered with ES cell-derived neurons,
primary cultures do not represent a straight-forward alternative. As primary cultures from
S1p1r-/- mice cannot be established due to lethality of the deletion at the embryonic stage
(Liu et al. 2000), a conditional gene deletion would be needed. Cre-mediated excision of
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target genes in primary cultures of neurons is typically not efficient enough to allow
subsequent biochemical analyses of cell lysates and therefore, other approaches need to
be considered. For example, S1p1rloxP/loxPEmx1/CreERT2 mice could be used as it allows
significant expression of CreERT2 earlier during brain development than Thy-1. The
homeobox protein Emx1 is already detected at E10 in the mouse forebrain (Boncinelli et
al. 1993; Cecchi and Boncinelli 2000). It has been used previously to successfully excise
genes specifically in neurons of the forebrain (Baquet et al. 2004; Kessaris et al. 2006).
Also, primary cultures prepared from the mouse line GLAST/CreERT2 would allow to
investigate the role of S1P1R both in neurons and astrocytes and to compare the results
with those obtained from cells isolated from the Emx1/CreERT2 line (Mori et al. 2006).
8.5 Effects of FTY720 in vivo
Not unexpectedly, the tamoxifen-induced excision of S1p1r failed to significantly alter
the effects of FTY720 in the two brain regions investigated, even if a small, but significant
reduction in the levels of S1p1r mRNA was noted in the hippocampus (Figure 6.2A).
While this small decrease shows that as expected the majority of S1P1R-expressing cells
are non-neuronal cells it does suggest that the S1p1r gene might also be expressed by
neurons, given that Cre expression is driven by a Thy-1 construct exclusively expressed
in neurons as documented by the expression of YFP (Young et al. 2008). As noted in the
above, more detailed investigations of the important point of the relative levels of
expression of S1P1R by neurons versus other cell types will need the development of
more specific reagents than the S1P1R antibodies available so far (Discussion, section
8.2). A previous study used human GFAP, nestin as well as synapsin promoters to drive
the expression of Cre for the excision of a floxed S1p1r allele to explore the role of the
receptor in mice challenged by EAE (Choi et al. 2011). Interestingly, this study revealed
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that the excision of S1P1R in cells targeted by the GFAP and the nestin, but not the
synapsin promoter decreased the EAE score following injection of the myelin
oligodendrocyte glycoprotein (MOG) peptide. In both cases, FTY720 also lost its
protective effects and failed to ameliorate the clinical scores of treated animals. The
overall conclusion of the study was that an important part of the mode of action of
FTY720 towards ameliorating the symptoms of EAE can be accounted for by its ability
to downregulate S1P1R expression on astrocytes which were suggested to be the main
S1P1R-expressing cells. The same study also concluded that S1P1R is not expressed by
neurons. However, the interpretation of these S1P1R localisation results was largely
based on the use of Cre deleter lines (Choi et al. 2011). Indeed, the synapsin promoter
used to drive Cre is not expressed in all neurons (Zhu et al. 2001), while at the same time
the human GFAP promoter is known to be expressed by the progenitors of both neurons
and astrocytes (Malatesta et al. 2003), thus undermining the conclusion reached by Choi
and colleagues that S1P1R may not be expressed by neurons. The mouse line generated
in this study might help to clarify this question of S1P1R expression on neurons further.
Though this would require in situ hybridisation studies given the lack of specific S1P1R
antibodies (see above, section 8.2).
This study also investigated the effects of FTY720 on BDNF protein levels in vivo (Figure
6.3 and 6.4). In line with another report investigating the long-term effects of FTY720 on
BDNF levels in the hippocampus (Miguez et al. 2015), no increase could be observed in
the brain regions investigated. However, shorter treatments of just one injection 48 h prior
BDNF level assessment should be considered in future studies as this led to a significant
increase in multiple major brain regions (Discussion Chapter 6 and Deogracias et al.
2012). Furthermore, a significant increase on ERK1/2 (Di Pardo et al. 2014), and CREB
phosphorylation was reported 30 min after FTY720 injections in vivo (Deogracias et al.
2012). Currently it remains unclear why it was not possible to replicate this data in the
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hippocampus and cortex of corn oil treated Thy-1/CreERT2 S1p1rloxP/loxP mice (Figure 6.5-
6.8). However, a high variability was encountered between single mice and it appears
likely that significantly more animals should be examined before definite conclusions
could be drawn on the effects of FTY720 on ERK1/2 and CREB phosphorylation in these
mice. Additionally, the mouse strain was different in the studies reporting on a significant
increase compared to the one used in this study and the choice of mouse strain could also
impact the results (Sandberg 2000; Wahlsten et al. 2006; Mouri et al. 2012).
8.6 Sphingosine Receptors on Megakaryocytes
S1P receptors are present on a wide variety of cell types and S1P gradients are used for
various chemotactic processes including the generation of platelets from proplatelets
(Introduction, section 1.2). As cultured rat megakaryocytes express all five S1P receptors
at the mRNA levels (Figure 7.1), and especially S1p1r and S1p2r at high levels, it was of
interest to test whether or not pFTY720 would regulate Bdnf mRNA levels, given work
recently published by our laboratory indicating that the expression pattern of the Bdnf
transcripts in megakaryocytes is identical to the pattern found in neurons (Chacon-
Fernandez et al. 2016). The suggestion that Bdnf transcription might be regulated
similarly in neurons and megakaryocytes was further supported by the finding that
increased levels of intracellular calcium enhanced Bdnf transcription in megakaryocytes,
which is known to be also the case in neurons (Chacon-Fernandez et al. 2016). While the
results suggest that pFTY720 may modulate Bdnf mRNA levels (Figure 7.2) the
interpretation of these experiments is complicated by the fact that the addition of
pFTY720 most likely affects the maturation of proplatelets as well as the release of
platelets. This is important given the realisation that Bdnf mRNA is present in platelets,
at least in humans (Rowley et al. 2011). Rats were used here as the Bdnf gene is not
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expressed at significant levels in mice (Chacon-Fernandez et al. 2016). Interestingly,
platelet counts analysed 12 h after FTY720 administration are significantly increased in
the blood circulation, indicating an increased release by megakaryocytes (Zhang et al.
2012). In contrast platelet counts are decreased in humans after several weeks of drug
administration, possibly due to the functional antagonistic action of FTY720 after long-
term treatments (EMA 2014).
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8.7 Conclusion and Perspectives
One of the most unexpected finding of these investigations is that short-term exposure of
pFTY720 to neurons lacking S1P1R elicited a transient increase of Bdnf mRNA levels
not observed with WT neurons. However, this intriguing result needs to be interpreted
with caution as an additional control cell line still expressing S1P1R of the same genetic
background as B2 should be analysed additionally. This would be needed to exclude other
explanations such as differences in the genetic background of the different ES cell lines
used in this study. Another important result is that following long-term exposure, it
appears that S1P1R may be involved in the pFTY720-dependent increase of BDNF
protein levels in ES cell-derived neurons in vitro (Figure 5.1). When comparing the results
of this study with the findings previously obtained in primary cortical cultures
(Deogracias et al. 2012), it cannot be excluded that cells others than neurons are required
for pFTY720 to deploy its full activity.
In sum, it appears that the mode of action of FTY720 even in the simplified in vitro system
used here is complex and requires further detailed investigations. It will be of particular
interest to delineate the possibility that pFTY720 may also act through other receptors,
including S1P3R expressed by these neurons. This could be explored by reconstituting a
system based on for example CHO cells expressing just one of the five S1P receptors at
a time as well as constructs reporting on activation of CREB phosphorylation. This
strategy would allow the investigation of the signalling pathways elicited by one of the
receptor’s subtype only, and introduction of additional receptors can be controlled and
interactions therefore better understood. In addition, the role of the endogenous
production of sphingosine, most likely an intrinsic complicating factor would need to be
investigated in detail. In the context of developing new drugs targeting S1P receptors, an
elegant approach has been recently developed allowing the efficient screening of
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exceptionally large libraries of agonist antibody candidates (Xie et al. 2013). This system
could also be used to screen receptor-activating antibodies by infecting a S1P receptor-
expressing CHO reporter cell line with viruses expressing this large antibody libraries.
Such receptor-selective reagents may help delineating what appears to be a complex
interplay between different S1P receptors and to better define their potential to treat
neurodegenerative diseases.
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Appendix
Analysing the potency of 4-OHT
The potency of 4-OHT was tested on Rosa26/CreERT2 x HA-TrkA-127 ES cells (Figure
A.1A). The time course experiment revealed that 0.8 μM 4-OHT is most potent between
8 h and 20 h and therefore subsequent experiments were performed overnight. These
results demonstrated that 0.05 μM 4-OHT treatment activated CreERT2 in the
Rosa26/CreERT2 x HA-TrkA-127 ES cells, which led to the successful excision of the stop
cassette and the subsequent expression of HA-TrkA as demonstrated by Western blot
(Figure A.1B).
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Figure A.1 4-OHT induced CreERT2 mediated recombination in mouse ES cells
A ES cells carrying a CreERT2 transgene in one allele of the Rosa26 locus and an HA-TrA-127
transgene with a stop-cassette (Neo-pA) flanked by two lox P site (red arrows) at its 5’ end on
the other Rosa26 allele were used to test the potency of 4-OHT. Map kindly provided by Dr.
Xinsheng Nan. B Western blot represents HA-TrkA recognised by an antibody against the HA
tag. 40 μg cell lysate was loaded per lane. ES cells were treated with 0.8 μM of 4-OHT for 3
to 49 h. Dose response experiment was performed overnight with 0.05 – 0.8 μM 4-OHT. The
successful excision of the stop cassette was demonstrated by the expression of HA-TrkA on
Western blot. These results were performed and analysed by Dr. Xinsheng Nan.
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Effects of pFTY720 on BDNF levels in primary mouse cortical
neurons
pFTY720 has recently been shown to induce increased BDNF protein expression in
primary mouse cortical neurons (Deogracias et al. 2012). In the current study, these
experiments were repeated to serve as a positive control for short-term experiments with
pFTY720 on ES cell-derived neurons. First, primary mouse cortical neurons 8 DIV were
exposed to different concentrations of pFTY720 for 24 h, followed by a time course
experiment with pFTY720 10 nM. Both experiments revealed no significant effect by
pFTY720 on BDNF protein levels (Figure A.2B and D). However, the lack of increase
could be due to immaturity of the neurons, as a previous report has shown that primary
mouse cortical neurons reach their maturity between 10 and 20 DIV (Lesuisse and Martin
2002). Also, characterisation experiments by Deogracias et al. 2012 were done in 2 weeks
old neurons. This led to the repetition of dose response and time course experiments in
primary cortical neurons 12 DIV. Nevertheless, in both experiments no significant
increase of BDNF protein levels was observed after pFTY720 exposure (Figure A.3B and
D).
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Figure A.2 Short-term effects of pFTY720 on primary cortical neurons 8 DIV
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Figure A.2 Short-term effects of pFTY720 on primary cortical neurons 8 DIV
A 8 DIV old primary mouse cortical neurons were treated with different concentrations of
pFTY720 for 24 h. Western blot represents BDNF expression of primary cortical neurons after
short-term exposure to pFTY720 10 nM, 100 nM and 1 μM. 20 µl of neuronal lysate was
loaded per lane. B pFTY720 did not increase BDNF protein levels at any concentration in
primary cortical neurons significantly compared to controls (Kruskal-Wallis test, p > 0.05,
n = 3). C A time course experiment with primary cortical neurons 8 DIV was performed.
Neurons were treated with pFTY720 10 nM for 4 h, 8 h or 24 h and BDNF levels were
analysed using Western blot. D BDNF levels were not increased by pFTY720 10 nM at any
time point compared to controls. Data are represented as mean ± SEM relative to internal
control βIII-tubulin. Changes are in percentage vs. control. Ø: vehicle (DMSO) treated cells.
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Figure A.3 Short-term effects of pFTY720 on primary cortical neurons 12 DIV
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Figure A.3 Short-term effects of pFTY720 on primary cortical neurons 12 DIV
A 12 DIV old primary mouse cortical neurons were treated with different concentrations of
pFTY720 for 24 h. Western blot represents BDNF expression of primary cortical neurons after
short-term exposure to pFTY720 10 nM, 100 nM and 1 μM. 20 µl of neuronal lysate was
loaded per lane. B pFTY720 did not change BDNF protein levels significantly at any
concentration in primary cortical neurons (Kruskal-Wallis test, p > 0.05, n = 3). C Neurons
were treated with pFTY720 10 nM for 4 h, 8 h or 24 h and BDNF levels were analysed using
Western blot. D BDNF levels were not increased by pFTY720 10 nM at any time point
compared to vehicle-treated controls. Data are represented as mean ± SEM relative to internal
control βIII-tubulin. Changes are in percentage vs. control. Ø: vehicle (DMSO) treated cells.
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Exploring possible causes of biochemical endpoint variability
in ES cell-derived neurons
As the biochemical parameters investigated all show significant variability attempts were
made to test whether some could be the results of the tissue culture conditions used,
including in particular medium exchange as the system requires a complete medium
exchange on day 2, 4, 8 and 12 of neuronal culture (see Materials and Methods). To this
end, 14 DIV cultured J1 neurons were subjected to a complete medium exchange and
BDNF protein levels analysed at different time points. As shown in Figure A.4, BDNF
protein levels did not change significantly 8 h after a complete medium exchange. At
16 h however, a trend towards an increase can be observed (Figure A.4). In view of these
results, Bdnf mRNA levels were also analysed under the assumption that while medium
exchange may not be sufficient to stimulate the translational machinery, it may be
sufficient to activate the MAPK pathway activation and the transcription of the Bdnf gene.
However, this turned out not to be the case (Figure A.5).
As a potentially sensitive indicator of the metabolic state of cultured neurons, the levels
of Arc were also investigated. Unlike BDNF, which is stored in large dense core vesicles
until its release from neurons, Arc is known to rapidly turn over, not only at the level of
its mRNA, but also as a protein that is rapidly degraded after its biosynthesis. For this
reason, Arc is attracting considerable attention in studies related to the biochemistry of
synaptic plasticity (Rao et al. 2006; Bramham et al. 2008) . When 14 DIV J1 neurons
were lysed 2 h after the medium exchange reference, Arc protein levels were significantly
increased (Figure A.6).
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Figure A.4 Effects of medium exchange on BDNF protein levels in J1 neurons 14 DIV
A complete medium exchange was performed and neurons were lysed after either 8 or 16 h.
A 20 µl of neuronal lysate were loaded per lane. B Densitometric analysis did not reveal a
significant BDNF increase (Kruskal-Wallis test, p > 0.05, n = 3). Data are represented as mean
± SEM relative to internal control βIII-tubulin. Ø stands for cells where no medium exchange
was performed.
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Figure A.5 Effects of medium exchange on Bdnf mRNA levels in J1 neurons 14 DIV
A complete medium exchange was performed and neurons were lysed after either 2, 4 or 8 h.
BDNF mRNA levels did not change significantly after medium exchange (Kruskal-Wallis
test, p > 0.05, n = 4 individual experiments). Data are represented as mean ± SEM relative to
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Figure A.6 Effects of medium exchange on Arc protein expression in J1 neurons
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Figure A.6 Effects of medium exchange on Arc protein expression in J1 neurons
Arc protein levels were analysed in J1 neurons 14 DIV 2 h after a complete medium
exchange. A Representative western blot of Arc in J1 neurons before and after medium
exchange. Pierce staining for densitometric analysis of total protein is shown on the right.
B Graph represents densitometric analysis. Arc levels increased significantly (Unpaired t-
test, **p (no medium exchange vs. medium exchange) < 0.01, n = 4). Data are represented
as medium ± SEM.
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Effects of pFTY720 on Arc protein levels in ES cell-derived
neurons
Arc levels were also investigated following exposure to pFTY720. Fourteen day-old J1
ES cell-derived neurons were treated with different concentrations of pFTY720 for 7 h
and Arc protein levels analysed by Western blot (Figure A.7). These experiments failed
to reveal any consistent increase of Arc levels following pFTY720 treatment. A time-
course experiment performed with 10 nM did indicate a transient, but not significant
increase of Arc levels 2 h after treatment (Figure A.8).
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Figure A.7 Dose response experiment – Effects of pFTY720 on Arc expression
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Figure A.7 Dose response experiment - Effects of pFTY720 on Arc expression
14 DIV J1 neurons were exposed to different concentrations of pFTY720 10 nM for
7 h. A Western blot for Arc expression in J1 neurons. 30 μg of protein were loaded per lane.
Pierce staining for densitometric analysis of total protein is shown on the right panel. B Graph
shows densitometric analysis. Arc protein expression did not change after 7 h exposure to
different concentrations of pFTY720 (Kruskal-Wallis test, n.s. p > 0.05,
n = 3). Data are represented as mean ± SEM relative to total protein and normalised to the
control. Ø stands for vehicle (DMSO) treated cells.
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Figure A.8 Time course experiment - Effects of pFTY720 10 nM on Arc expression
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Figure A.8 Time course experiment - Effects of pFTY720 10 nM on Arc expression
14 DIV J1 neurons were exposed to pFTY720 10 nM for the indicated time periods. A Western
blot for Arc expression in J1 neurons. 30 μg of protein were loaded per lane. Pierce staining
for densitometric analysis of total protein is shown on the right. B Graph shows densitometric
analysis. Arc protein expression was not significantly increased at any time point (Mann-
Whitney test, p > 0.05, n = 3). At 2 h a trend was observed (differences between medians =
0.882). Data are represented as mean ± SEM relative to total protein and normalised to the
control. Ø stands for the vehicle DMSO.
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Recording activity of neurons derived from ES cells
One possibility to explain the variability of the biochemical results, is the neuronal
activity in the cultures. Indeed, neither the maturation of the neurons themselves nor the
time-course of the development of synaptic contacts can be controlled. Yet, FTY720 has
been shown to require ongoing neuronal activity to exert biochemical effects, including
the regulation of BDNF levels (Deogracias et al. 2012). In addition, previous studies by
others using the same in vitro differentiation system reported significant variability even
between individual neurons in the same cultures by monitoring activity using intracellular
recording (Barth et al., 2014). In an attempt to approach this question, ES cell-derived
neurons were plated on MEA plates suitable for extracellular recordings allowing data on
spike counts to be collected (see Materials and Methods). The difference between single
wells was striking (Figure A.9). Neurons generated from J1 and B2 ES cells were
examined at different time points and in five different wells. The results indicate that in
every well, different spike counts were recorded even though the neurons originated from
the very same progenitors (Figure A.9). These neurons were also treated with either
DMSO or pFTY720 10 nM and spike counts determined after 60 min, with and without
medium change (Figure A.10). While the medium exchange did increase spike counts in
J1 neurons, this was not the case with B2 neurons. However, spike counts were very low
in mutant neurons for reasons that remained unclear. Neither did the addition of DMSO
or of pFTY720 10 nM alter the spike counts whereby the differences in spike counts
between single wells remain remarkable (Figure A.10).
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Figure A.9 Spike count measurements in J1 and B2 neurons
Spike counts in J1 and B2 neurons 14 DIV were measured in five different wells
(n = 3 measurements of the same well). Spike counts vary between wells.
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Figure A.10 Spike Counts in J1 and B2 neurons after treatment
Neurons were exposed to the indicated treatment for 1 h before another measurement
of the spike counts was performed. In J1 neurons medium exchange increased the spike
count by 330 %. In J1 and B2 neurons treatment with pFTY720 10 nM did not result
in an increased spike count.
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Vegfd mRNA levels were unaffected by pFTY720 treatment in
ES cell-derived neurons
A recent in vivo study on FTY720 showed that mRNA of the vascular endothelial growth
factor (Vegfd) is significantly increased in mice treated with the drug (Hait et al. 2014).
The researchers showed that the increase is mediated through the inhibition of the class I
histone deacetylases by pFTY720. This mode of action was shown to be independent of
the S1P1R (Hait et al. 2014). As the generated mutant cell line B2 is the ideal tool to
confirm this result both J1 and B2 neurons were treated with pFTY720 10 nM for different
time periods and Vegfd mRNA levels were analysed using RT-PCR (Figure A.11).
In J1 and B2 neurons no significant increase of Vegfd mRNA levels was induced after
treatment with 10 nM pFTY720 (Figure A.11).
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Figure A.11 Vegfd mRNA levels in J1 nor B2 neurons after pFTY720 treatment
14 DIV old neurons were treated with pFTY720 10 nM for 1 h, 4 h, 8 h and 16 h. No change
of Vegfd mRNA levels was observed after exposure to 10 nM pFTY720 (Kruskal-Wallis test,
p > 0.05, n = 3). Data are represented as mean ± SEM relative to internal control 18S rRNA.
Ø: vehicle (DMSO) treated cells.
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Exposure of J1 and B2 neurons to KCl
It is well established in the BDNF field that membrane depolarisation in neurons induces
increased transcription of the Bdnf gene (Kokaia et al. 1993; Elliott et al. 1994) and
thereby enhances neuronal survival (Ghosh et al. 1994; Shepherd et al. 2005). To
understand if the ES cell-derived neurons used here behave similar, J1 neurons 21 DIV
were exposed to 60 mM KCl for 24 h and BDNF protein levels were analysed by Western
blot. However, no significant increase could be found (Figure A.12). In 14 days old B2
neurons the same experiment was conducted and a clear trend towards an increase was
observed compared to NaCl-treated neurons (Mann-Whitney test, actual difference
between medians = 10.27, Figure A.13). However, no firm conclusion can be drawn from
this experiments as a higher number of repeats is needed. The lack of a significant
increase suggests that BDNF protein levels could have been secreted during KCl
treatment. Indeed, it has been shown before that a significant amount of BDNF is secreted
after overnight treatment with 50 mM KCl in J1 ES cell-derived neurons (Oliveri 2014).
This could be investigated by BDNF immunoprecipitation in the supernatant of the
neuronal cultures. In line with this Bdnf mRNA levels should be measured in both cell
lines upon depolarisation of the neurons with KCl (Zafra et al. 1990).
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Figure A.12 BDNF expression levels in J1 neurons after exposure to 60 mM KCl
J1 neurons 21 DIV were exposed to 60 mM KCl for 24 h and BDNF levels were analysed.
A Western blot of BDNF. 20 μl of neuronal lysate was loaded per lane. B BDNF levels were
not significantly increased after 24 h exposure to 60 mM KCl (Mann-Whitney test, p > 0.05,
n = 3 independent wells). Data are presented as mean ± SEM relative to βIII-tubulin. Ø: vehicle
(NaCl) treated cells.
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Figure A.13 BDNF expression levels in B2 neurons after exposure to 60 mM KCl
B2 neurons 14 DIV were exposed to 60 mM KCl for 24 h and BDNF levels were analysed.
A Western blot of BDNF. 20 μl of neuronal lysate was loaded per lane. B BDNF levels were
not significantly increased after 24 h exposure to 60 mM KCl but a trend towards an increase
was observed (Mann-Whitney test, actual difference between medians = 10.26, p > 0.05,
n = 3 independent wells). Data are presented as mean ± SEM relative to βIII-tubulin. Ø: vehicle
(NaCl) treated cells.
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Analysis of different culture conditions to investigate BDNF
modulation by pFTY720
Results in J1 neurons 14 DIV revealed no significant modulation of BDNF levels by
short-term treatment with pFTY720 (Figure 5.2). It was unclear if this lack of effect might
be due to the accumulation of BDNF in these cultures. It is conceivable that these
relatively high levels could induce a negative feedback loop thereby inhibiting further
Bdnf transcription (see Introduction and Haapasalo et al. 2002). This hypothesis was
tested with a monoclonal antibody (mAb #9) capturing secreted BDNF (Materials and
Methods, section 2.11). However, BDNF levels were not affected by 50 nM pFTY720.
Also, there was no difference observed in BDNF levels between antibody-treated and
untreated controls (Figure A.14).
Another approach to decrease basal BDNF levels was tested by lowering the plating
density of J1 neurons. Plating densities of as low as 0.85 x 105 cells/cm2 and
1.4 x 105 cells/cm2 were tested. At the lowest plating density BDNF was barely detectable
by Western blot in J1 neurons 14 DIV, so that a quantification by densitometry was not
possible (Figure A.15). In neurons of a slightly higher plating density detection of BDNF
protein levels was improved allowing quantification of BDNF expression levels. Also in
these cultures, no increase in BDNF expression was induced by 10 nM pFTY720
treatment after 24 h (Figure A.16).
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Figure A.14 Pre-treatment of J1 neurons with mAb #9
J1 neurons 14 DIV were exposed to 10 μg/ml mAb #9 for seven days before they were treated
at 21 DIV with 50 nM pFTY720 for 8 h. A Western blot of BDNF. 20 μl of neuronal lysate
was loaded per lane. B BDNF levels were not significantly affected by 50 nM pFTY720
treatment (Kruskal Wallis test, p > 0.05, n = 5 from 3 independent experiments). Data are
presented as mean ± SEM relative to GAPDH. Changes are in percentage vs. control.  Ø:
vehicle (DMSO) treated cells.
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Figure A.15 BDNF levels in J1 neurons cultured at low density
J1 neurons were cultured at a density of 0.85 x 105 cells/cm2 and treated at 14 DIV with 10 nM
pFTY720 for 8 h and 24 h. A Western blot shows that BDNF was barely detectable in J1
neurons cultured at this low plating density and a quantification of BDNF levels by
densitometry was not possible. 20 μl of neuronal lysate was loaded per lane.
Observation from 2 independent experiments. Ø: vehicle (DMSO) treated cells.
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Figure A.16 BDNF levels were unaffected in neurons cultured at 1.4 x 105 cells/cm2
J1 neurons were cultured at a density of 1.4 x 105 cells/cm2 and treated at 14 DIV with 10 nM
pFTY720 for 24 h. A BDNF detection was improved in J1 cultures of 1.4 x 105 cells/cm2
density. 20 μl of lysate was loaded per lane. B No increase of BDNF expression was induced
by a 24 h exposure to 10 nM pFTY720 (Mann-Whitney test, p > 0.05, n = 3 independent
wells). Data are presented as mean ± SEM relative to βIII-tubulin. Ø: vehicle (DMSO) treated
cells.
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Investigations of the longitudinal expression of BDNF in ES cell-derived neurons showed
that levels start to be detectable around 10 DIV onwards (Figure 3.29B). This was also
seen for the expression levels of synaptophysin and suggested that low levels of synaptic
transmission might be detectable. By treating ES cell-derived neurons with pFTY720 as
early as 10 DIV it was investigated if this level of neuronal activity would be high enough
to induce a pFTY720-dependent increase in BDNF expression. However, BDNF
expression levels were not affected by 10 nM pFTY720 treatment for 8 h or 24 h (Figure
A.17), suggesting that these neurons might indeed be too immature.
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Figure A.17 BDNF levels in J1 neurons 10 DIV after pFTY720 treatment
J1 neurons 10 DIV were exposed to 10 nM pFTY720 for 8 h and 24 h. A Western blot for
BDNF. 20 μl of neuronal lysate was loaded per lane. B No change in BDNF expression was
observed after 24 h exposure to 10 nM pFTY720 (Kruskal Wallis test, p > 0.05, n = 3 from 2
independent experiments). Data are presented as mean ± SEM relative to βIII-tubulin. Changes
are in percentage vs. control. Ø: vehicle (DMSO) treated cells.
